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ABSTRACT
In a collaborative effort with the Massachusetts Eye and Ear Infirmary, Draper Laboratory is
developing an implantable microfluidic drug delivery system for long-term treatment of inner ear
disorders and prevention of sensorineural hearing loss. This versatile device is envisioned to deliver
multiple therapies and control the sequence and rate of drug dosing. Such a system could have an
immediate application in the treatment of ototoxic and inflammatory conditions affecting the inner ear,
including autoimmune inner ear disease and cisplatin-induced ototoxicity. Current efforts include
ongoing refinement of the design, miniaturization of components, and testing in an in vivo guinea pig
model.
This thesis focuses on the interactions between the device and inner ear, including the
investigation of drug transport due to convective diffusion in the cochlea during drug delivery. A
lumped-parameter model was implemented in an electrical circuit simulator after converting
mechanical variables to their electrical analogues. A flow module described the output of the
microfluidic system and used storage and loss elements to represent cochlear anatomy contributing to
the flow profile. In the other portion of the model, a transport module solved for the drug
concentration profile within the cochlea resulting from diffusion and convection. The model was
validated using a bench-top fluorescent flow study and was compared to in vivo animal drug delivery
studies.
Additionally, mechanical and biological interactions related to protein and tissue biofouling
were investigated. The protein composition of the endogenous fluid of the inner ear was analyzed using
a mass-spectrometry approach, and in vitro flow experiments were implemented to quantify biofouling
in the device due to protein build-up and determine the impact of biofouling on microfluidic device
performance. The effects of tissue build-up on the implanted system were studied through the use of
histology preparation of the cochlea after long-term implantation. Further work included the
fabrication and testing of microfluidic components, diaphragm-based capacitive elements and manual
valves, for integration into the device. Through this research, both the impact of this device on the
animal and the result of implantation on the device were more fully characterized.
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1.0 INTRODUCTION
In recent years, a great deal of effort has been applied to molecular biology approaches to the
prevention and reversal of sensorineural hearing loss. Additionally, researchers are addressing clinical
opportunities related to the long-term delivery of compounds to regenerate sensory cells in the inner
ear [1]. As these treatments become reality, a barrier exists in supplying the compounds to the
necessary sites in the inner ear.
Many inner ear disorders are not adequately treated by current methods. Systemic drug
delivery is limited by the existence of a blood-labyrinth barrier, similar to the blood-brain barrier, which
serves as an impediment for many charged or large molecules entering the inner ear [2]. Existing
techniques for direct delivery of drugs into the inner ear are extremely limited due to challenges specific
to the inaccessibility and sensitivity of cochlear structures.
Local delivery methods are constrained in their ability to precisely deliver drugs into the cochlea
for extended periods. Delicate inner ear structures are extremely sensitive to changes in pressure or
volume associated with bolus or perfusion-type delivery. Distribution of drug to the inner ear via
diffusion from the middle ear has been used in a variety of applications such as Menibre's disease and
sudden sensorineural hearing loss. Variations include placing a drug-filled gel or foam in the middle ear
or utilizing wicks extending from the tympanic membrane [3-5]. These passive systems rely on diffusion
through the round window for access to the inner ear fluids and are inefficient due to loss of drug
through the Eustachian tube and to lack of dosing control [5]. Other groups have used small osmotic
drug pumps with catheters entering the middle or inner ear. These micropumps are passive and
operate only for short durations [6]. They operate at only a single infusion rate. Finally, research is
being conducted to combine drug delivery capabilities with the electrodes used for cochlear implants
[7]. These, however, are not being tested in ears with normal hearing. Currently, there are no available
devices for extended perfusion of drugs directly into the inner ears of hearing humans.
To address the need for precise, well-controlled drug delivery directly to the inner ear, a
collaboration between Draper Laboratory and the Massachusetts Eye and Ear Infirmary (MEEI) is
developing a fully implantable long-term microelectromechanical system (MEMS)-based delivery device
[8, 9]. This microfluidic system incorporates microfabricated components with electrical controls and
appropriate packaging for implantation behind the ear, and it utilizes a novel single-lumen based
reciprocating approach with no net volume increase in the cochlea over time.
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The critical elements of the device consist of an overall size consistent with surgical placement
within a small cavity behind the ear, a pumping element capable of infusing drug into recirculating
perilymph, a valve-controlled drug reservoir, and integration with sensors for control of flow rate.
Ultimately, an integrated drug delivery device with sensors for flow, concentration and bioactivity would
provide customized therapy based on individual responses to treatment. The device would infuse
highly-concentrated solution into the cochlea over a few seconds. The same volume of less
concentrated fluid would then be withdrawn back into the device over minutes. This process would be
repeated at sufficient time intervals, and with delivery occuring through diffusive and convective
transport in the inner ear.
Immediate applications of this system in the treatment of otologic disorders include delivery of
otoprotective drugs during chemotherapy and radiation and delivery of therapeutics for autoimmune
inner ear disease. Future applications based on regenerative approaches will provide powerful clinical
tools in the treatment and prevention of hearing loss.
1.1 SPECIFIC AIMS
This thesis focused on investigating various aspects of interactions between the device and the
animal. System design must incorporate factors originating from the mechanical-biological interface.
The device must adequately deliver drugs to optimal effect and must provide stable performance in the
biological environment. Research for this thesis was divided into three specific aims.
Aim 1: Characterize drug transport within the cochlea using computer modeling and in vivo
experimental data
A lumped-parameter model was constructed to characterize the diffusive and convective drug
transport in the cochlea from the delivery device. Mechanical and biological aspects of the device-
cochlea system were converted to electrical analogues. A circuit simulation was implemented and
solved using MicroCap software.
The model was validated in a bench-top environment using fluorescence delivery to a glass tube
to track transport of the molecules along the tube length. Experimental data was compared to modeled
results from the circuit simulator.
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In vivo drug delivery experiments utilizing the microfluidic device implanted into guinea pigs
were undertaken. Hearing responses were measured to infer the drug delivery profile, and these results
and model output were compared.
Minimal changes to the lumped-parameter model would allow for its use in predicting drug
delivery in human applications of the device. Because pharmacokinetic studies in the cochlea meet with
great difficulty, this model would be useful in the development of the device and of novel drugs for
inner ear applications.
Aim 2a: Investigate the impact of protein biofouling on the microfluidic system using bench-
top testing
A mass-spectrometry-based proteomics analysis of perilymph, endogenous inner ear fluid, was
performed to identify the major proteins. Various proteins impact both the delivery system and the
drugs delivered. Some, such as albumin, may adsorb to material surfaces and cause flow restrictions
and lead to changes in device flow profiles. Additionally, many proteins may bind to drug molecules or
change their composition limiting drug effectiveness and availability.
A bench-top flow study of protein solution was undertaken to compare protein build-up on
several device materials. The study was meant to mimic perilymph flow through the channels of the
delivery device.
Aim 2b: Examine in vivo cellular and tissue biofouling of system using histology
A guinea pig was implanted with a functioning device for 30 days, and the cochlea, with the
embedded cannula, was processed for histological evaluation. After sectioning, the cannula was
examined microscopically for evidence of cellular ingrowth or other occlusion. Also, surrounding tissue
was examined for evidence of immunological response.
Aim 3: Fabricate and test microfluidic components
In order to miniaturize the delivery system and move to a more fully-integrated platform, device
components were fabricated from polymer laminate sheets using a micromachining tool. A diaphragm-
based capacitive membrane replaced a long length of compliant tubing used to tune the device delivery
profile. A membrane-based manual valve was constructed to enable flow control, and a 5-valve
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manifold assembly allowed for filling, purging, and drug loading of the device. These fluidic components
were tested for their flow characteristics including compliance and fluidic resistance.
In this thesis, Chapter 2 contains a literature review of the current state of inner ear drug
delivery for auditory applications including delivery methods and current and horizon applications. Drug
transport modeling and experimentation are covered in Chapter 3. The following chapter describes a
protein composition analysis and studies to examine biofouling of the device. Chapter 5 includes
information on the fabrication and testing of two microfluidic components, a membrane capacitor and a
manual valve, that were developed for integration in the delivery system.
1.2 REFERENCES
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2.0 BACKGROUND
2.1 INTRODUCTION
The inner ear provides a unique opportunity for local drug delivery. Access to the inner ear is
limited by the presence of a blood-cochlear barrier, which is anatomically and functionally similar to the
blood-brain barrier [1, 2]. Due to tight junctions between cells, substances in systemic circulation
encounter substantial physical barriers to entry, preventing many molecules with potentially therapeutic
effect from gaining access to their inner ear targets. Additionally, the cochlea is a closed space, and
cochlear function is sensitive to small changes in fluid volume. Therefore, delicate approaches are
required to avoid possible damage from the delivery method itself.
Otologic practice requires drug delivery to the inner ear, but current methods of delivery utilize
inefficient routes. Drugs are commonly delivered systemically, with the expectation that they will reach
their intended inner ear targets in the necessary form and concentration, and without deleterious side
effects. Systemic corticosteroids, for example, are used in the otologic management of sudden
sensorineural hearing loss (SSNHL) and autoimmune inner ear disease (AIED) [3-5]. Their clinical
usefulness, however, is limited by undesirable side effects arising from the high systemic doses required
to achieve therapeutic concentration in the cochlea [6].
Additional applications include otoprotection from a variety of sources toxic to the inner ear. An
active area of research is focused on preventing hearing loss due to cisplatin chemotherapy, radiation
for cancer treatments and aminoglycoside antibiotics. Noise induced hearing loss (NIHL) affects
millions of people and represents another target for local therapy.
Recent advances in the pharmacology and molecular biology of hearing have revealed new
possibilities for preventing or minimizing hearing loss. Sensorineural hearing loss results from death of
the cochlear sensory and neural cells. In humans, these cells do not regenerate, and loss is often
followed by secondary degeneration of auditory neurons. Scientists and clinicians are making progress
in understanding the molecular mechanisms associated with cochlear and auditory nerve degenerative
processes [7] and in finding agents that can minimize degeneration and facilitate repair [8, 9]. These
insights offer the potential for development of novel and precise drug treatments. Moreover, the
extraordinary progress that has been made in defining genes and protein activities offers hope for gene
transfer and cell-based approaches to treat these diseases [10, 11].
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For current applications and new therapies based on these discoveries to be clinically relevant, it
is necessary to develop safe and reliable mechanisms for the direct delivery of compounds into the inner
ear. Methods for local delivery can be categorized as either intratympanic or intracochlear approaches.
Intratympanic delivery can be accomplished via perfusion of the middle ear with the goal of
diffusion through the round window membrane (RWM) into the fluid spaces of the inner ear. This
method, introduced over 50 years ago [12], remains in common use in the treatment of inner ear
diseases. Technological advances beyond the simple middle ear injection method include the use of
hydrogels, nanoparticles, and microcatheter systems. These systems aim to maintain therapeutic levels
of drug on the round window for extended periods of time.
Direct intracochlear drug delivery involves placement of drugs within cochlear perilymphatic
spaces via a cochleostomy in the surrounding bone or RWM [13, 14]. This mode of delivery allows drugs
to reach their intended targets more directly than with systemic delivery. Molecules perfused into a
perilymph compartment (ideally the scala tympani) have direct access to the cells of the inner ear [15].
Methods of delivery include direct perfusion using micropumps and osmotic pumps. Research is being
conducted on modifying the electrodes of cochlear prostheses to integrate drug delivery components,
while yet others are developing novel implantable delivery devices [16-19].
In this review, we provide a brief overview of the anatomy and physiology of the inner ear as it
relates to local drug delivery. Current and horizon applications for conditions that may be treated via
direct inner ear delivery are discussed. Finally, methods to locally deliver drugs to the inner ear for both
clinical and research applications are presented. These approaches are categorized by the location of
delivery and by the passive versus active mode of distribution.
2.2 ANATOMYAND PHYSIOLOGY
The inner ear, which contains both the organ of hearing, the cochlea, and the organ of balance,
the vestibular system, is embedded deep within the skull near the brainstem in the petrous bone, one of
the hardest bones in the body. The extreme inaccessibility of the cochlea, coupled with its very small
size, creates unique though tractable problems for cochlear drug delivery. The complexity of the
cochlear structures and their extreme sensitivity to the changes in fluid volume also must be considered.
The cochlea can be thought of as a long coiled tube, 31-33 mm in human, [20] looking much like
the snail shell from which it derives its name. It varies in diameter along its length from apex to base.
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Stretched across the middle of the tube is the organ of Corti, which is the highly organized basilar
membrane that contains the mechano-sensory cells of the inner ear. The basilar membrane moves in
response to sound waves that enter the inner ear. The structure of the organ of Corti is tonotopically
organized so that high frequency sounds produce the greatest motion in the base of the tube and low
frequency sounds move the organ most at the apex.
The mechano-sensory cells of the ear are called hair cells because early microscopists
considered the stereocilia at the apical surfaces to look like tiny hairs. Hair cells are organized into rows
that run the length of the coil from its base to its apex and are organized tonotopically in their response
to sound. There are two types of hair cells: a single row of inner hair cells responds to sound by releasing
a neurotransmitter to excite afferent auditory neurons, and three rows of outer hair cells serve to
amplify the sound-evoked motion of the basilar membrane to more effectively deliver frequency-
specific stimulation to the inner hair cells.
If one looks at a cross section through the cochlea, as shown in Figure 1, a distinctive feature is
the presence of three relatively large fluid-filled compartments. These three compartments coil up the
cochlea along with the organ of Corti. The middle compartment is the scala media, which is filled with
endolymph (discussed below). The scala media forms a border of the organ of Corti, and the apical
surfaces of cells in the organ of Corti, including the hair cells, project into the scala media. The lower
and upper fluid compartments respectively are the scala tympani and scala vestibuli, both of which are
filled with perilymph. These two compartments communicate with each other at the apex of the
cochlea through the helicotrema. There are two orifices in the surface of the cochlear bone, both of
which are located at the base of the cochlea. The round window is a membranous opening in the bone
within the scala tympani. It sits at the base of the scala tympani and is very compliant, capable of
bulging into the middle ear. It separates perilymph from the middle ear space. The oval window, in the
scala vestibuli, contains the footplate of the stapes, one of the middle ear bones, that transmits acoustic
vibrations from eardrum to the inner ear.
Perilymph is the primary fluid of the cochlea. It bathes most of the cells within the cochlea
including the basolateral surfaces of the sensory cells, the neurons, and most of the other specialized
structures within the cochlea. Perilymph is similar to cerebrospinal fluid (CSF), with which it is in
diffusional continuity, though some studies have shown that protein concentration in perilymph is
significantly (10 to 20 times) higher than in CSF [21-26]. The volume of perilymph in the human cochlea
is about 70 pL, with around 40 pi in the scala tympani [26].
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The scala media is filled with endolymph, about 8 l.L in human, which has an ionic composition
similar to the intracellular environment, high in potassium and low in sodium. The fluid space provides a
highly unique environment for the apical surface of the hair cells. The cells that form the borders of the
scala media are all connected by tight junctions. The primary function of the scala media is to provide
an electrochemical environment that supports the hair cells' ability to transduce mechanical motion into
electrical potentials. It contains a relatively large (100 mV) positive electrical potential. This unique
electrochemical environment is created by a structure called the stria vascularis, which is, as its name
implies, highly vascularized. It runs along the outside of the scala media and extracts energy from the
blood that is needed to create the electrochemical battery of the scala media.
The cochlea can be viewed as a set of membranous tubes within a coiled bony tunnel with the
organ of Corti, containing the hair cells, stretched across the middle, the scala media providing the
electrochemical battery for transduction forming the apical border of the organ of Corti, and tubes
containing perilymph and bathing most of the cochlear structures on either side of the organ of Corti
and scala media. The stria vascularis runs along the outside of the scala media. Finally, the coil of the
cochlea winds around the modiolus, into which are packed the cell bodies of the auditory neurons,
appropriately termed the spiral ganglion neurons (SGN). These bipolar neurons send dendrites to the
inner hair cells and axons to the brain.
Airborne sound passes through the external auditory canal and moves the tympanic membrane.
Motion of the membrane by the sound waves is transmitted through the ossicles (3 tiny bones: the
malleus, the incus, and the stapes) to transfer the airborne sound into the movement of the footplate of
the stapes, which is inserted in the oval window of the inner ear. The piston-like motion of the stapes
transfers a pressure wave to the fluid-filled space of the inner ear behind the oval window. Thus the
middle ear functions to match the acoustic impedance of the airborne sound to that of fluid
environment of the inner ear.
Motion of the basilar membrane ultimately produces movement of the stereocilia at the apical
surfaces of the hair cells. As the stereocilia move, mechanically sensitive ion channels on the stereocilia
open and shut in synchrony with the motion. As a result, the hair cells depolarize and repolarize with an
electrical waveform that is similar to the mechanical motion. The outer hair cells possess resonance
properties that are tonotopically organized to correspond to the maximum sensitivity of the basilar
membrane, so that they in essence amplify the motion of the basilar membrane over a narrow range of
frequencies, enhancing the frequency discrimination of the system. The inner hair cells respond to the
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outer hair cell-enhanced basilar membrane motion by releasing neurotransmitter from the base of the
hair cell. This release activates the auditory nerve fibers.
There are a number electrophysiological parameters one can monitor to assess cochlear
function, and some of these (distortion product otoacoustic emissions (DPOAEs) and auditory brainstem
responses (ABRs)) are often used clinically. Current flowing through the transduction channels in the
hair cells will generate a cochlear microphonic (CM) potential that mimics the acoustic waveform. One
can record the CM potential to get an indication of hair cell function or to assess the effects of drugs on
the hair cells. The CM is dominated by response of the outer hair cells. Another monitor of hair cell
function, DPOAEs, takes advantage of the mechanical motion induced in the basilar membrane by the
outer hair cell resonance. This mechanical response by the outer hair cell is propagated back out
through the middle ear as an acoustic signal that can be measured in the auditory canal. This mechanical
response is inherently nonlinear and will generate distortion products that can be detected
noninvasively in the ear canal. The distortion product corresponding to a particular frequency is quite
robust and is commonly used as a metric of cochlear function, and in particular, outer hair cell function.
Responses of the auditory neurons can be monitored individually with microelectrodes, but it is
also feasible to monitor the synchronous activity of groups of nerve fibers. The compound action
potential (CAP) is measured with a ball electrode placed near the RWM in response to a click or a tone
pip. In this case, a group of fibers discharge synchronously in response to the stimulus, producing a
signal large enough to measure even at a distance. Tone pips of varying frequency allow the
investigator to assess specific regions along the length of the cochlea, e.g. responses to high frequency
tone pips are generated in the basal portion of the organ of Corti. This measure is surgically invasive but
useful in animal experiments. Clinically, it is possible to monitor these responses with electrodes placed
on the surface of the scalp by averaging responses to a large number of stimuli. These ABRs are
clinically useful in providing objective assessment of cochlear function noninvasively.
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Figure 2.1 (a) A mid-modiolar section from a human temporal bone indicates the coiled structure of the
cochlea as it winds around a central modiolus, which contains the spiral (auditory) ganglion and its
associated auditory nerve fibers. (b) Each segment contains 3 fluid filled structures, the scala tympani
(s.t.), scala media (s.m.), and scala vestibuli (s.v.). The organ of Corti, which contains the sensory cells of
the cochlea (hair cells), separates the scala media and the scala tympani with the apical surface of the
epithelium facing the fluid space of the scala media and all other cell surfaces bathed in perilymph of the
scala tympani. The scala vestibuli is the fluid space at the upper portion of each turn. The outer edge of
each turn is occupied by the spiral ligament, which is in diffusional continuity with perilymph. The outer
edge of the scala media is bordered by the stria vascularis. The scala tympani and scala vestibuli are
joined at the apical extreme of the cochlea at the helicotrema. The cochlear aqueduct connects the fluid
space of the scala tympani with the cerebrospinal fluid space.
2.3 PHARMACOKINETICS
2.3.1 Absorption
2.3.1.1 Fluid compartments
Most of the structures of the cochlea are protected from the systemic circulation by the
presence of a blood-cochlear barrier (or blood-labyrinthine barrier), similar to the blood-brain barrier.
The extracellular fluid spaces of the ear can be considered pharmacologically as comprising four
components: (1) the systemic circulation - largely confined to the stria vascularis and to fluid contained
within the blood vessels and capillaries; (2) perilymph, a fluid similar in composition to CSF that provides
a favorable milieu for sensory cell and neuronal function; (3) endolymph, a fluid high in potassium ions
which provides the electrochemical drive for sensory cell function; and (4) the extracellular fluid of
cochlear bone, which seems to be a transitional region between the systemic circulation and the
perilymph.
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A small portion of the inner ear, the stria vascularis, is readily accessible from the systemic
circulation. It is surrounded by cells connected with tight junctions, which provide a part of the blood-
cochlear barrier [27]. Drugs that act in the stria vascularis can be administered systemically, and the
most likely action is a reduction of the endocochlear potential. Because the endocochlear potential is
the battery that drives the cochlear transduction process, a reduction in the endocochlear potential will
decrease hearing capability. The vascularization of the rest of the cochlea is relatively sparse, though the
modiolus and walls of the scala tympani are exceptions [28]. The endothelial cells that line the
vasculature are connected with tight junctions and no fenestrations [27, 29], and this network of tightly
coupled endothelial cells is the dominant component of the blood-cochlear barrier.
Perilymph, the primary fluid of the inner ear, is in diffusional continuity with CSF via the cochlear
aqueduct in most animals, though the transfer of fluid between the two spaces is limited [30]. In
humans, the aqueduct is usually not patent [31], though diffusional continuity is achieved via other
pathways, most notably the spaces around and within the auditory nerve [32].
Perilymph is primarily produced locally via the vascular supply to the cochlea (reviewed in [33,
34]), though a minor contribution from the CSF is possible. The site of production of perilymph is not
known, though the vascular supply to the modiolus and walls of the scala tympani have been suggested
[32, 35]. Perilymph resembles CSF in composition, and this similarity likely arises from a similar mode of
production of perilymph and CSF.
Endolymph, the highly specialized extracellular fluid that fills the scala media, bathes the apical
surfaces of the sensory cells. Endolymph is primarily produced in the stria vascularis and is secreted by
the marginal cells of the stria vascularis, which face the endolymph. Endolymph contains high
concentrations of potassium, low concentrations of sodium, and very low concentrations of calcium.
The scala media is lined with cells that contain tight junctions. The tight junctions help the scala media
retain its unusual electrical potential - around +100 mV, called the endocochlear potential. The
endocochlear potential and the high potassium concentration of the scala media provide the
electrochemical drive to the hair cells to allow their transduction of mechanical motion.
The cochlea is surrounded by petrous bone. This bone normally does not remodel and is very
poorly vascularized. The bone is accessible to perilymph via lacuna canaliculi which are canals or holes
in the bone in free communication with the scala tympani [32, 36, 37]. However, the bone is also
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accessible to the systemic circulation via fenestrated blood vessels. The bone has not been
characterized with regard to its presence in or out of the blood-cochlear barrier.
2.3.1.2 Barrier mechanisms
The prime component of the blood-cochlear barrier is a continuous capillary endothelium lining
blood vessels in the cochlea. The endothelial cells are connected with tight junctions and no
fenestrations [27]. Thus drugs entering the perilymph from the systemic circulation must either be
transported across, or dissolve into and out of, the capillary endothelia.
The scala media is also surrounded by cells connected by tight junctions. Chemicals entering the
scala media from the vasculature must either enter via the marginal cells of the stria vascularis, or by
first entering the perilymph. Either way, the drugs must be transported across the cell lining to enter the
scala media. Because the scala media has a relatively high positive charge due to the endocochlear
potential, the charge a drug carries will be a significant factor in its ability to enter the scala media, with
positively charged drugs at a disadvantage.
As with the blood-brain barrier, there are other elements of the barrier as well. The relatively
high protein content of perilymph [23, 24, 38] will tend to bind drugs that do enter, buffering the
concentration of such drugs. There are also likely to be other components to the blood-cochlear barrier,
such as enzymes and cellular uptake systems that can reduce the concentration of chemicals that enter
the cochlea, but these are not well characterized in the cochlea.
2.3.1.3 Properties of drugs that can cross the barrier
As with the blood-brain barrier, drugs that are large or highly charged have difficulty crossing
passively. Drugs with high lipid solubility cross more readily. Drugs with high protein binding are less
likely to cross. The unusual positive potential in the scala media poses an additional constraint for drug
entry. Drugs that are positively charged tend not to enter the scala media since the electrical gradient
works against them.
2.3.2 Distribution
Once a drug enters the cochlear fluids, its distribution is governed by many of the same
pharmacokinetic variables seen in the bloodstream. Most of the structures of the cochlea are in
diffusional continuity with the perilymph. Thus a drug placed into the perilymph can diffuse into the
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organ of Corti, which contains hair cells, neuronal terminals, and other specialized cells. The perilymph
is also in diffusional continuity with the spiral ganglion and structures within the modiolus of the
cochlea. Access to structures in the modiolus is enhanced by the presence of numerous lacuna
canaliculi on the surface of the osseous spiral lamina [37]. These perforations are on the order of 0.2 to
23 microns in diameter [36]. Finally, the spiral ligament and spiral limbus are also in diffusional
continuity with perilymph.
Cochlear structures that are not accessible from the perilymph include the stria vascularis and
the scala media, and thus the surfaces of cells that line the scala media. Both of the structures are lined
with cells that are connected via tight junctions [27].
The protein composition of perilymph in the human has a number of elements in common with
that of blood, though perilymph concentrations are lower [23], and protein interactions with drugs are
as important in the perilymph as in blood. Albumin levels are high and can bind acidic drugs, and acid
glycoproteins can bind basic drugs. Partition coefficients of drugs with these proteins will determine
free concentration of the drug. These proteins can provide a reservoir for accumulation of the drug in
perilymph over time.
The distribution of drugs within the inner ear is dependent upon the point of entry of the
agents. There are 3 practical entry points: through or near the RWM (at the base of the cochlea on the
scala tympani side), through or near the oval window (at the base of the cochlear on the scala vestibuli
side), or through the bone of the cochlea via application in the middle ear.
The cochlea is a long set of coiled tubes. The perilymph of the scala tympani can be thought of
as beginning at the base of the cochlea near the RWM, continuing apically to the end of the tube where
it then connects with the perilymph of the scala vestibuli and continues back down to the base to the
oval window, where the footplate of the stapes is located. Drug transport via simple diffusion along the
length of the perilymphatic space, because of the large length relative to cross section would require
very long times (hours to days) for significant drug distribution throughout the cochlea.
Salt, Plontke, and colleagues have extensively modeled the distribution of drugs applied at the
RWM [39, 40]. They suggest that in addition to diffusion along the length of the cochlea, diffusion
through the tissue of the cochlea from one scala to another must be considered as well [41, 42]. The
magnitude of the interscalar distribution will be highly dependent upon the drug [43]. Highly lipid
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soluble drugs, like steroids, will have a greater component of its distribution through tissue than would a
drug with a high rate of cellular uptake via carrier systems.
Many drugs are delivered into the middle ear space with the hope that they will diffuse through
the RWM into the scala tympani of the basal turn. The round window is an Achilles heel in the blood-
cochlear barrier. It is permeable to water and many drugs [44, 45]. The major problems with this mode
of entry from a pharmacokinetic perspective are that it relies on simple diffusion to pass drug from the
middle to the inner ear, and once in the scala tympani, the only mode of distribution is simple diffusion
in a fluid space with little turnover. Using implanted electrodes and tracer ions, the longitudinal volume
flow in the scala tympani was determined to be negligible, approximately 1.6 nL/min directed apically
[46]. The RWM can vary greatly in thickness [44] which can lead to variability in absorption of drug into
the scala tympani.
Delivery of agent into the scala vestibuli does not provide as favorable access to the structures
of the organ of Corti as application via the scala tympani. In theory, access to the auditory neurons
should be possible via canal perforantes in the scala vestibuli portion of the osseous spiral lamina [32].
Also, there are possible diffusion pathways to the scala tympani via entry into and exit from the
modiolus as well as into and out of the spiral ligament.
2.3.3 Metabolism and clearance
Issues of metabolism and clearance of drugs are specific for each drug. Some of the same
barriers that limit drug entry, e.g. tight junctions, will also limit exit of drugs once they enter. Uptake
systems to remove agents from the perilymph and either metabolize or transport agents to the systemic
circulation will be important. Plasma has enzymes, such as esterases, which are likely to be present in
perilymph as well and can alter the structure of drugs that enter the perilymph.
2.4 INNER EAR DRUG DELIVERY APPLICATIONS
Current applications for inner ear drug delivery are grouped into three main categories,
otoprotection, SSNHL, and AIED. The sensory cells of the cochlea must be protected from noise and
surgical trauma, ototoxic drugs such as cisplatin and aminoglycoside antibiotics, and head and neck
radiation. In addition, drugs are used to minimize or reverse hearing loss due to sudden events of
unknown nature and to immune reactions within the cochlea.
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Future application research is focused on maintenance of spiral ganglion cells after hearing loss,
and regeneration of hair cells. A variety of techniques including gene transfer and stem cell
transplantation are being explored.
2.4.1 Current applications
2.4.1.1 Noise induced hearing loss
Hearing loss is associated with both acute and chronic noise exposure. The overwhelming of the
natural antioxidant system by the formation of free radicals is a hypothesized cause of NIHL [47]. Many
types of steroids, antioxidants, and nerve and growth factors have been studied to protect the ear from
trauma or to minimize or reverse damage [48].
The effectiveness of steroids in reducing hearing loss due to noise has been inconclusive. In one
study, dexamethasone was administered intracochlearly manner using an osmotic pump, and the animal
was exposed to noise trauma on day four. A dose dependent reduction in outer hair cell loss was seen
seven days after exposure, and the highest dose tested, 100 ng/mL, resulted in less ABR shifts than
control [49]. Using a different methodology, Sendowski et al. directly infused methylprednisone for
seven days into the cochlea after exposing the guinea pig to impulse noise trauma. The steroid
accelerated the recovery of temporary hearing shifts during the period and reduced hair cell loss.
However, the drug did not limit permanent threshold shifts [50]. Both cyclosporine A and
immunosuppressant, FK506, delivered intraperitoneally immediately prior to sound exposure showed
decreased ABR threshold shift after both one and two weeks [51]. Steroids, if proven effective, may be
excellent candidates for local delivery as patients can experience significant side effects when given at
high doses systemically. High doses are likely necessary to achieve a therapeutic concentration within
the cochlea.
Other researchers have used antioxidants such as D-methionine and N-acetylcysteine to prevent
NIHL [52-54]. Caroverine, a glutamate antagonist and antioxidant, was delivered to counteract excess
glutamate and reactive oxygen species released during noise trauma. An osmotic pump was implanted
to deliver subcutaneously, and the guinea pig was pretreated for 48 hours prior to noise exposure. The
protective properties of the caroverine resulted in 5-10dB shifts after four weeks compared to 30dB
shifts seen in the controls [55].
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A variety of new therapies, such as growth factors and peptides, are being introduced to combat
the effects of NIHL. Insulin-like growth factor-1 (IGF-1) applied in a hydrogel to the RWM reduced ABR
shifts and outer hair cell loss at seven and thirty days post noise exposure [56]. Likewise, neurotrophic
factor-3 (NT-3) protected the inner ear from noise induced damage, but brain-derived neurotrophic
factor (BDNF) showed no protection [57]. Researchers attempting to inhibit the apoptotic cascade
initiated by noise trauma have met with promising results using AM-111 and D-JNKI-1 peptides, among
others [58-60]. Large and complex molecules such as peptides will likely require local delivery to the
inner ear as they may have difficulty in traversing the blood-cochlear barrier or may be quickly
inactivated by enzymes.
2.4.1.2 Cisplatin ototoxicity
Cisplatin, a chemotherapy agent commonly used in cancer treatment, is ototoxic, and
compounds such as antioxidants and platinum binders are being investigated for co-administration to
mitigate the hearing loss associated with cisplatin treatment [61, 62]. A study of the dose dependency
of cisplatin ototoxicity in guinea pigs revealed that a sudden drop in CAP of 40 dB occurred from one to
five days after cisplatin was administered, depending on dose, which varied from 3 to 300 Ipg/mL [63].
The drug resulted in loss of outer hair cells, especially in the basal turn of the cochlea. Cisplatin
generates reactive oxygen species by activating the NOX-3 enzyme, unique in the cochlea, and leads to
apoptosis of outer hair cells [64]. With damage occurring first at high frequency, some reports show
hearing thresholds elevated in 75-100% of patients taking cisplatin. Ototoxicity is both dose and age
dependent with elderly and children affected to a greater extent [61, 65].
Antioxidants, such as methionine, are useful in scavenging free radicals from the inner ear [66].
When delivered with cisplatin, hearing loss is reduced [67]. Unfortunately, a study where L-methionine
was delivered systemically with the cisplatin resulted in hearing protection but also made the cisplatin
ineffective [68]. Locally delivered, antioxidants may protect hair cells without inactivating the
chemotherapy treatment. Two studies have proven inconclusive, though. D-methionine was delivered
to the RWM via osmotic pump in combination with systemic cisplatin. Chemotherapy was given for five
days, and the D-methionine treated ears had better DPOAEs on days 3 and 4. The threshold shifts were
not significant by days 5 and 6 [69]. A different antioxidant, thiourea was also investigated by delivering
it directly through a cochleostomy via osmotic pump. Five days after starting thiourea, cisplatin was
started. The study resulted in less outer hair cell loss but threshold shifts were not affected [70].
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Thiols neutralize cisplatin since the sulfur has a high affinity for the platinum. However, sodium
thiosulfate (STS), if administered systemically, will inactivate the cisplatin and reduced its anti-tumor
activity [71]. In order to utilize the otoprotective aspects of STS, it must be contained within the inner
ear, making it an excellent candidate for local delivery. Wang, et al. used an osmotic pump for
intracochlear delivery and showed that six days after cisplatin the thiol protected 93% of inner and outer
hair cells [72]. Guinea pigs were treated with STS, half via osmotic pump in the middle ear and half via
daily injections into the middle ear. Cisplatin was started two days later, and both delivery methods
resulted in less hearing loss [73].
2.4.1.3 Aminoglycoside ototoxicity
Another possible application for inner ear drug delivery is in the prevention of aminoglycoside
antibiotic ototoxicity due to the generation of oxygen free radicals [74]. Some reports show the
incidence of hearing loss associated with these antibiotics is as high as 33% [61, 65]. There is a dose
dependent effect, and patients experience high frequency hearing loss due to the loss of outer hair cells
in the basal turn. Hypotheses that reactive oxygen species leading to apoptosis are involved have led to
testing protective agents such as antioxidants and iron chelators. The assumptions are that the
antioxidants scavenge free radicals, and the iron chelators bind iron in the cochlea so it cannot react
with aminoglycosides to generate reactive oxygen species [61, 65]. A study by Sergi et al. showed that
antioxidants delivered with gentamicin resulted in less hearing loss [67].
Steroids have also been tested for their otoprotective attributes during antibiotic treatment.
The intracochlear infusion of dexamethasone before and after kanamycin delivery protected hearing.
More outer hair cells survived, and shifts in ABR were decreased [75].
2.4.1.4 Radiation ototoxicity and trauma
Hearing loss due to head and neck radiation and intracochlear surgical trauma represents a
possible area that would benefit from local delivery of otoprotective agents. During radiation treatment
of head and neck tumors, the cochlea is often exposed. Hearing loss is dependent on both dose and
tumor site and can result in sudden or progressive hearing loss [76]. This side effect occurs in
approximately one third of patients and results from loss of hair cells, degeneration of the stria
vascularis, and loss of spiral ganglion cells [77]. Patients are commonly given steroids to reduce
inflammation, but local delivery would reduce the side effects associated with systemic steroid
treatment. Inflammation often results from inner ear surgical trauma, as well. The application of
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corticosteroid by syringe following cochleostomy enhanced the recovery of CAP thresholds over four
weeks [78].
2.4.1.5 Sudden sensorineural hearing loss
SSNHL is defined as the loss of more than 30 dB of hearing in three consecutive frequencies in
less than three days [79]. There are two hypothesized causes: viral infections and vascular events
resulting in a local decrease in blood flow [80]. Steroids have some effectiveness in treating SSNHL, and
the best indicators of treatment success are the severity of hearing loss and the time before treatment
is started [80].
This disorder is an excellent candidate for local delivery because the high systemic doses of
steroids needed for treatment cause significant side effects. The Microwick, a device for facilitating
diffusion through the RWM has been utilized as one method of local delivery [81, 82]. In a human study
of ten patients treated intratympanically, hearing improved in 80% of participants [83]. Often, patients
who have failed to tolerate systemic steroids or could not take them have been treated locally.
Dexamethasone or methylprednisone delivered intratympanically has shown varied success [84, 85].
Hearing improvement in 44% to 75% of patients has been reported [86-88].
Results of treatment have varied, and some studies point to a strong correlation between
success and time to commencing treatment [89]. A retrospective study of a single intratympanic
injection of dexamethasone showed no improvement if treatment began more than 36 days after SSNHL
onset. If begun sooner, 40% of patients show improvement [90]. Battista reported no significant
hearing recovery for 25 patients given dexamethasone intratympanically. The mean time until
treatment was 28 days, but there was evidence of improvement for those patients whose treatment
started within eleven days [91].
2.4.1.6 Autoimmune inner ear disease
AIED results in the loss of hearing when the immune regulation system is compromised [92].
Treatment results from high dose systemic steroids and locally delivered steroids have been inconclusive
[81, 93]. Encouraging results have been shown with methotrexate [94]. Ryan et al. suggested a
treatment of high dose prednisone with the addition of methotrexate if relapse occurred when the
steroid was tapered [8]. Improvements in treatment may be facilitated by local delivery for both SSNHL
and AIED.
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2.4.2 Horizon Applications
Hearing loss is associated with progressive degeneration of the cochlea, loss of the sensory hair
cells, and their associated neural connections. In the human, hair cells and neurons do not regenerate
spontaneously after they have been lost. Thus, clinical treatments to date have focused mainly on
functional improvement, such as cochlear implants. While cochlear implantation can provide sensory
function for individuals with impairment, the effectiveness of application inherently depends upon the
residual function of surviving sensory cells and neurons. As a first pass effort, the ability to preserve
existing sensory cells and their functions can be used to enhance therapeutic efficacy of cochlear
prostheses. However, with a better understanding of the inner ear cell cycle machinery, emphasis can
also be placed on discovering therapies for the regeneration of new sensory hair cells, and ultimately a
clinical treatment for restoring functional hearing. Ideally, concurrent advances in therapeutic
development and drug delivery technologies to the auditory system will be developed in order to realize
a clinically relevant treatment of progressive hearing loss.
2.4.2.1 Neurotrophin therapy
The loss of hair cells in hearing loss is followed by the degeneration of spiral ganglion cells. This
degeneration can be attributed to the loss of hair cell activity as well as survival factors, such as
neurotrophins. Neurotrophic factors have the ability to influence cell growth, differentiation, division,
and survival. Application of neurotrophic factors as a clinical therapeutic for hearing loss has been
limited due to their short half-life in vivo, as well as poor pharmacokinetics, proteolytic degradation, and
the potential side-effects of high-dose, systemic delivery. However, the advent of novel drug delivery
systems, as described below, has allowed for localized neurotrophin delivery to the inner ear and the
decrease in chances of non-specific and undesirable side-effects.
Neurotrophins can be delivered to the inner ear by direct injection or longer-term continuous
delivery by methods such as polymer release, cannula microinfusion systems, or osmotic pump [95].
Delivery of exogenous neurotrophic factors to the inner ear has been shown to preserve both hair cells
and SGN. The neurotrophic factors NT-3, glial cell-derived neurotrophic factor (GDNF), BDNF, and
fibroblast growth factor (FGF) have all been shown to protect hair cells from cell death in models of
ototoxicity [95-99]. Nerve growth factor, NT-3, BDNF, GDNF, and ciliary neurotrophic factor promote
SGN survival in numbers similar to pre-deafened states, individually and in combination [95, 100-102].
BDNF and NT-3, in particular, have been implicated as the principal neurotrophins involved in the
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neuronal development of the cochlea, and consequently, the in vivo survival and rescue of adult
auditory neurons [11]. More recently, it has been shown that rescue can occur even after delayed
neurotrophin delivery. Miller et al. [102] examined the effects of chronic infusion of BDNF and FGF
initiated 4 days, 3 weeks, and 6 weeks after de-afferentiation from deafening and found that
maintenance and regrowth of spiral ganglion cells could occur with delayed treatment out to 6 weeks.
However, relatively little is known about the longevity of effects after treatment is withdrawn. There is
evidence that SGN survival is maintained well after cessation of neurotrophin administration [103].
However, it has also been demonstrated that as early as 2 weeks after cessation of BDNF treatment, a
rapid decline in neuron survival could be seen in that the number surviving was not significantly
different from deafened, untreated cochleae [104, 105]. Furthermore, the rate of neuronal
degeneration after cessation of treatment was more rapid than in the deafened, untreated cochleae.
The exact mechanism behind loss of survival effects is unclear. It is thought that this accelerated
degeneration may be due to the loss of direct trophic support to the auditory neurons from BDNF, plus a
loss of endogenous survival factors from supporting cells that were also preserved by BDNF. It has also
been shown that BDNF increases nitric oxide synthase expression, leading to an increase in nitric oxide
production, which can initiate a neurotoxic cascade. Furthermore, the reaction of NO with superoxide
radicals associated with certain ototoxic agents leads to the formation of even stronger oxidative agent,
which accumulates and only elicits a response after BDNF withdrawal [104].
However, the effect of neurotrophins can be enhanced when administered in combination with
other forms of therapy, such as electrical stimulation. In vivo studies have demonstrated enhanced SGN
survival in deafened cochleae treated with concurrent exogenous neurotrophin delivery and electrical
stimulation [10, 106]. More importantly, continued chronic electrical stimulation after cessation of
neurotrophin delivery significantly reduced the rate of SGN loss, although this effect was localized to the
region of the cochlea proximal to the electrode array [105]. Therefore, a system which can provide
electrical simulation as well as concurrent delivery of antioxidants would be synergistic to continuous
exogenous neurotrophin treatment.
2.4.2.2 Gene Therapy
Gene therapy is the addition or transfer of a segment of genetic material into a cell that results
in expression of transgenic protein, and ultimately a change in the function or behavior of the cell.
Although the development of gene therapy for the human ear to date has been limited due to technical
and ethical issues, it still remains a promising technique for treating both genetic and acquired forms of
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hearing loss [107, 108]. In the inner ear, gene therapy is generally targeted at three main application
areas: the introduction of protective factors to enhance spiral ganglion and hair cell survival, the
regeneration of functional hair cells by transdifferentiation of supporting cells, and the treatment of
hereditary disease by insertion of a functional wild-type gene.
Local delivery to the inner ear of genes that can express therapeutic products is an alternative to
the delivery of exogenous molecules for spiral ganglion and hair cell protection and survival. Transfer of
BDNF [11, 109], GDNF [110, 111], or NT-3 [112] genes in the cochlea gave comparable outcomes to
conventional exogenous delivery of neurotrophic factors in terms of SGN and hair cell survival in the
injured inner ear. Gene therapy to deliver GDNF in conjunction with chronic electrical stimulation has
also been applied. Individually, both treatments exhibited significant rescue of SGN compared with
deafened controls, with GDNF being more effective than chronic electrical stimulation [10]. However, as
with exogenous neurotrophin delivery, combining treatments was significantly more effective than
either treatment alone. Aside from long term delivery of neurotrophins, gene therapy has also been
used to provide overexpression of antioxidants. Overexpression of catalase and manganese superoxide
dismutase was able to protect hair cells and hearing thresholds in a guinea pig aminoglycoside
ototoxicity model [113]. The overexpression of antioxidant genes may prove beneficial in protecting the
cochlea against oxidative stress due to other forms of ototoxicity, such as noise, as well as aging.
Because the mature cochlear sensory epithelium has only sensory hair cells and non-sensory
supporting cells, regeneration in the inner ear sensory epithelium must depend on the
transdifferentiation of one cell type to another. Many of the genes and factors which determine cell
fate in the inner ear have been identified. By re-expressing these developmental genes in the injured
tissue, supporting cells could potentially be forced into a hair cell phenotype. One such gene is Atohl
(also known as Mathl, or the human homolog Hathl). Atohl is a basic helix-loop-helix transcription
factor which is necessary to induce cell differentiation in the epithelial ridge of the developing organ of
Corti. Atohl has also been shown to be successful in transdifferentiation of supporting cells into new
hair cells in the deafened adult guinea pig by demonstration of increased hair cell counts and lower
thresholds on ABR relative to untreated, deafened controls [114, 115].
Genes whose dysfunction or mutation is associated with hearing loss are also possible targets
for inner ear gene therapy. Advances in molecular biology and genetics have enabled the identification
of over 75 different genes contributing to hereditary hearing loss; each of these is a potential target for
gene therapy [116, 117]. The largest proportion of hereditary sensorineural hearing loss cases are due to
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mutations in the GJB2 gene, which encodes the gap junction channel protein connexin 26 (cx26).
Connexins are transmembrane proteins that assemble to form the gap junction channel of a cell, which
in turn regulates intracellular signaling. In the inner ear, cx26 is widely expressed throughout non-
sensory epithelial and connective tissue cells, allowing these cells to communicate in regulating fluid and
ion balance. Potassium ions are transported by gap junctions to maintain high levels of the
endocochlear potential for hair cell excitation [118, 119]. Alterations in cx26 cause a disturbance in
potassium homeostasis by preventing potassium ions from being recycled by the hair cells back to the
endolymph, ultimately leading to hair cell death by potassium intoxication. However, because GJB2
knockout mice are embryonic-lethal, the pathogenesis of deafness due to mutations of this gene has
been difficult to examine. Therefore, several groups are working towards viable mouse models to study
the pathological role of GJB2 [118, 120, 121]. Relevant mouse models for studying abnormalities of
GJB2 in the pathogenesis of deafness will be needed before clinical applications of gene therapy can be
considered for such cases of hereditary hearing loss.
The final common pathway in any case, acquired or genetic hearing loss, and inner ear
dysfunction, is hair cell injury and loss. By targeting hair cells, supporting cells, or neurons, gene therapy
can be used to change cellular phenotype for preservation, rescue, and even regeneration of hair cells.
The various cell types of the inner ear can be selectively transfected by viral vectors, including
adenovirus, adeno-associated virus, herpes simplex virus, vaccinia virus, lentivirus, and nonviral cationic
liposomes. However, cytotoxicity and short-term expression of gene products remain problematic.
Reviews regarding the practicality of utilizing these transfer agents can be found in the literature [117,
122, 123].
The ear itself is considered a particularly attractive target organ for the study and potential
application of gene therapy. The bony housing of the sensory epithelium isolates the organ system,
thereby limiting unwanted systemic diffusion of transfer agents. However, delivery of vectors into the
inner ear requires increasingly sophisticated methods of delivery. Although liposomes and some viral
vectors can follow pathways for small molecules, such as diffusion across the RWM, most vectors
cannot. Therefore, efforts in delivery of transfer agents have focused on delivery to the basal turn of
the cochlea through a cochleostomy, or by injection directly through the RWM. Vector delivery can also
be achieved by accessing the inner ear through the stapes footplate or the semicircular canal [123].
However, similar to the delivery of other therapeutic agents to the inner ear, diffusion of vectors
through the cochlea shows a gradient of transfection with the greatest at the site of injection.
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Therefore, one important consideration in moving towards clinical applications will be determining a
method to provide the uniform distribution of transfer throughout the entire cochlea. Another
consideration will be the duration of expression of the transgene. Currently, expression is often short-
lived, lasting only days to months. A method of delivery which ensures continued expression of the
therapeutic gene over an extended period of time will also be crucial in the successful applications of
gene therapy.
2.4.2.3 RNA Interference
In certain situations, it is desirable to decrease or eliminate the expression and function of a
particular gene. Studies on mouse cochleae have shown that a large number of negative cell growth
genes are upregulated in later development, including cyclin-dependant kinase inhibitors (p27kipl and
pl9inkd) [124] and tumor suppressor genes (pRb) [125]. Their expression coincides with cell cycle exit,
as well as establishment and maintenance of the quiescent status of cochlear sensory epithelia. Certain
genes may also be upregulated as a result of injury. For example, ototoxic insult from aminoglycosides,
cisplatin, and noise can all lead to a common cascade of cell death genes leading to cell cycle arrest and
apoptosis. Potential targets in this cascade include caspases, the Bcl-2 family of proteins, p53, and the
c-jun NH2-terminal kinases [126].
The effects of these genes have been well characterized by creating null cells in culture and in
knockout animal models. Targeted inhibition of gene expression can be carried out utilizing homologous
recombination, antisense vectors, ribozymes, and DNAzymes. However, recently, a new method of
gene manipulation known as RNA interference (RNAi) has shown to be a promising therapeutic
approach in shutting off gene expression. RNAi is a method used to silence gene expression post-
transcriptionally through the introduction of double stranded RNA. The double stranded RNA induces
the sequence-specific degradation of complementary messenger RNA. RNAi provides a rapid means to
assess the loss of gene. However, double stranded RNA longer than 30 base pairs provokes the
antiviral/interferon pathway in mammals and results in the global shutdown of protein synthesis.
Therefore, the use of RNAi as a clinical therapy did not become apparent until the advent of chemically
synthesized small interfering RNAs (siRNAs) of 21-22 nucleotides, which could be used to target
mammalian genes by RNAi while evading the interferon response [127, 128].
In order to realize RNAi as a therapeutic modality for gene silencing, several obstacles need to
be addressed. SiRNAs are relatively small and are rapidly excreted when administered through the
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blood stream. They are also relatively unstable in a serum environment with a half-life of approximately
0.8 hours, and can be degraded by RNase activity within a short window of time [129]. As with other
molecules, when administered systemically, a nonspecific distribution occurs, which in turn decreases
the local concentration at the site of action. Even at the target site, cellular uptake requires efficient
endocytosis of the double stranded siRNA. The duration of siRNA effects is also limited, lasting only 3-5
days in rapidly proliferating cells and up to three weeks in non-dividing cells [129]. To increase stability,
techniques to chemically modify siRNA oligonucleotides are being explored including changes in
backbone structure, replacement of nucleotides with analogs, and addition of conjugates. Both viral
and non-viral carrier systems are also being examined as a means to efficiently transfect cells.
However, the development of systems for local delivery will be highly dependent on the accessibility of
the target tissue.
Several siRNA-based drug candidates are in pre-clinical commercial development for
applications in the inner ear, and recently, lipocomplexed siRNA has been effectively delivered intact by
Gelfoam to the RWM in rats with successful silencing in the cochlea [130]. Also, siRNA complexes
perfused directly to the scala media of the guinea pig have shown uptake in strial cells along the length
of the cochlea [131]. However, before a clinical development program can be initiated for siRNA in the
inner ear, basic information such as residence time of siRNA in the inner ear cells and duration of
therapeutic effect will need to be examined. With long-term expression of siRNAs, RNAi may become a
potential therapeutic strategy to preserve hearing.
2.4.2.4 Cell-Based Therapy
Recent advances have also made possible the potential for cell-based approaches to preserve
hearing as well as for regeneration [122, 132, 133]. Cells have been transplanted to the inner ear as an
answer to the need for long term stable delivery of neurotrophins, which is not possible with current
methods of exogenous neurotrophin delivery and gene transfection. Fibroblasts transduced with BDNF
transgene have been encapsulated in a matrix of agarose and delivered via a modified electrode through
a cochleostomy site [134]. These cells were shown to express transgene and secrete BDNF in vivo. The
BDNF-excreting electrodes were also able to preserve significantly more spiral ganglion cells than
control electrodes, though this effect decreased with distance from the basal turn. Although, this
approach combines the electrode stimulation with a possible method for long term growth factor
delivery, a method would need to be set in place to ensure that these transplanted cells would not
proliferate, invade or obliterate the cochlea. Another cell-based method for neurotrophin delivery is the
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transplantation of neural stem cells [135]. Neural stem cells injected by infusion pump into the lateral
semicircular canal were found attached to the cochlea in every turn after 28 days. Most of these cells
expressed markers for glial cells and were positive for GDNF, while approximately 50% of the cells were
positive for BDNF. If injected at the time of cochlear implant surgery, the spontaneous production of
neurotrophin by these transplant cells could provide an effective mechanism for spiral ganglion
preservation.
Although these neural stem cells are able to survive in the inner ear environment, they have not
been found to migrate into the sensory epithelium in normal ears, but have had limited success in
migration and transdifferention into hair cells in ears subjected to traumatic injury. Parker et al. [136]
found that neuronal stem cells from a clonal cell line were able to migrate as well as receive signals from
the microenvironment to upregulate genetic cell fate programs expressed by local endogenous cells -
either neural, glial, hair cell or supporting cell types. Therefore, though the inner ear cannot regenerate
sensory cells from its own endogenous population, it is still able to influence stem cell differentiation
among particular cochlear phenotypes.
The cell type with the greatest capacity for differentiation into multiple cell types is the
pluripotent embryonic stem cell. Survival of embryonic stem cells in the inner ear after transplantation
has been well documented, and migration can occur in the auditory nerve fibers of the rat cochlea [137-
140]. However, undifferentiated cells grafted into the inner ear also showed no potential to
differentiate into hair cell phenotype [140]. Embryonic stem cells can, however, be directed by applying
cues such as in normal development. It has been shown that, from embryonic stem cells, it is possible to
enrich a population of inner ear progenitor cells which express marker genes that define the developing
inner ear by culture in the presence of endothelial growth factor and IGF-1 [141]. Injection of these
cells into chick embryonic ear resulted in integration into cochlear sensory epithelia and a hair cell
phenotype. Recently it has been shown that endogenous stem cells exist and can be isolated from the
adult ear and expanded as neurospheres in vitro in the presence of mitogenic factors to obtain sufficient
numbers of cells for transplantation [142, 143]. Injection of these inner ear progenitor cells into the
chick inner ear resulted in similar results to the injection of embryonic stem cell derived progenitors in
terms of survival, integration, and differentiation into hair cells.
Another option for cell regeneration is bone-marrow derived cells, which can be obtained from
the recipient patient, enabling autologous transplant [144, 145]. When introduced into the chinchilla
inner ear without selection for inner ear progenitors, the cells showed the upregulation of neural and
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glial markers [145]. However, the number is limited, and a method to induce neuronal differentiation
would be needed in order to induce regeneration of SGN from transplants.
Stem cell therapy is a promising step in the regeneration of sensory cells in the inner ear and the
restoration of hearing. However, it is difficult to predict how this technology can be translated into
clinical practice. Functional restoration will depend not only on the introduction of new cells, but also
differentiation of cells to the correct phenotype, and the formation of appropriate three-dimensional
tissue structures. This will rely heavily on the ability to control the local microenvironment of the cells
once transplanted. The derived cells and tissues will also need to be mechanically and structurally
compliant with the native tissue, and able to integrate into the host without immunological rejection.
Before stem cells can be considered for therapeutic applications, these issues of sustainability and
functionality must be addressed. In this relatively young field, it is currently unclear what environment
is needed to induce functional cells and tissues of the inner ear. It is possible that a treatment for
hearing loss does not exist in any one therapy, and the ability to restore hearing will ultimately rely on
an intricate combination of drug treatment, gene manipulation, as well as transplantation in conjunction
with implanted devices, such as integrated delivery systems and cochlear prostheses.
2.5 INNER EAR DRUG DELIVERY METHODS
Inner ear drug delivery methods can be divided into two main categories based on the location
of entry of the drug. Intratympanic delivery involves depositing the therapeutic agent in the middle ear,
relying primarily on diffusion through the RWM for access to the scala tympani. The second method,
intracochlear, depends on a cochleostomy with direct delivery into the inner ear space, completely
bypasses the middle ear.
Intratympanic delivery must rely solely on diffusion through the round window and for
dispersion throughout the scala tympani. Therefore, access to the apical regions of the scala tympani
can be limited, and large concentration gradients may develop. Also, the RWM presents a physical
barrier to delivery. A great deal of variability of condition and thickness of the membrane across
population has been observed [146, 147], limiting dosage control from patient to patient. Alzamil
reports, for example, round window niche obstruction in a third of human ears [148]. Also, due to the
anatomy of the round window, substances may be more or less likely to transverse the membrane
based on size and constitution [45, 149]. Because it is applied in the middle ear, drug can be lost
through the Eustachian tube, which leads from the middle ear to the pharynx. These factors, along with
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the inability to control specific delivery parameters, combine for a lack of precise control of dosage in
intratympanic delivery. This method of delivery does offer less opportunity for surgical trauma or
damage than the intracochlear method, and the middle ear is relatively easy to access. Many of these
implantation procedures do not require general anesthesia.
Intracochlear delivery provides direct access to neural and sensory cells and does not necessarily
rely solely on diffusion for drug distribution. Fluid flow may augment diffusion which could provide
access to more apical regions of the cochlea. Because drug is deposited directly into the perilymph, the
types of molecules and/or particles are not limited by RWM transit. While dosage may be precisely
controlled, a greater possibility of surgical trauma exists. Additionally, indwelling devices are at risk of
biofouling due to tissue growth and protein build-up in the scala tympani.
Both intratympanic and intracochlear delivery offer opportunities for inner ear drug delivery and
can be utilized as required for optimal delivery parameters.
2.5.1 Intratympanic drug delivery
For intratympanic delivery, multiple passive and active drug delivery approaches are being
explored, with applications ranging from protection from NIHL to delivery of regenerative compounds
aimed at arresting sensorineural hearing loss. This research is often aimed at establishing extended
release profiles with controllable and predictable kinetics using compounds within the middle ear. In
the following, examples of passive drug delivery to the cochlea will be described for several principal
approaches: biodegradable polymers, hydrogel-based systems, and nanoparticles. In addition, examples
of active intratympanic delivery are described using a variety of components and devices, including
microcatheters, microwicks, and osmotic pumps. Here, we define active as any device used for
intratympanic dosing of therapeutics, although in some cases, these devices by themselves do not
provide a mechanism for changing dosing.
2.5.1.1 Passive intratympanic delivery
Passive drug delivery systems are designed to deliver drug compounds with specific kinetic
profiles using local triggers for release, such as hydrolysis in the in vivo environment, or in response to
local stimuli such as temperature or pH. Drug may be dispersed within a matrix or contained within a
reservoir encapsulated by a shell of bulk polymer, depending upon the specific application.
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2.5.1.1.1 Biodegradable polymer intratympanic delivery
Early biodegradable polymer drug delivery systems, developed for a wide range of therapeutic
applications, were based upon poly (lactic) co-glycolic acid (PLGA), and this approach has also been
employed for the inner ear. Biodegradable polymer delivery has been successfully employed for a
number of clinical applications, including implantation of wafers to treat glioblastoma multiforme, depot
systems for contraception and treatments for endometriosis or estrogen replacement therapy, and
inserts for patients with glaucoma. Biodegradable polymer devices for delivery may take the form of
degradable microparticles or nanoparticles, hydrogels or larger microfabricated structures with specific
release profiles.
Sustained release structures based on siloxane have been investigated as fast- and slow-release
vehicles for delivery of compounds of interest for inner ear disease therapies and tinnitus. Release rates
for devices on the order of 1 mm in dimension ranged from 15 - 50 Ig/day, and were filled with
glucocorticoid or beclomethasone and placed on the RWM to study effects on hearing over the 28 day
duration of the guinea pig studies. Monitoring of auditory function via ABR, assays of perilymph
following delivery, and histology were all conducted. Histology appeared normal in the guinea pig
cochleae, and assays demonstrated the presence of beclomethasone in the perilymph of the scala
tympani of virtually all implanted animals. Auditory function over a range of frequencies from 3 - 12
kHz was altered as monitored by ABR thresholds, and by day 28 there were significant differences in
hearing for all but the placebo groups [150].
The specific nature of the biodegradable polymer delivery vehicle can determine whether
efficacious therapy is achieved, such as in the targeting of SGN [95]. Meniere's disease patients have
been treated using a biodegradable gelatin polymer matrix known as Gelfoam, with high success rates
for elimination of vertigo and tinnitus following gentamicin-soaked Gelfoam material placement on the
RWM [151]. When Gelfoam was applied in an animal model as a means to reverse hearing loss and
promote SGN survival in deafened guinea pigs, however, there was no evidence of enhanced response.
Specifically, SGN survival was not observed when neurotrophin-soaked Gelfoam was administered to
deafened guinea pigs, in spite of the fact that radiolabeling confirmed that release of the drug was
sustained. When alginate polymer was substituted for Gelfoam, SGN survival was maintained in the
implanted ear, suggesting that the kinetics and maintenance of drug concentration is dependent upon
the specific polymer chemistry and degradation characteristics of the delivery vehicle [152].
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2.5.1.1.2 Hydrogel-based intratympanic delivery
Hydrogel-based delivery for therapeutic applications can enable precise targeting of tissues and
organs through the use of triggering mechanisms. These triggers may be chemical, including pH or other
ionic factors or the presence of specific molecular species, or may be physical, such as temperature,
pressure or electrical potential. Triggering will cause the hydrogel to swell and release its payload of
drug in a controlled fashion. Many of the investigations of hydrogel-based delivery for treatment of
inner ear diseases have employed biodegradable hydrogels, often with a hyaluronic acid-based
chemistry. In one such study, a rescue agent was delivered locally onto the RWM following impulse
noise trauma. The JNK inhibitor AM-111 was prepared in a hyaluronic acid gel formulation and applied
to the RWM in a chinchilla, following exposure to acute acoustic trauma. The gel-based delivery
approach was observed to provide significant and rapid recovery from the original insult, presumably
due to fast degradation of the gel and subsequent transport of the drug across the RWM and into the
cochlea [58].
Cochlear protection from NIHL has also been investigated using IGF. In one study, recombinant
human insulin-like growth factor -1 (rhlGF-1) was loaded into a biodegradable hydrogel produced by
glutaraldehyde cross-linking of collagen, and delivered by placement on the RWM. Auditory response
was monitored using ABR measurements following noise exposure, and immunostaining was conducted
to monitor outer hair cell degeneration. These evaluations concluded that significant protective benefit
to the outer hair cells was conferred by the biodegradable hydrogel treatment with rhlGF-1 [56].
In another set of studies, BDNF was delivered to assess protection of auditory neurons, using
the same biodegradable hydrogel carrier. Concentrations of BDNF in the perilymph were seen to be
much higher in the cochleae of guinea pigs from the hydrogel group than in either control animals or a
group that received an injection through the RWM. Analysis using ELISA confirmed sustained delivery of
growth factor for periods of 7 days after placement of the hydrogel on the RWM [153-155].
2.5.1.1.3 Nanoparticle delivery
Nanoparticle delivery to the inner ear has emerged as a promising new avenue for delivering
compounds to the cochlea in a sustained and controllable manner. The nanoparticles may be comprised
of biodegradable or nondegradable materials, depending upon the application and the desired
pharmacokinetic profile. In one study, Tamura et al. [156] encapsulated traceable fluorescent dye into
PLGA nanoparticles and compared delivery profiles with transport of the unencapsulated rhodamine
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molecule in a guinea pig model. Nanoparticles with diameter of roughly 150 nm were prepared using a
50/50 ratio of lactic / glycolic acid and with rhodamine B contained within the matrix. For both systemic
application and placement on the RWM, nanoparticles containing rhodamine B produced significant
levels of rhodamine in the cochlea, as assessed by counting of fluorescent particles. The presence of
rhodamine was not observed in the cochlea following either systemic application or RWM placement of
the free molecule.
Nanoparticles have been investigated as an alternative to viral vector systems, which have
shown promise for treatment of inner ear diseases but carry concerns about safety as well as precision
of targeting of specific cells and tissues [157]. As a model system, Praetorius and co-workers delivered
silica nanoparticles labeled with the fluorescent cyanine dye, Cy3, to the cochlea by placement on the
RWM of mice. The silica particles had a diameter of 20 nm and their transport was observed via
immunohistochemistry and histology, accompanied by ABR testing to ensure that hearing thresholds
were not altered. No evidence of cytotoxicity was observed, and silica nanoparticles were observed in
inner hair cells, vestibular hair cells and in the spiral ganglia. An interesting observation stemming from
this work was the occurrence of retrograde axonal transport [157].
In another study, PLGA nanoparticles were prepared with a uniform dispersion of
superparamagnetic iron oxide nanoparticles within the PLGA matrix and delivered in a chinchilla. The
PLGA nanoparticles ranged from 100 - 300 nm in diameter, while the embedded magnetic materials
were in the 5 - 15 nm range. Nanoparticles were placed upon the RWM for duration of 40 minutes.
Either with or without magnetic field exposure, magnetite and PLGA-coated nanoparticles were
observed throughout all turns of the cochlea, within the perilymph and within the inner and outer hair
cells, as well as in the stria vascularis and the spiral ligament [158]. It is well known that low molecular
weight compounds such as gentamicin can cross the RWM quite readily [44], either through tight
junctions or via an intracellular pathway. The application of magnetic fields and modulation of
degradation profiles of the PLGA can provide additional levels of control over long-term drug delivery to
the inner ear structures.
Liposomes represent another particle-based mode for delivery to the inner ear, and these
vehicles have been explored as a means for gene therapy. Cationic liposomes can be mixed with DNA
for transfection of numerous cell types, and introduced into the cochlea via microinjection. In one such
study, Wareing et al. [159] reported that 14 days of transgene expression was observed with an absence
of toxicity or inflammatory response. Guinea pigs were treated with either injection or an osmotic
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pump delivery of cationic liposomes containing DNA complexes, and tissue sections were evaluated
using immunohistochemistry and PCR analysis. From the base to the apex, beta-galactosidase was
observed in virtually all tissue types, with highest concentrations in the spiral ligament; PCR-based
assays confirmed these observations. Persistence of the transgene expression for two weeks was
observed for both microinjection and osmotic pump infusion; however the osmotic pump delivery was
associated with local trauma and inflammatory responses [159]. This suggests that liposome delivery is
a viable approach for intratympanic delivery but that the means to transport the liposomes to the
cochlea is a critical element of the strategy.
2.5.1.2 Active intratympanic drug delivery
Active intratympanic drug delivery was explored at least as early as the 1950's for streptomycin
ablation treatment of vertigo associated with Meniere's disease [160]. This study showed that vestibular
function could be attenuated, but a majority of test cases lost all cochlear function. It appears that
interest in intratympanic drug delivery did not substantially accelerate until the 1990's, although there
were earlier large-scale efforts underway, e.g. Sakata's study of dexamethasone treatment for tinnitus
[161]. Intratympanic delivery is now the most frequently used first-line treatment for the vertigo of
Meniere's disease [82]. The methods for and uses of intratympanic drug delivery are sufficiently
numerous that review articles have been dedicated to the topic [43, 79, 82, 162]. Treatments have
expanded beyond those initially performed for vertigo, and now include perfusion methods to treat
SSNHL, AIED, tinnitus, and the hearing loss associated with Meniere's Disease. The compounds tested
are numerous and include aminoglycosides, corticosteroids, glutamate receptor antagonists, protease
inhibitors, antioxidants, and neurotrophins [95, 163]. The specific methods for intratympanic infusion
are varied. Direct infusion via syringe was successfully used to treat patients 3-5 times per day in a study
where gentamicin resolved vertigo in Meniere's Disease as long as 25 years after therapy started in
greater than 90% of cases [164]. The residence time of drugs delivered by this method of direct infusion
can be increased by placing Gelfoam [162], fibrin glue [165], or other compounds at the round window,
thereby increasing the likelihood of sustained diffusion into the cochlea across the membrane. Device
development efforts have focused on at least two goals: the ability to improve the likelihood of
delivering compound directly to the round window niche and the capability for either continuous or
multi-dose drug administration, in some cases self-administered. Concentration of drug delivered and
residence time at the niche site are affected not only by the exact placement of the infusion line but also
by residual fluid in the middle ear and the patency of the Eustachian tube. Numerous devices which can
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be used for sustained release or multi-dose delivery have been developed in attempts to overcome the
shortcomings of direct transtympanic injection. These include the Silverstein MicroWick (Micromedics,
Eaton, MN), the Round Window Microcatheter or pCath TM (Durect Corp. Cupertino, CA) in conjunction
with an electronically controlled pump, the Alzet osmotic pump (Durect Corp. Cupertino, CA) and other
devices still in earlier stages of development. While these devices are sufficiently promising to warrant
further study and development, the clinical results achieved by intratympanic delivery have to date been
mixed. Despite demonstrations that higher concentrations of medication can be delivered to the
cochlea, and that side effects are either completely alleviated or dramatically reduced as compared with
systemic delivery methods [166], there are still major impediments to controlled, repeatable
intratympanic drug delivery. As described earlier, anatomical variations can significantly alter the
pathway from the delivery site to the round window. These include extraneous or false membranes,
fibrous tissue and fatty plugs, and may be present in as high as one third of all patients [167]. In
addition, there is a need for better characterization of pharmacokinetics in both the inner and middle
ear. While substantial progress has been made on this front, particularly by Salt and Plontke [168-170],
the inability to define consistent and accurate methods (or the lack of broad acceptance of such
methods) for withdrawal and analysis of fluid samples taken from the inner ear during preclinical animal
studies substantially impedes progress [43]. Certainly most reported clinical results do not include
measurements of drug concentration at the round window or other quantities like middle ear fluid
clearance rate that might be used to infer an approximate concentration. Even in preclinical animal
experiments, measurement of cochlear concentrations is difficult. The need for continued development
of improved methods for quantifying drug concentration in both the middle and inner ear is clear.
Combined approaches, for example Hashimoto's combination of hearing test and subsequent
morphologic examination of hair cell death [171] appear promising. Ultimately it appears as though
wide acceptance of a particular device or method may require the development of measurement
techniques that provide data which permits evaluation of drug delivery and treatment outcome against
a pharmacokinetic model.
2.5.1.2.1 Round Window Microcatheter
The Round Window Microcatheters (p-Cath TM and e-Cath TM ) were developed by IntraEAR and
later acquired by Durect in 1999. While they have been used for a wide variety of applications in both
human and animal studies, Durect discontinued sales of these devices in September 2003 due to a
change in business focus (2003 Form 10-K SEC filing) and subsequently entered into a licensing
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agreement with Neurosystec in the area of local drug delivery to the middle or inner ear for tinnitus
(2004 Form 10-Q Ex.-10.39 SEC filing). The i-Cath TM has two lumens, one for infusion and one for fluid
withdrawal, and the e-Cath TM has a third lumen with electrode for monitoring ear signals. The
microcatheter has a bulbous tip of 1.5, 2.0 or 2.5 mm diameter. General anesthesia is typically required
to produce a tympanomeatal flap through which the round window niche is exposed. The tip of the
catheter system is compressible and is designed specifically to lock in place in the round window bony
niche. In theory, a variety of pumping methods can be used to infuse the catheter, but frequently
pumps developed for wearable insulin dispensing (e.g. Disetronics pumps from Roche) are used because
their size provides the portability required for extended treatment protocols [85]. As described earlier,
anatomical variation can produce variability in the quantity of drug actually delivered to the cochlea. At
least one effort has been made to formalize the surgical procedure for Microcatheter implantation,
advise the use of a transtympanic endoscope, and identify likely complications [146, 172].
Human treatment studies are numerous and with varied results. As an example, Seidman
reported preliminary data from a nine patient study using gentamicin for vertigo, methylprednisolone
for SSNHL, papaverine and methylprednisolone for mild labyrinthitis and the glutamate antagonist
magnesium sulfate for tinnitus [163, 173]. Improvements in vertigo, hearing and tinnitus were recorded
for a majority of the patients. Methylprednisolone steroid infusion for 8-10 days was used to treat six
patients with SSNHL, with measurable hearing improvement achieved in all patients [174].
Numerous animal studies have also been performed in an effort to understand
pharmacokinetics using this delivery method. Two radioactively labeled antioxidants (D-methionine and
thiourea) were administered for 1 hr in rat ears and elimination half-lives in the cochlea were found to
be less than 1 hr for both compounds [175]. Ototoxic kanamycin was used in guinea pigs with differing
concentration and delivery time intervals [171]. Outer hair cell disappearance rates were quantified as a
function of position through the basal and second turn of the cochlea. As expected, large outer hair cell
disappearance rates correlated with high delivery concentrations and longer delivery intervals, and
much lower total quantities of compound were required to achieve a specific level of outer hair cell
disappearance as compared to systemic delivery.
2.5.1.2.2 Silverstein MicroWick TM
The primary use for the MicroWick in humans since its first description [176] has been the
treatment of Meniere's related vertigo by perfusion of gentamicin. The polyvinyl acetate wick (1 mm
Erin E. Leary Swan 451Page
diameter by 9 mm length) absorbs medication administered external to the ear and transports it directly
to the RWM. The wick is inserted through a ventilation tube which passes through the ear drum via
myringotomy or laser tympanostomy. The insertion procedure requires only local anesthesia and a
noncertified office surgery room. Patients are able to self-administer medication, and hearing and
vestibular functional tests are used for appropriate medication titration and therapy discontinuation. A
typical administration protocol requires three fifteen minute sessions per day using from 5 to 10 mg/ml
gentamicin for one to three weeks. The MicroWick has also been used to administer dexamethasone
for the treatment of SSNHL and AIED [176, 177]. While quantitative studies of drug concentration in the
cochlea have not been published to our knowledge, therapeutic effect has been shown [82].
Complications include the removal of middle ear plugs or extraneous membranes prior to wick insertion,
extrusion of the vent tube, and the administration of topical antibiotics (in the case of steroid infusion).
Finally, the MicroWick has also been implemented as a delivery tool in numerous animal studies aimed
at understanding pharmacokinetics. Chinchilla ears were perfused with gentamicin (10 mg/ml) to
characterize hearing loss over time [178]. However, we know of no reported quantification of the
MicroWick's effective delivery rate of drug as a function of time.
2.5.1.2.3 Preclinical Alzet osmotic pump
The implantable Alzet osmotic pump provides the means for continuous sustained delivery in a
very small volume with simple form factor. This preclinical device was developed by ALZA Corporation
and is now commercially available through Durect Corporation. The pump has reservoir volumes of 100
IL, 200 IlL or 2 mL and flow rates ranging from 0.11 to 10 IL/hr. The device can be configured with a
microcatheter or other infusion cannula and implanted in small animals such as guinea pigs and other
rodents. Typically, access to the RWM occurs through a drilled hole in the bulla, and the pump is
implanted subcutaneously [16]. Depending on the model, these pumps provide continuous infusion
ranging from 1 day to 6 weeks; however, they provide no capability to change delivery rates in situ. The
pump operates with a semi-permeable outer membrane surrounding an osmotic driving agent. Within
the agent compartment, an impermeable reservoir holds the drug. As water flows into the
compartment holding the osmotic agent, pressure is exerted on the flexible drug reservoir, and the drug
is forced out through the delivery port [179]. These systems have been widely used for middle and
inner ear drug delivery as described in Section 4.
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2.5.1.2.4 Other systems
A miniaturized fully-implanted device for discontinuous drug delivery has been evaluated for
animals. The Totally Implantable Drug Delivery System (TI-DDS®) is implanted subcutaneously and
dispenses 5 to 10 pL of fluid via push button and can be refilled transcutaneously [180, 181]. We have
not found publicized descriptions dated later than 2001 and are thus unclear on the status of
development of this promising device.
2.5.2 Intracochlear drug delivery
A second local delivery approach for the inner ear is intracochlear delivery. A variety of tools
including syringes, osmotic pumps, and other newer devices have been employed. Access is created via
a cochleostomy through the RWM or directly through the otic capsule.
2.5.2.1 Syringe delivery
A simple method of delivering therapeutics directly into the inner ear is with a syringe. Direct
injections and perfusions have been used in the clinical setting as well as in research. They allow for
study of pharmaceutical effects without the added complications of more advanced delivery systems.
However, direct injections do not allow for prolonged delivery.
Currently the only clinical use of direct intracochlear injection is in conjunction with cochlear
prosthesis implantation. Cochlear prosthesis implantation has been show to elicit an inflammatory
response. As reported by De Ceulaer et al., at the time of prosthesis insertion, a single dose of steroid
was placed in the cochlea with a syringe. The treatment resulted in reduced reactive fibrosis that is
usually caused by tissue insult. In general, fibrosis leads to increased impedance of the electrode which
decreases electrode performance. The steroid injection was done to maintain optimal performance of
the implant through reduced tissue growth [182]. Similarly, a direct injection of triamcinolone
immediately prior to insertion of the electrode array reduced electrode impedance for 5-10 days post-
surgery. The improvement was more pronounced at basal contacts than apical contacts showing an
uneven distribution of steroid along the scala tympani [183].
2.5.2.2 Direct injection
Direct injection is a useful tool for researchers to study the effects of novel therapies for the
inner ear [184, 185]. Stover et al. tested the use of adenovirus for gene transfer of reporter gene
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though both the round window and cochleostomy. The round window was injected with a 5 pL bolus
using a 30 gauge needle, and a cannula was sealed in the cochleostomy to facilitate delivery. The
cochleostomy delivery route resulted in better distribution throughout the cochlea and a higher degree
of transfection [186]. Similarly, liposomes with plasmid DNA were injected via the RWM to test them as
alternatives to viral vectors. Gene expression persisted for 14 days without evidence of inflammation
[159]. Other work has been done to deliver agents to reduce damage in the inner ear, such as D-JNKI-1
to block the apoptotic cascade or glutamate antagonists to block firing of inner hair cell afferents [185,
187].
2.5.2.3 Syringe pump delivery
A variation on the direct injection method involves sealing a cannula into the cochlea and
employing a syringe pump for drug infusion, usually with an outlet hole placed in the apex [188]. While
the pump allows for continued delivery and can be easily programmed for constant infusion, it can only
be used for acute animal experiments while the subject remains under anesthesia. In developing a
surgical technique for delivery to the mouse cochlea, a syringe pump was used to deliver agents to
confirm maintenance of hearing during surgery [189]. Also useful in pharmacokinetic studies, ions and
microspheres can be delivered for tissue labeling and concentration studies [190, 191].
2.5.2.4 Osmotic pump delivery
Initial tests were used to show the effectiveness and safety of delivery by osmotic pump. The
device delivered the toxin, TTX, for three days [16], and later experiments improved on cannula
materials and sealing [192]. Carvalho et al. used the pump to deliver artificial perilymph to show the
effect of cochleostomy and infusion on hearing. ABR was tested at 3 and 7 days after implantation, and
results showed some threshold shifts at high frequency while low frequency hearing was preserved
[193].
The osmotic pump has proven useful in testing a variety of compounds for many applications
including otoprotection and neural preservation, as it offers a controlled delivery profile and proven
surgical technique. Steroids have been administered at the time of cochlear prosthesis implantation to
protect the cochlea from electrode insertion trauma [194] and at the time of ototoxic antibiotic
exposure to prevent hair cell death [75].
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Osmotic pumps were employed to test the effectiveness of steroid treatment to prevent hearing
loss from noise trauma. The devices allowed for a dosage study of pre- and post-treatment with
dexamethasone for noise exposure, and histology showed less hair cell loss than in untreated cochleae
[49]. A similar study showed that 7 day infusion of steroid following impulse noise trauma resulted in no
significant threshold difference after 14 days [50].
In order to study the ototoxicity of cisplatin chemotherapy treatment, researchers have utilized
osmotic pumps to infuse various doses of cisplatin and record the increase in hearing thresholds [63].
To counter the damage to hair cells inflicted by cisplatin, STS was infused using the Alzet pump with a
glass cannula [72]. STS protects the hair cells from death when given in combination with cisplatin.
However, the local delivery afforded by the osmotic pump is essential, as the STS would inactivate the
cisplatin throughout the body if dosed systemically. Other compounds have been investigated to block
signaling events in the apoptotic pathway started by cisplatin ototoxicity [195].
Osmotic pumps allow testing of novel therapies such as growth factors for various applications.
Neurotrophins, such as BDNF, have been studied as treatments to preserve neurons in deafened ears.
This has implication in the degree of success a patient would achieve using a cochlear implant. Several
studies continued to deliver neurotrophic factors for two to four weeks after deafening, and these
therapies show increased survival of SGN in the inner ear [102, 104, 196-198].
The pump is being used to test other compounds such as D-JNKI-1, a peptide inhibitor of the
apoptotic pathway, and BN82270, a peroxidation inhibitor to reduce free radical production, for their
protective effects on the cochlea. BN82270, delivered into the cochlea via osmotic pump prior to
trauma, was used to prevent damage from NIHL [199]. The application of D-JNKI-1 to rescue hair cells
from aminoglycoside antibiotic ototoxicity or NIHL resulted in protection from both types of damage. In
this study, the cochlea was perfused for seven days beginning two days after exposure [60].
2.5.2.5 Cochlear prosthesis-based delivery
Since the introduction of cochlear prostheses, researchers have worked to continuously improve
their effectiveness in providing enhanced auditory function to patients. Cochlear implants stimulate the
auditory neurons in the cochlea through an electrode inserted into the scala tympani. Hearing loss that
causes patients to receive implants causes the continued degradation of neurons which can reduce the
effectiveness of the electrodes. Evidence suggests the application of drugs in combination with the
electrode can lead to better outcomes (reviewed in [200, 201]). By combining a drug delivery platform
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with the implant electrode, drugs such as neurotrophic factors may prevent further auditory
degradation and maintain the number of surviving nerve fibers, thus improving the effectiveness of
cochlear implants for long-term use [202]. In addition, steroids and other compounds could be used to
prevent tissue growth on the electrode to keep impedance and, thus, power requirements low [203].
Med-El is a cochlear implant company investigating the combination of drug delivery with a
prosthesis. Their development effort includes an electrode with a fluid channel connected to an
infusion pump with outlets that allow delivery of drug into the basal turn. Cross-turn diffusion would
supply the apical regions of the cochlea [203]. Cochlear, Ltd. is another cochlear implant company
investigating drug delivery combined with the prosthesis [204].
Significant work has gone into testing these devices on the bench top prior to study in a guinea
pig. Dyes were used to visualize the flow and delivery through the electrode platform and ensure
patency, and various numbers and locations of openings in the fluid channel were tested to optimize the
delivery profile [203-205]. Multiple openings led to the fastest distribution in a plastic cochlea model
[206].
Testing in guinea pigs began with a standard electrode having polyimide tubing running through
its center to an osmotic pump. The electrode was inserted through the round window and delivered
200 lL of drug over 28 days. Using neomycin, an ototoxic antibiotic, as a model compound, the
assembly remained operational for the full delivery duration and showed minimal tissue response [18].
In a study using therapeutic agent BDNF designed to protect neurons for 28 days, results showed
reduced hearing thresholds when compared to control [106].
2.5.2.6 Other delivery devices
Multiple pumping devices are in development, including a micro-injector and a reciprocating
drug delivery device. Kingma et al. created a micro-injector from a syringe fitted with a screw to
regulate the infused volume of drug for a chronic animal study. The cannula remained implanted
allowing for daily injections of a toxin for 8 to 14 days [17].
Chen et al. have reported on a reciprocating drug delivery system [19]. The microfluidic device
is being developed for use as an implantable long-term infusion system for a variety of drug types. The
device uses a reciprocating fluidic system with one cannula directly implanted in the scala tympani that
acts as both the inlet and outlet. The drug concentrated in this fluid diffuses and mixes with the
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perilymph in the scala tympani. During withdrawal, the same volume of less concentrated fluid is
returned to the device. This pulsatile method may protect the sensitive hair cells from damaging
changes in cochlear volume and pressure while also creating a net increase in drug concentration. The
electronically-controlled device provides for precise control of delivery volumes, delivery of multiple
therapeutics, and timed, sequenced delivery that can be altered as indicated [19, 207].
2.6 CONCLUDING REMARKS
As treatment options improve for many inner ear diseases and injuries, methods for delivering
precise and controlled doses become vital. Researchers in the field of inner ear drug delivery will
continue to advance new and existing techniques that will support the arrival of better and better
therapeutic compounds. Those suffering from hearing related disorders can look forward to improved
quality of life as the field progresses.
Rights were reserved to reprint portions of this chapter from: Swan, E., et al., Inner ear drug delivery for
auditory applications. Adv Drug Del Rev, 2008. 60: p. 1583-1599.
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3.0 DRUG DELIVERY MODELING AND EXPERIMENTATION
A lumped-element model of the delivery system and cochlea was constructed. Mechanical
parameters were converted to their electrical analogues, and two modules were created. The flow
module incorporated the flow parameters in the delivery system and the physical aspects of the cochlea
influencing the flow profile. The transport module coupled the convective and diffusive elements of
transport to predict the concentration profile of the drug along the length of the cochlea. The model
was validated using a bench-top glass capillary tube as a reservoir to allow for flow visualization. The
concentration was measured by fluorescence intensity and compared to modeled results. Animal
experimental data was also compared to modeled concentration predictions.
3.1 DESCRIPTION OF THE DEVICE
The basis of the delivery device is a reciprocating flow system for perfusion of drugs into the
cochlear perilymph through a single hole in the basal turn of the scala tympani (ST). The single cannula
was directly implanted in the scala tympani and acted as both inlet and outlet. The system has been
constructed and tested with acute perfusion in the guinea pig. The guinea pig is an excellent animal
model to develop the microfluidic interface, because the inner ear is large and accessible and because a
large body of knowledge exists about its physiology, biochemistry, and pharmacology. Using the
endogenous perilymph as the fluid, the system repeatedly injects a small volume (0.2 to a few pl) of
liquid into the cochlea over a short (few sec) time, and then withdraws the liquid over a period of
several minutes. A diagram of the microfluidic loop is shown in Figure 3.1. The critical elements of this
device consist of an overall size consistent with surgical placement within a small cavity behind the ear,
a pumping element capable of infusing the drug into recirculating perilymph, a valve-controlled drug
reservoir, and integration with sensors for control of flow rate. Ultimately, an integrated drug delivery
device with sensors for flow, concentration and bioactivity would provide customized therapy based on
individual responses to treatment.
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Figure 3.1: Recirculating microfluidic delivery system with resistive and capacitive elements to
tune the delivery profile through the cannula
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Figure 3.2: Example flow profile exiting the microfluidic system
By balancing resistances and capacitances in the fluidic network of the device, a series of fixed
volume pump pulses results in approximately 0.5 to 2 pL of fluid exiting the cannula over a few seconds
as shown in Figure 3.2. A combination of compliant diaphragm membranes and high resistance tubing is
incorporated into the system to reduce the peak flow rate and volume exiting the cannula. Tubing
compliance and resistance in the fluid network can be used to scale and filter the output pulse entering
the cochlea as desired. This is done to reduce damage to sensitive structures in the inner ear that are
susceptible to large volume or pressure changes. The volumes and pressures of the exiting fluid are
tunable through the circuit parameters, minimizing the possibility of cochlear trauma.
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The basic principle of the recirculating system is that a fluid pulse is ejected through the
discharge capillary, a cannula placed in the ear, and slowly drawn back into the recirculating loop. The
system has the following characteristics: 1) the pump generates discrete volume displacements over
short periods of time when in the on state (0.5 pL over 30 msec) and blocks flow in the reverse direction
when in the off state, 2) the tubing and components of the pump-outlet portion of the loop and the
outlet cannula have a combined fluidic compliance and flow resistance that result in a charging time
constant on the order of seconds, 3) the tubing and components on the pump inlet side of the pump
have a combined compliance and resistance resulting in a charging time constant on the order of
minutes. The system operates in the following way: during excitation the pump displaces a net volume,
approximately 1 pL, from its inlet to outlet, and thus charges the outlet to a high positive pressure, and
the inlet to a negative (gauge) pressure. Because of the designed difference in charging time constants
of the loop, the pressured pump outlet is forced to quickly discharge out the cannula, rather than back
into the pump-inlet side of the loop. The pump-inlet side of the loop slowly recharges, pulling fluid
primarily from the cannula. Consequently fluid is ejected over a few seconds and then returns to the
loop slowly over a period of minutes. The cycle may be repeated at whatever interval is required to
achieve the desired fluid delivery rate and circulation rate of the drug in perilymph. Multiple pulses may
be applied in rapid succession to increase the volume ejected per cycle. The result is a system capable
of safely accommodating the pulse volumes from the pump, restricting the flow into and out of the ear,
and producing no net average flow into the cochlea. Actual drug delivery occurs through diffusion and
mixing of the high concentration fluid injected into the inner ear. Lower concentration fluid is returned
to the recirculating loop. Over time, no net volume change in the cochlea occurs while the drug
concentration in the cochlea increases. The intent of this method is to protect the sensitive hair cells
from changes in perilymph volume and pressure while also creating a net increase in drug
concentration.
The apparatus incorporates a miniature biocompatible solenoid pump manufactured by Wilson
Greatbatch (Clarence, NY) with a stroke volume of 500 nL at pressures up to 100 MPa. The pump is
controlled with a lab-designed electronic controller which delivers a low voltage pulse to the solenoid at
frequencies selectable from 0.1 to 10 Hz. Supply, return, and discharge tubing join at a 3-port manifold,
machined in the lab. To achieve the desired compliance mismatch, a large compliant diaphragm is
located on the return side of the pump, while lines to and from the pump are rigid. A smaller capacitor
on the pump outlet side reduces the maximum flow rate upon infusion. By selecting the resistance of
the return line in relation to the resistance of the discharge cannula, the discharged volume at each
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outlet cycle is controlled. To introduce drugs or other compounds to the circulating liquid, a
micromachined valve manifold (see Chapter 5) was designed and fabricated for insertion into the supply
line.
Design of circuit parameters allows for precise control of delivery volumes and times, and can
allow for dosing of multiple therapeutics [1].
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Figure 3.3: Sample output volume and pressure from fluidic circuit
A second fluidic system is also used. The concept is an actuator pushing on a membrane-
covered reservoir for delivery into the cochlea, coupled with relaxation of the actuator and capacitance
of the membrane for return of the fluid to the system. In normal operation, the solenoid actuator
impinges on the pumping chamber's membrane to decrease its chamber volume and dispenses fluid
from the reservoir into the cochlea. Releasing the membrane refills the system with cochlear fluid.
Similar to the circulating system, the infusion and withdrawal cycles are timed such that substantial
mixing of drug and perilymph occurs in the cochlea. The refill step draws diluted fluid back into the
reservoir. This system results in similar output volumes and flow rates. The oscillating device was
designed to reproduce the flow rate and dispense volume characteristics of the recirculating system, but
with sufficient flexibility to alter these parameters either by component modification or by electrical
input. While it is being developed, a syringe pump is utilized in initial bench-top and in vivo experiments
to achieve identical flow characteristics. The pump substitutes for the membrane and actuator. A
commercial flow sensor (Sensirion 1430, Staefa, Switzerland) is added to the system just prior to the
cannula outlet for improved flow monitoring.
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3.2 DESCRIPTION OF A PREVIOUS COCHLEAR DELIVERY SIMULATOR
A large body of work in computer simulation of drug transport within the cochlea has been
published by Alec Salt and Stefan Plontke and coworkers [2-5]. The analyses have shown that the drug
distribution is highly dependent on delivery protocol and application location along with drug choice and
biological aspects of the inner ear.
Salt developed a one-dimensional finite-element model entitled "Washington University
Cochlear Fluids Simulator" that is available for download free of charge at
http://oto2.wustl.edu/cochlea/. The simulator [4] utilized cross-sectional area measurements of the
scalae as functions of distance from [6] and area and location measurements of the round window
membrane from [7]. Salt outlined the algorithm for his model in 1991 [2, 3]. Each scala had two arrays:
A for cross-sectional area of each segment, and M for amount of agent in each segment. The
concentration for any element (c;) was defined as
M.
c. = Equation 3.1
where x was the segment length. The transport was predominated by passive diffusion, so the rate of
solute movement (dn/dt) was defined by Fick's 2 nd Law
dn dc
= -DA-- Equation 3.2
dt dx
where A was the cross-sectional area, and dc/dx was the concentration gradient as a function of
distance. For short segments, the concentration gradient was assumed to be linear. Therefore, the
amount of agent (N) was found by
N = -DAt(c - ci+ ) Equation 3.3
x
and iterative calculations were done for each scala. For processes in addition to diffusion, such as bolus
injections or perfusion, the amount of agent was added to each array element. For example, the bolus
injection was addressed as
N = c, V Equation 3.4
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where cb and Vb were concentration and volume of the bolus [2]. Salt published an overview of the
model as it appears on the website and described a summary of the features including the available
drug applications of round window diffusion, bolus injection, and steady perfusion [5].
A number of publications compared the simulation to experimental results for middle ear
delivery, direct injection, and others [8-11]. Additionally, Plontke and Salt developed a three-
dimensional model and then compared a simplified geometry with the one-dimensional model for
diffusion through the round window membrane. No flow was incorporated [12].
These models are useful due to a general lack of knowledge of the pharmacokinetics within the
inner ear. In addition, samples cannot be withdrawn during experimentation due to the possibility of
damage to sensory elements and contamination from cerebrospinal fluid (CSF). However, the Salt
model lacks the ability to use the reciprocating fluidic delivery and does not account for protein
interactions with the drugs.
3.3 GOVERNING EQUATIONS
Prior to constructing the model, an analytical understanding of the governing equations is
necessary. Drug transport in the cochlea is governed by the law of mass conservation as
ac
= -V N + R-(v. V)c Equation 3.5
at
where c is drug concentration, t is time, N is flux, R is reaction, and v is velocity. The flux is defined by
passive diffusion. The constitutive equation is Fick's Ist Law,
N = -DVc Equation 3.6
where D is diffusivity, assumed to be constant in this case. These equations define the phenomena
contributing to drug transport. The passive diffusion proceeds through Brownian motion of the
particles. The reaction depends on multiple biological processes including drug binding, tissue uptake,
and clearance to the vascular system, among others. Finally, the velocity is defined by the flow exiting
the delivery system. The perilymph flow rate within the scala tympani is negligible, based on the
measurement by Ohyama of 1.6 nL/min directed basally [13].
In defining the fluid velocity from the delivery system, the fluid is assumed to be incompressible
and Newtonian. The mass conservation equation is
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V v = 0 Equation 3.7
and the momentum conservation is defined as
Dv
p -=FDt
Equation 3.8
where p is density and F is the sum of forces.
cochlea,
Re = pUL
where U is average velocity, L is characteristic length, and p is viscosity, was computed using the average
velocity generated by the root mean square of the pressure input. The result, Re on the order of 1,
suggests laminar flow. Re calculated with maximum pressure yields a Re of the same order. The
catheter dimensions were used in the calculation. The mass and momentum conservation equations
result in the Navier-Stokes equation
The Reynolds number (Re) of the fluid flowing into the
Equation 3.9
Dv
p - = -VP+ uV 2vDt
Equation 3.10
where P is the pressure driving the flow.
The Peclet number (Pe)
ULPe =
D
Equation 3.11
is also based on the average velocity of fluid leaving the device. The Pe on the order of 10 3 displays the
relative dominance of convective transport over diffusive transport. In this case, diffusion is enhanced
due to the parabolic shape of the flow since both radial and axial diffusion can occur. The Re and Pe
were calculated, as noted, using the cannula flow. Once the flow enters the cochlea, it splits, which may
produce different values for this numbers.
For radially symmetric, unsteady flow in a circular tube, the Navier-Stokes equation reduces to
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Equation 3.12
av 1p 1U Ia a v
a= p---+ r-
at p az pr ar )r
where r is radius. For a pressure gradient periodic in time and independent of r or z, the solution was
published by Aris [14].
For this tube, the mass transport equation simplifies to
ac a2C I ac
= D +-- r- -v-
at Lz 2 r ar ar Iz Equation 3.13
for no reaction.
Equation 3.13 cannot be solved analytically for this system. In this thesis, a lumped-element
model was constructed to develop an approximate solution to the concentration distribution. This
method was chosen to provide intuitive insight into the interactions of the device and cochlea.
Alternatively, one may choose a standard numerical algorithm to solve the equation. For example, the
equation is rewritten below for solution using the finite difference method. Concentration, c(ri, zj, tk), is
equal to the value of c at r=i, z=j, and t=k. The centered difference approximation for the first order
partial derivative is as follows:
c Ci, j,k+ - Cij,k + O(At 2 )
at 2t +(At 2)3t 2At Equation 3.14
where the order of accuracy is given by O(At). The z-spatial derivation can be discretized in the same
fashion. The second order derivative can be approximated as
1 a r c = Ci+l,j,,k -2 Ci,j,k Ci- jk Ci+l,j, k + (Ar 2)
ar rr (Ar) 2 + 2r(Ar) Equation 3.15
using the centered difference method. From equations 3.14 and 3.15, the concentration at any point
(r,z,t) can be approximated by
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Cij=k+1D c-D j+1.k - 2 ijk + Cij-1k i+ 1 jk - 2 cj.k + Ci-jk Ci+.j.k - Ci-.j.k
2At (Az) 2  (Ar) 2  2r (Ar)
-vz (r,t)[ Cij+Lk - Cij-1 k1
2Az
Equation 3.16
This finite difference equation may be solved using commonly available numerical solvers. The finite
difference method provides a continuum approach to solution for r, z, and t. On the other hand, this
approach uses lumped elements. It may not provide the level of precision the finite difference method
offers without adding significantly more components; however the lumped-element approach allows for
a more intuitive understanding of the relative contributions of various components.
3.4 LUMPED PARAMETER MODELING
The model was constructed with two coupled modules using lumped-element electrical circuit
analogues and analyzed with circuit simulation software. The first module predicted pressure-driven
flow in the cochlea generated by the delivery system and influenced by the various fluid loss
mechanisms and compliances of the system and cochlea. The second module used input from the flow
module to simulate transport of drug through the cochlea by combined flow and drug (solute) diffusion.
The flow module used a pulsatile flow source, compliant elements and resistive elements to describe
the delivery system. The drug transport module implemented lossy transmission line elements to
simulate diffusion through the cochlea and current sources dependent on the first module's flow data to
distribute the drug through the cochlea via bulk flow. In the lumped-element model, the cochlea was
segmented, and the attributes of each segment, or lump, were assumed to be uniform over the volume
of the segment [15]. As the model system's complexity evolves, additional components may be added
to represent various other biological mechanisms such as drug binding, clearance to the vascular
system, etc. The model was validated using simplified sets of input conditions, which permitted direct
comparison with simpler bench-top experiments and an existing simulation tool.
Electrical analogues were used to describe the physical phenomena in the system. All of these
electrical components were equivalent to their hydraulic and diffusive-transport counterparts with
appropriate transformations. Equations of the same form are considered analogous equations and can
be solved with substituted variables and constants. In all the systems, a potential difference applied to
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an element causes flow. For example, in an electrical system, voltage applied to a resistor causes
current just as pressure difference applied to resistive tubing causes fluid flow in a hydraulic system [16].
All of the model components had electrical component analogues available in the Micro-Cap
electrical circuit simulator (Spectrum Software, Sunnyvale, CA), and their specific values were
transformed to maintain consistency throughout the model. This tool had a wide range of simple-to-use
components, including the nonlinear elements necessary to simulate both the delivery system and the
biological system. The lumped parameter model allowed for intuitive interpretation of various aspects
of the two systems and provided versatility for examining the drug transport effects due to changes in
the system (fluid flow, cannula placement, etc.).
3.4.1 Flow module
Lumped-element modeling of the flow module entailed describing the flow created by the
device and incorporating elements of the reservoir, or cochlea, which influenced the fluid flow within
the cochlea. The pump was modeled as a current source, and capacitive and resistive elements were
utilized. The transformed mechanical to electrical analogues are shown in Table 3.1, as well as the
associated symbols used in the electrical circuit simulator.
Table 3.1 Mechanical to electrical analogues and associated symbols.
Pressure (P) Voltage (V)
Volume (v) Charge (q)
Volume flow (Q) Current (I)
Fluidic resistance (Rfl) Electrical resistance (R)
Fluidic capacitance, compliance (Cp) Electrical capacitance (C) I.
3.4.1.1 Recirculating system
The first fluidic delivery system that was modeled was the recirculating system detailed above.
Figure 3.4 shows the electrical circuit layout drawn in the simulator.
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Figure 3.4: Micro-cap circuit representing the recirculating flow system.
In this drawing, Ip,mp represented the driving force applied to the system by the mechanical pump. The
pump was modeled with a pulse defined by the 25 msec-stroke time and 1200 pL/min-constant flow
during that time. These values were the inherent values of the commercial pump. The four resistors
labeled Rin and R0ou described the resistance to flow due to the diameters and lengths of various tubing
in the recirculating loop. The Rcannuia described the resistance of the cannula at the flow outlet. These
resistances were calculated from the Hagen-Poiseuille flow equation for laminar, incompressible,
cylindrical pipe flow.
128/lLR. = Equation 3.17fr d4
where L was tube length and d was tube diameter. The value of viscosity, p, was 7.2e-4 Pa*sec for
perilymph. The resistor labeled Reservo,,i described any generic reservoir where the fluid exited and was
changed for various tests to describe the cochlea or test capillary tubes, as necessary. The two fluidic
capacitors labeled C, and Cout were diaphragm components designed and built specifically for this
application. The capacitance of these elements was based on their diameter, membrane material, and
membrane thickness. The elements and capacitance calculations are discussed below in Chapter 5.
Just as Ohm's Law describes electrical circuits, the mechanical analogues are related. Ohm's
Law states that
V = IR Equation 3.18
and the mechanical system is described by
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P = QRf Equation 3.19
Likewise, the current and volume flow are described as
d= , Q= Equations 3.20, 3.21
dt dt
respectively. Finally, electrical capacitance and fluidic capacitance are described as
C = d C dv Equations 3.22, 3.23
dV dP
respectively. The volume flow output of the system at the node immediately after Rcannuia was
coupled to the transport module, described below.
The modeled flow is shown in comparison to measured flow out of the recirculating system in
Figure 3.2. In this example, the pump was turned on for six pulses, and the flow was measured using a
Sensirion 1430 flow sensor. Many configurations of pump pulses, different compliance values, and
resistance values may be combined to yield various flow profiles as required for optimal delivery.
3.4.1.2 Biological considerations
Additions to this flow module allowed for representation of biological aspects of the cochlea
affecting fluid flow as shown in Figure 3.5. First, the general Rreservoir was replaced with resistance values
of the scala tympani and scala vestibuli. These were calculated using Equation 3.17 above. The
diameter and length values were obtained from [6] using MRI images. Because the cannula was
inserted at 1.8 mm from the base of the cochlea (the 28 kHz region) as shown in Figure 3.6, the total
fluid resistance was lumped into two values representing the sections on each side of the insertion site
(RSTbasal, RSTapical). The RSTbasal was calculated to be 6.67x10-8 psi/pL/min and the RSTopical was 9.77x10-5
psi/pL/min. RSTapical was much larger because the length of the segment was 30 mm including the apical
region of the scala tympani as well as the entire scala vestibuli.
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Figure 3.5: Fluidic module for reciprocating flow with cochlear elements (Elements below the
dotted line are external to the device.)
Figure 3.6: Three-dimensional reconstuction of a guinea pig scala tympani (from histological sections)
showing the insertion point of the cannula. The round window membrane is shown at the base in dark
blue.
As described in Chapter 2, the guinea pig cochlea has a patent aqueduct connecting the scala
tympani to the CSF space. This tube is located at the base of the scala tympani near the round window
and provides a path for the fluid to flow out of the cochlea. As the aqueduct is a tube ending in a
relatively larger fluid space, a resistor and a capacitor are required to represent the anatomy. The
cochlear aqueduct resistance (Raqueduct) values were published by Wit [17]. The resistance is nonlinear as
shown in Figure 3.7; however at pressures over 0.08 psi, Raqueduct is approximately linear with a value of
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0.025 psi/pL/min. The capacitance of the CSF space (CCSFspace) was assumed to be large compared to the
other capacitance values and set at 10 pL/psi.
The round window, at the base of the scala tympani, is a compliant membrane and modeled as a
capacitor (Cround window). As shown in Figure 3.7, Cround window is slightly nonlinear [17], but output of the
model showed no change whether a nonlinear or linear capacitive element was used. Therefore, Cround
window was set to 0.8 pL/psi. The compliance of the oval window (Co0,l window), at the end of the scala
vestibuli is estimated to be approximately one order of magnitude less compliant than the round
window [18]. Thus, CoalwindowWas set to 0.08 pL/psi.
0.06
So.osU 0.05
5 0.04
E 0.03
- . 0.02
S 0.01
0
- ---------- *
0 0.05 0.1 0.15
pressure (psi)
Figure 3.7: (left) Cochlear aqueduct resistance and (right) round window compliance as a function of
pressure. *Plots were reproduced from data in [17].
3.4.1.3 Syringe pump system
The second flow system that was used was a syringe pump system that approximated the next-
generation microfluidic flow system. This simplified set-up was used in both bench-top and animal
studies, as discussed below. The system, as described by lumped elements, is shown in Figure 3.8.
Again, the pump was represented by the current generator, and Rcannuia represented the small-bore
tubing used for the cannula. Parasitic compliance in the syringe and syringe pump and intentionally
introduced compliance in the pump's outlet tubing were lumped int a single element, Cpump. This value
was dependent on the amount of air trapped in the system during filling, the types of syringe and
tubing, and the security of the syringe placement in the pump holder. This value was fit to the
experimental data.
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'pump mp
Figure 3.8: Circuit diagram of simplified syringe pump delivery system
A bench-top experiment to visualize and model flow from the syringe pump system into a glass
capillary tube is described below. This experiment was used to validate the model. In order to
accurately represent the flow exiting the device, the flow module shown in Figure 3.8 was modified and
is shown in Figure 3.9.
Figure 3.9: Circuit diagram of syringe pump system used in experiments
The syringe pump itself required two pulse current sources, one representing flow into the
cochlea (positive) and the other representing flow exiting the cochlea (negative). The resistor and
capacitor modeled measured parasitics. The other change was the addition of a volume integrator so
that the flow rate at node (fl) could be integrated to determine the volume discharged from the system.
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Rcannula and Rtube (glass capillary) were calculated from Equation 3.17 using the dimensions of these tubes.
Ctube end represented the open end of the capillary opposite the in-flow end and was set to a high value
since capacitance was infinite there. Figure 3.10 shows an example flow rate graph comparing model
output to measured flow for this module. The flow was measured using the Sensirion Model 1430 flow
sensor.
Figure 3.10: Example comparison of flow rate experimental results to modeled results
Figure 3.11 shows how the flow module in Figure 3.9 was modified to represent flow into the
guinea pig cochlea. Rtube and Ctube end were replaced by resistances of the scala tympani and scala
vestibuli, compliances of the round and oval windows, and resistance and compliance of the aqueduct
and associated CSF space, as described above.
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Figure 3.11: Circuit diagram of syringe pump system for delivery into guinea pig cochlea.
The flow module of the lumped parameter model is highly versatile and easily changed to
represent different flow systems and different reservoirs. By describing the flow in this way, intuitive
understanding of the role of each element can be gained, and the effects of changes of values of each
element can be shown.
3.4.2 Drug transport module
Lumped parameter modeling of transport and dispersion of the drug or solute within the
cochlea was accomplished using the transport module. Both diffusive and convective forces were
represented. Additional elements may be added to represent clearance mechanisms and drug binding
encountered in the cochlea. As in the fluidic module, electrical analogues were used in place of
transport parameters. These transformations are summarized in Table 3.2.
Erin E. Leary Swan
..............................................
831Page
Table 3.2: Transport to electrical analogues and associated symbols.
Transport element Electrical element Element symbol
Concentration (c) Voltage (V)
Number of particles (#) Charge (q)
Bulk solute flow (f) Current (/) ( JaN
Diffusive resistance (Rd) Electrical resistance (R)
Segment volume (vs) Electrical capacitance (C)
Concentration was represented by voltage at any point along the cochlea or tube, and the initial
concentration of the drug was defined by the experimental parameters. Electrical charge was analogous
to the number of particles of the drug (concentration multiplied by volume). Current was defined in
Equation 3.20. Similarly, concentration in a given segment was described by
Equation 3.24
Segment volume was represented by electrical capacitance. The segment value is calculated by
the average cross-sectional area of the segment multiplied by the length of the segment. In the glass
tube experiment, the tube was constant in diameter; however in the case of the guinea pig cochlea, the
diameter was not constant. Values from literature [6] were used to calculate the segment volumes.
The diffusive resistance was defined as
Rd= DA
Equation 3.25
where Ls is segment length, D is solute diffusivity, and As is segment area. Rd was represented by
electrical resistance.
Current represented bulk solute flow. The bulk solute flow (f) was generated by the delivery
device and defined as concentration multiplied by the volume flow from the device. The flow module
was coupled to the transport module through the current source.
An example circuit representation of the transport module is shown in Figure 3.12.
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Figure 3.12: Circuit diagram of transport module.
In order to more clearly explain the nonlinear current values, the current sources at points 1, 2,
and 3 in Figure 3.12 are defined below in Table 3.3.
Table 3.3: Current source definition in circuit
1 If Vfl>O, .9Vfl(Vc-Vb), else -.9Vfl(Va-Vb)
2 If Vfl>O, Vfl(Vinitial-Vc), else -Vfl[.9Vb+.1(Vd-Vc)]
3 If Vfl>O, .1Vf(Vc-Vd), else -.1Vfl(Ve-Vd)
where Vfl is the fluid volume flow from the flow module, Vo-e are the segment concentrations, and Vinitil
is the solute concentration of the drug in the device. Note that the current source at point 2 was a
special case as this was the entry point of the cannula into the cochlea. Also, the 0.9 and 0.1 factors
represent the fact that the oval window was one-tenth less compliant than the round window, and as a
result approximately 90% of the fluid flow is toward the round window and only 10% towards the oval
window. For the glass tube case, these definitions were simplified by removing the multiplied factors.
The cannula was placed at the end of the tube rather than some distance in, as was the case for the
cochlea.
The R-C pair in each segment can be replaced by a lossy transmission line as shown below. The
R-C pair describes diffusion of the solute. Figure 3.13 shows a transmission line schematically and as an
element in the circuit solver.
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Figure 3.13: (left) Schematic interpretation of a transmission line and (right) Micro-cap
transmission line element
From the schematic representation,
dV
- dz = -RIdz
dz
Differentiating both sides with respect to z results in
d 2V dl
= -R
dz2 dz
Equation 3.26
Equation 3.27
Also, from the schematic,
dl dV
__dz = -Cdz -
dz dt
Equation 3.28
Cancelling dz yields
dl dVdI= -CdV
dz dt
Equation 3.29
Combining Equations 3.27 and 3.29 yields
d2V dV
= RCd
dz2 dt
Equation 3.30
which is Fick's 2nd Law of diffusion in one dimension. RC is equivalent to the inverse of diffusivity, and
voltage is equivalent to concentration.
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Calculations of lumped volume and diffusive resistance were based on diameter values of the
cochlea along the length of the scala tympani and scala vestibuli. An example calculation of one
segment of the cochlea is shown in Table 3.4. This segment extended apically from 1 mm from the base
up to 1.7 mm from the base.
Table 3.4: Sample calculation of lumped parameters
Length Diameter volume Lumped v,
Rd (Sec/cm3 ) Lumped Rd (SeC/Cm )(mm) (mm) (ILL) (IpL)
1 1.281 0.128 1.66E+05
1.1 1.279 0.129 1.65E+05
1.2 1.266 0.127 1.67E+05
1.3 1.244 0.124 1.72E+05 0.974 7.31E+05
1.4 1.235 0.121 1.76E+05
1.5 1.229 0.119 1.79E+05
1.6 1.197 0.116 1.84E+05
1.7 1.182 0.111 1.92E+05
In Rd, diffusivity was 4.70e-6 cm 2/sec for the example solute. The lumped volume was the sum of the
individual values for the given segment. The lumped diffusive resistance was the sum of the individual
resistances from the center of one segment to the center of the next segment.
Two transmission lines in parallel can be assigned to each segment with the lumped volume and
diffusive resistance split between them. With a resistor between them, the model can better represent
laminar flow. The shape of the laminar flow in a pipe is parabolic with higher velocity flow in the inner
core and slower flow in the outer ring. A fast core may be defined as some portion of the tube diameter
and the R and C values calculated from the new diameter. Likewise, the outer ring represents the
remainder of the diameter. The resistor connecting the two transmission lines represented the radial
diffusion due to the difference in velocity. This lumped element was calculated by dividing the segment
length by the diffusivity and the cross-sectional area of the midpoint of the inner core to the midpoint of
the outer ring. Additionally, a second current source is added so both average flow rates are
represented at the same proportion as the diameters. The fast and slow cores will model the larger
concentration gradient due to varied convective transport across the tube cross-section. More
transmission lines could be added for improved accuracy and better defined flow. An example of the
circuit is shown in Figure 3.14.
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Figure 3.14: Circuit showing additional transmission lines to better translate laminar flow
3.5 COMPARISON OF THE MODEL TO THE DIFFUSION-ONLY ANALYTIC SOLUTION
The first validation of the transport module compared the model configured for diffusion only to
the analytical solution of diffusive transport. For one-dimensional diffusion in a pipe, the solution for
concentration at any point along the pipe (x) is
c= co 1-erf )2 /2 Equation 3.31
where co is the initial concentration of the solute entering the tube. The diffusivity of fluorescein, 7.83e-
6 cm 2/sec, was used in the analysis and model. Figure 3.15 shows the circuit that was used to solve the
diffusion-only case. It represented a simplified version of the general transport module. The initial
concentration, 100 [M, was modeled as a battery with voltage equal to co since there was a constant
source of fresh solution at the entrance to the tube. The current sources were removed because there
was no volume flow. The 100 mm-long glass tube was divided into eight segments. The first seven
segments were each 1 mm long, and the last one was 93 mm long. The lumped resistance was 2.2e6
sec/cm 3 and the lumped capacitance was 5.8e-4 cm 3 based on the tubing diameter of 0.86 mm.
Figure 3.15: Circuit diagram of diffusion-only transport module.
The results of the analytical solution and the model solution are compared in Figure 3.16 for the first 6
mm of tubing. Very precise overlay of the two solutions is apparent. Even for a shorter time interval,
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the solutions match very closely, as shown in Figure 3.17. This demonstrates that the transmission lines
accurately represent diffusion.
Figure 3.16: Comparison of analytical solution of diffusion to modeled solution for several hours
Figure 3.17: Comparison of analytical solution of diffusion to modeled solution for one hour
3.6 DRUG TRANSPORT MODELING IN GLASS CAPILLARY TUBE
Another validation of the model involved flow visualization in a glass capillary. Bench-top
experiments were conducted using the syringe pump system to deliver fluorescein into glass tubes.
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Fluorescence intensity was continuously imaged under a microscope and converted to a relative
concentration. The model was used to predict the fluorescein concentration over time due to pulsatile
flow and diffusion and was compared to experimental results. Figure 3.18 shows a montage of false-
color images of fluorescein transport into the tube. Each image shows a 2-sec time-step, and the series
of images shows one delivery system infusion cycle followed by withdrawal of the fluid back into the
system.
Figure 3.18: Time-step images of fluorescein output into tube
3.6.1 Method
The syringe pump (Harvard Apparatus PHD 2000) was connected to the computer to allow for
Labview control using a customized program that set the flow parameters and controlled pump infusion
and withdrawal at intervals set by the user. A length of large bore, rigid Teflon tubing was connected to
a flow sensor (Sensirion 1430). The sensor provided input to the Labview program so volume and flow
could be continuously monitored throughout the experiment. The outlet of the flow sensor was then
connected to the manifold housing the cannula for cochlear implantation. As shown in Figure 3.19, a
second manifold connected the solute reservoir to the infusion line. A pump attached to a timer-
controlled power source ensured that the solute was completely refreshed in the slug of fluid about to
enter the cochlea between each cycle. The solute loop was filled with 100 pM fluorescein (Sigma, St.
Louis, MO) in deionized water. All other components were carefully filled with deionized water as the
system was built to eliminate bubbles in the system. After filling, the other end of the Teflon tubing was
connected to a 100 pL glass Hamilton syringe that was placed on the syringe pump.
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Figure 3.19: Diagram of syringe pump flow system
The cannula was placed in a water reservoir for system testing. The Labview program was set to
the required infuse and withdraw rates and durations to achieve the following desired flow
characteristics: 12 pL/min infusion rate, 1 pL infused volume, complete withdrawal over 1 min, repeated
every 150 sec. The sensor output was monitored to ensure agreement between the settings and actual
flow from the cannula. The solute loop pump was also tested. It was cycled enough times to push 1 pL
of fresh drug solution into the infuse loop, usually 2-3 pump pulses. The timer box was set to repeat
every 150 sec to match the period of syringe pump cycling. After demonstration of proper performance
of the pump on the bench, the cannula was inserted into a water-filled glass capillary (0.86mm ID, Chase
Scientific Glass, Rockwood, TN). The microscope camera (Olympus SZX12, Center Valley, PA) was set to
save an image every 1 sec for the duration of the test.
At the conclusion of the experiment, the images were loaded into ImageJ software (freeware
from http://rsbweb.nih.gov/ij/) as a stack. The fluorescence intensity, at lengths of 1-6 mm from the
cannula, was measured for all images in the stack.
A set of fluorescence standards was constructed of identical glass capillary tubes filled with
concentrations of fluorescein varying from 300 piM down to 300 nM. The linear region on the log plot,
as shown in Figure 3.20, was used to convert the fluorescence intensity measurements from the
experiment to concentration values.
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Figure 3.20: Relationship between fluorescence intensity and concentration
3.6.2 Results
Results of the experiment are shown in Figures 3.21 and 3.22. The figures show the change in
concentration with time at 4 locations along the length of the glass tube. The results of the pulsatile
flow were apparent in the periodic spikes in concentration followed quickly by reduction in
concentration. The overall trend, however, shows increasing concentration over time. Figure 3.21
shows the maximum concentration values at the points of interest across the diameter of the tube,
while Figure 3.22 shows the mean concentration across the diameter.
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Figure 3.21: Maximum concentration as a function of time for 4 locations along tube length
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Figure 3.22: Mean concentration as a function of time for 4 locations along tube length
The model utilized the syringe pump flow module discussed above. The circuit is shown below
in Figure 3.23 with key component values. Figure 3.9 above has these components labeled to show the
physical system parts they represent.
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Figure 3.23: Syringe pump flow module where I1 and 12 have the following settings (initial
current value[pL/sec], pulsed current value, time delay before pulse [sec], pulse rise time, pulse fall
time, pulse width, pulse period): 11 (0, 0.64, 1.2, 0, 2.8, 0.2, 150), 12 (0, -0.016, 35, 0, 0, 59, 150)
The values for the syringe pump were fit to flow sensor output data as the Labview syringe pump
settings did not exactly match flow sensor data due to resistance and compliance in the delivery system.
The flow rate and displaced volume from the experiment and model are compared in Figure 3.24. Only
one cycle is shown, but it was repeated every 150 sec for the duration of the experiment.
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Figure 3.24: Comparison of measured versus modeled flow rate (top) and displaced volume (bottom)
versus time in glass tube experiment.
The flow sensor was placed in the system upstream of the cannula, which has a high resistance, so the
flow data does not accurately represent the flow entering the glass tube. Figure 3.25 shows the
measured data from the flow sensor compared to the modeled flow at the cannula exit. This was done
to illustrate the effects on flow characteristics due to the high resistance of the cannula, a lower
maximum flow rate but an equal maximum displaced volume.
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Figure 3.25: Modeled flow (top) and volume (bottom) going into tube versus measured flow upstream of
cannula.
The transport module shown above in Figure 3.14 was used to model the convective diffusion of
fluorescein along the length of the glass tube. Table 3.5 shows values used to calculate the electrical
components used in the circuit.
Table 3.5: Component values of transport module in glass tube experiment
Segments tube divided into (#) 10
Glass capillary tube length (mm) 100
Glass capillary inner diameter (mm) 0.86
Fluorescein diffusivity (cm 2/sec) 7.83e-6
Fluorescein concentration (pM) 100
Lossy transmission line (fast core)
Capacitance (kIL) 0.209
Resistance (sec/mm3 ) 6.11e3
Lossy transmission line (slower outer ring)
Capacitance (1IL) 0.372
Resistance (sec/mm3 ) 3.44e3
Lossy transmission line length (mm) 9 segments: 1 mm, last segment: 91 mm
Radial diffusive resistance (sec/mm3 ) 8.8e3
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Results of the model are compared to experimental data in Figures 3.26 to 3.31 for points at 1, 2
and 3 mm from the cannula along the length of the glass tube. In Figures 3.26 to 3.28, the results are
compared to maximum concentration, while Figures 3.29 to 3.31 compare mean concentration. The
modeled data shows the long-term trend of concentration increase with time that was seen in the
experimental data. The peaks in concentration correspond to the pulsatile flow profile, and the peaks in
the modeled data match the mean experimental concentration better than the maximum
concentrations. This agrees with the way the model was designed as the output voltage at each location
represents the average concentration at that point. The diffusivity that was used was the published
value, but it appears that a slightly lower value may provide better agreement to the experimental
results.
1000 2000 3000 4000 5000
time (s)
Figure 3.26: Maximum measured concentration at 1 mm compared to modeled concentration
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Figure 3.27: Maximum measured concentration at 2 mm compared to modeled concentration
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Figure 3.28: Maximum measured concentration at 3 mm compared to modeled concentration
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Figure 3.29: Mean measured concentration at 1 mm compared to modeled concentration
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Figure 3.30: Mean measured concentration at 2 mm compared to modeled concentration
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Figure 3.31: Mean measured concentration at 3 mm compared to modeled concentration
3.7 MODELING OF DRUG DELIVERY IN GUINEA PIG COCHLEA
The model was altered for use in understanding transport in the cochlea, and it was compared to
experimental results from guinea pig tests. For the experiment, a bioassay was used for in vivo monitoring
to follow the time course of drug activity in the ST. The cochlea is organized so that the range of frequencies
that can be heard is tonotopically distributed along its length, as shown in Figure 3.32 [6, 19].
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Figure 3.32: (left) Reconstruction of guinea pig cochlea showing tonotopic relationship of frequency,
(right) characteristic frequency along length of guinea pig cochlea (reproduced from data in [19]).
Electrophysiological assessment of solute transport allowed real-time analysis of delivery over
periods of hours [1]. A drug that increases hearing thresholds, 6-7-dinitroquinoxaline-2,3-dione (DNQX),
was delivered to the guinea pig cochlea, and as thresholds at frequency locations were sequentially
elevated, the progression of the drug along the length of the cochlea was tracked. Hearing tests to
measure compound action potentials and distortion products, as described below, tracked the sound
level thresholds for response. One drawback to this method was that the exact concentration of drug
needed to eliminate hearing at a specific site was not known and has only been estimated through dose-
response curves [1]. In addition, direct fluid sampling was not possible as hearing thresholds would be
elevated or destroyed by the surgical technique and withdrawal of perilymph. Also, in the guinea pig,
the ST is in direct fluidic communication with CSF through the cochlear aqueduct. Removal of perilymph
would lead to the infiltration of CSF, dilution of perilymph and drug, and inaccurate measurements. For
these reasons, only indirect measurements of drug levels through the bioassay were possible.
The necessary changes for the flow module to represent delivery into the guinea pig cochlea
were addressed above. The reservoir resistance was replaced by the flow resistance of the scala
tympani and scala vestibuli, and the components representing the round window, oval window, and
cochlear aqueduct were added (Figure 3.11). Precise dimensions of the guinea pig cochlear fluid spaces
are available from magnetic resonance imaging [6]. For each 0.1 mm-segment of the scala tympani and
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scala vestibuli, the cross-sectional area was reported. The perilymph viscosity was 1.75e-9 psi*min. The
cannula was placed at 1.8 mm from the base. The flow resistance values were calculated using Equation
3.17. The other component values were provided in the literature.
The diffusive resistors and capacitors in the transport module for the guinea pig cochlea were
calculated in a similar manner as for the glass tube. In animal experiments, as described below, the
fluorescein was replaced by DNQX. Also, for comparison purposes, the scalae were divided into unequal
segments to match locations of measured frequencies in the experiment. Table 3.6 summarizes the
values.
Table 3.6: Circuit element values in the transport module for the guinea pig experiment
Segments cochlea divided into (#) 11
DNQX diffusivity (cm 2/sec)
4.70e-6(estimated from molecular weight=232)
DNQX concentration (pM) 300
Capacitance (jpL) (45 kHz region) 0.932
Resistance (sec/cm3 ) 1.57e6
Capacitance (pL) (32 kHz region) 0.974
Resistance (sec/cm 3 ) 1.37e6
Capacitance ([IL) (28 kHz region) 0.108
Resistance (sec/cm3 ) 1.97e5
Capacitance (L) (24 kHz region) 0.655
Resistance (sec/cm3 ) 3.04e6
Capacitance (iL) (16 kHz region) 0.927
Resistance (sec/cm3 ) 4.99e6
Capacitance (pL) (12 kHz region) 0.232
Resistance (sec/cm3 ) 6.15e6
Capacitance (lIL) (8 kHz region) 0.227
Resistance (sec/cm3 ) 7.97e6
Capacitance (ipL) (5.6 kHz region) 0.191
Resistance (sec/cm 3 ) 2.65e7
Capacitance (pIL) (4 kHz region) 0.515
Resistance (sec/cm 3 ) 1.21e8
Capacitance (pL) (2.78 kHz region) 0.432
Resistance (sec/cm3 ) 2.27e8
Capacitance (pL) (more apical ST and SV) 3.652
Resistance (sec/cm3 ) 6.17e7
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It should be noted that the actual diffusivity of DNQX was not available. The value was
estimated from its molecular weight.
Additional biological aspects of the cochlea are not as easily modeled. Little is known of the
various clearance and binding mechanisms in the cochlea, and these are dependent on the specific drug
or solute. Protein binding is hypothesized to play a major role in limiting access of drugs to the target
tissues. As discussed in Chapter 4, a large amount of protein present in the perilymph is capable of
binding various types of drugs. Also, many enzymes are found in perilymph that could modify the
molecular structure of drugs. Other mechanisms include clearance through the vasculature, diffusion
into tissue, and metabolism. Time courses for these are not known. More details will be discussed
below.
3.7.1 Comparison of model to Salt simulator
As described above, a free cochlear delivery simulator is available online from A. Salt. Additional
validation of the lumped parameter model was done using the simulation tool developed by Salt [4, 5].
The Salt tool simulates bolus or steady infusion modes of delivery, and, similar to the lumped model,
captures drug transport via both diffusion and pressure-driven flow. The Salt model is not capable of
capturing the pulsatile flow profile of this delivery system and does not incorporate drug binding
mechanisms. Figures 3.33 to 3.35 show the user interface for the Salt simulator. Delivery parameters
included: bolus volume of 0.655 IL, solute concentration of 300 IpM, and solute diffusivity of 9.4E-6
cm 2/sec. The bolus was administered at a point 2.2 mm from the base of the scala tympani.
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Figure 3.33: Salt simulator window showing position of bolus entry in scala tympani
Figure 3.34: Salt simulator window showing bolus application inputs
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Figure 3.35: Salt simulator window showing time and diffusion parameters
Figure 3.36 shows comparative plots of the two simulators for a bolus delivery. Concentration profiles
in the 32 kHz and 8 kHz regions show good agreement in concentration amounts and in long-term
trends.
Figure 3.36: Comparison of Salt simulator to lumped element model for two frequency locations
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3.7.2 Guinea pig cochlea drug delivery experimental method
In vivo guinea pig studies were undertaken using the syringe pump system to compare results to
those of the delivery model. The guinea pig was used as the animal model because it has a large and
accessible inner ear and its anatomical, physiological and pharmacological properties are thoroughly
understood. The animals are easily kept in the laboratory and tolerate well the long surgery and
implantation of tubes and devices. The team has extensive experience perfusing the inner ear of guinea
pigs and in quantifying, electrophysiologically and histologically, the effects of various treatments in
guinea pigs. Animals were housed in the IACUC-approved animal care facility at the MEEI. Surgical,
perfusion, testing, euthanasia and tissue preparation protocols were approved and monitored by the
MEEI Animal Care Committee.
3.7.2.1 System preparation
In preparation for the guinea pig experiment, the artificial perilymph (AP) was thawed and
placed in the heated chamber to equilibrate to body temperature. The syringe pump (Harvard
Apparatus PHD 2000) was connected to the computer to allow for Labview control using a customized
program that set the flow parameters and controlled pump infusion and withdrawal at intervals set by
the user. A 6-foot length of large-bore, rigid Teflon tubing was connected to an electronically shielded
flow sensor (Sensirion 1430). The sensor provided input to the Labview program so volume and flow
could be continuously monitored throughout the experiment. The length allowed the syringe pump to
be maintained outside of the acoustically-shielded chamber while the remaining system components
resided in close proximity to the animal. The outlet of the flow sensor was then connected to the
manifold housing the cannula for cochlear implantation. As shown in the diagram (Figure 3.19), a
second manifold connected the drug reservoir to the infusion line. A pump attached to a timer-
controlled power source ensured that the drug was completely refreshed in the slug of fluid entering the
cochlea between each cycle. The drug loop was filled with 300 PIM DNQX. All other components were
carefully filled with AP as the system was constructed to eliminate bubbles in the system. After filling,
the other end of the Teflon tubing was connected to a 100 PL glass Hamilton syringe that was placed on
the syringe pump.
The cannula was placed in an AP reservoir for system testing. The Labview program was set to
the desired infuse and withdraw rates and durations to provide the desired flow characteristics, and the
sensor output was monitored to ensure agreement between the settings and actual flow from the
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cannula. The drug loop pump was also tested. It was cycled enough times to push 1 pL of fresh drug
solution into the infuse loop, usually 2-3 pump pulses. The timer box was set to repeat every 3 minutes
to match the period of syringe pump cycling. After demonstration of proper performance of the pump
on the bench, the animal was prepared for surgery.
3.7.2.2 Surgical Preparation
All procedures were accomplished in an acoustically and electrically shielded, heated (34 °C)
chamber. Adult albino guinea pigs (Charles River, 350-500 g) were anesthetized with a combination of
pentobarbital sodium (25 mg/kg intraperitoneal), fentanyl (0.2 mg/kg intramuscular), and droperidol (10
mg/kg intramuscular). Anesthetic boosters of one-third the original dose were administered every 2 hr
or as required to maintain an adequate depth of anesthesia. The head and neck/upper chest areas were
shaved, the animal was placed supine, and the surgical area of the ventral neck was cleaned. The bulla
was exposed via a retroauricular incision, and an opening in the bulla was created with a sharp blade to
visualize the cochlear basal turn and the round window membrane. A cochleostomy, an approximately
150-200 pm opening into the scala tympani of the cochlear basal turn, was created using a modified pick
shaved specifically for this purpose. During placement of the perfusion tubing (flexible fused silica; 150
pm O.D.; 75 pm I.D.) into the cochleostomy, dental cement (ESPE, 3M, St. Paul MN) was placed around
the tubing to secure it and to seal the cochleostomy. The perfusion line, attached to the manifold, was
then cemented to the bulla to prevent movement. Heart rate was monitored throughout the
experiment as an indicant of depth of anesthesia.
The compound action potential (CAP) electrode was placed near the round window niche and
acoustic apparatus was properly positioned in the ear canal. Baseline responses (CAP and distortion
product otoacoustic emission [DPOAE]) were monitored, as described below. After demonstration of
normal baseline sensitivity, the pump was started at 150 sec intervals with AP only. The round window
membrane was visualized through the bulla opening. Bulging of the round window membrane was seen
during the pulses, confirming proper functioning of the perfusion system. The AP alone was perfused
for a half of an hour, and stable hearing was maintained. The drug was then incorporated into the AP.
CAP responses were measured approximately half-hourly, and DPOAE responses were monitored hourly
throughout the course of drug perfusion.
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3.7.2.3 Control Solution and Drug
An AP solution served as a control solution and also as the vehicle for the test drug. It was
mixed in-house and was composed of (in mM): NaCI, 120; KCI, 3.5; CaCI2, 2; glucose, 5.5; HEPES, 20, and
it was titrated with NaOH to pH 7.5 in a deionized and filtered water base for a total Na of 130 mM.
The experimental drug, the glutamate receptor antagonist, DNQX (300 IpM), was dissolved in the AP and
pH-adjusted as needed. DNQX was first dissolved in a small amount of dimethyl sulfoxide (DMSO; final
concentration, 0.05%) which did not, on its own, produce significant changes in cochlear responses. All
drugs were from Sigma chemicals. DNQX acted to block transmission between inner hair cells and the
auditory nerve and effected CAP thresholds, which are described below. It had no impact on DPOAE
levels (described below) as these originated at the outer hair cells. DPOAE acted as an internal control
during drug delivery.
3.7.2.4 Electrophysiologic and otoacoustic measures
Stimuli were created and responses monitored using 16-bit A/D, D/A boards (National
Instruments, Austin TX) controlled in a Labview environment by a computer. Signals used to elicit CAP
and DPOAE were delivered to the ear using a custom coupler that accommodates transducers (Tucker
Davis EC1) and a Knowles EK3103 electret microphone to measure ear-canal sound pressure (for
DPOAEs) via a probe tube concentric with the 2.54 mm (O.D.) sound delivery tube. Sensitivity versus
frequency calibration curves were generated for the monitoring and probe microphones, respectively,
enabling conversion from voltage to sound pressure level (SPL) (in dB re: 20 pPa). The probe assembly
was then placed at the animal's ear canal where 'in-animal' calibration sweeps were accomplished and
used to determine the actual SPLs generated at the entrance to the bony canal. After calibration, the
probe assembly remained in place for the duration of the experiment.
CAP, a measure of activity of the auditory nerve, was elicited using tone pip stimuli (2.78 - 32.0
kHz, 0.5-ms duration, 0.5-ms rise-fall, cos2 onset envelope, 16/sec). Levels were incremented in 5 dB
steps from 0 to 80 dB SPL. Responses were detected via a silver-wire electrode at the round window
niche, amplified (10,000 times), filtered (300 Hz to 3 kHz), and averaged across 32 samples. Response
values (e.g., thresholds, peak-to-peak amplitudes) and waveforms were stored. CAP threshold was
defined as the lowest stimulus level at which response peaks were clearly and reproducibly present.
When two primary tones (fl, f2) were played simultaneously to the ear, acoustic distortion products
of their interaction in the cochlea were propagated back out through the middle ear and detected using a
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sensitive microphone placed in the external ear canal. The distortion product corresponding to the
frequency (2f1-f2) was used as a metric of cochlear and, in particular, outer hair cell function. These (2f1-f2)
DPOAEs were recorded as response amplitude versus primary level functions (L1=10-75 dB SPL, L2=L1-10,
primaries incremented together in 5 dB steps) spanning the frequency range f2 = 2.78 - 32.0 kHz (selected
to equal CAP test frequencies, f2/fl = 1.2). Ear-canal sound pressure was amplified, digitally sampled, and
averaged (25 discrete spectra at each frequency-level combination), and Fast-Fourier transforms were
computed from averaged pressures. DPOAE level at (2f1-f2) and surrounding noise floor values (± 50 Hz of
2f1-f2) were extracted. Iso-response contours (L2 levels required to generate a DPOAE amplitude criterion
of 0 SPL) were constructed from amplitude versus sound level data to facilitate comparison with CAPs.
3.7.3 Results
DNQX, at a concentration of 300 .pM, was delivered to the cochlea using the syringe pump
system. The system was configured to deliver a maximum volume of 750 nL at a maximum flow rate of
8.5 pL/min and withdraw the same amount in 90 sec. The cycle was repeated every 150 sec. Consistent
with a site of action at the inner hair cell-afferent fiber synapse, perfusion of DNQX elevated CAP
thresholds. Drug effects on CAP were frequency sensitive; responses to high frequency stimuli were
altered first and most, followed progressively by involvement of responses to mid- and then lower-
frequency stimuli. This reflected the influence of location of drug administration through the cannula in
the high frequency region (around 28 kHz). Threshold levels at 32 and 24 kHz immediately rose above
the saturation level of the equipment and could not be measured. No change in threshold levels was
seen in DPOAEs. This confirmed that the delivery mechanism itself did not cause damage to hearing.
The threshold shifts resulted from the delivery of DNQX.
Drug-induced changes as a function of frequency are plotted in Figure 3.37. The data represents
the averaged results of four guinea pig experiments. Threshold elevations in CAP were seen as far
apically as 12 kHz, though they were smaller than those at basal frequencies. This suggested that longer
perfusion times are needed for delivery to more apical regions of the cochlea. DPOAE thresholds are
shown in Figure 3.38.
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Figure 3.37: Average CAP response at several locations over time to DNQX delivery in guinea pigs
Figure 3.38: Average DPOAE response at several locations over time to DNQX delivery in guinea pigs
Identical experiments were conducted with maximum flow rates set at 13 pL/min and 21
pL/min. In general, similar results were seen. The onset of drug action at lower frequencies occurred
slightly more quickly with the higher flow rates, but DPOAE shifts were minimally higher suggesting
damage to the cochlear structures due to the higher flow rate. Experiments to determine the optimal
delivery profile with minimal damage continue.
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3.7.4 Dose-response relationship
In order for experimental results to be compared to the model, the hearing response at the
measurement points of the model must be inferred from the concentration based on a dose-response
relationship. Unfortunately, this relationship has not been established for a range of DNQX concentrations.
Equipment settings limit the recording of hearing threshold shifts above 30 dB. Any DNQX-induced changes
above this value cannot be measured. It was found that the 300 pM concentration used in this series of
experiments caused thresholds to increase beyond measurement limits at the higher frequencies.
Therefore, the maximum response to these concentrations is not known. Based on these findings, the
construction of an accurate dose-response curve was very difficult, and this proved to be one of the main
limitations encountered in the attempt to compare experimental to modeled results. Additional limitations
are outlined below. A dose response curve constructed with a linear fit for the small dB range (0-25dB)
measurable in these experiments. The intercept was set to 0 and the slope to 0.5 dB/uM as shown below in
Figure 3.39. This relationship was used to convert model output concentration to hearing response for
comparison to experimental results. Additional experiments need to be conducted to better understand the
relationship.
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Figure 3.39: Constructed DNQX dose-response relationship
3.7.5 Mechanisms limiting drug availability
DNQX binding to protein in perilymph is hypothesized to play a major role in limiting the amount
available to target tissue. As discussed later in Chapter 4, many proteins exist in perilymph that are capable
of binding various drugs. In the case of DNQX, proteins that bind both acidic compounds and lipophilic
Erin E. Leary Swan
- - - . ....
111 IPage
compounds may bind this drug. These proteins, including albumin and apolipoproteins, account for over
35% of all of the protein in perilymph.
Estimations of protein binding were undertaken to provide parameters to model the phenomenon.
The experimental threshold shift at the 12 kHz region was compared to the estimated concentration
expected due to diffusion alone. After approximately 200 min, the experimental concentration was only
approximately 1% of what would be expected from diffusion alone. This estimate is in line with 2%
estimated bioavailability of drugs with similar composition to DNQX.
In the short time period of acute experiments, the amount of protein present in the scala tympani is
constant. Therefore, after all the available protein has bound to the DNQX, the rest of the drug will be
available to cause a change in hearing response. On this short time course, the other loss mechanisms are
assumed to be much slower than the protein binding.
In order to model the binding, the capacitors representing the cochlear segments were given initial
conditions equal to -1.75e17, representing 99% of the DNQX concentration delivered. Only after the
amount of DNQX in each segment rose above this value did the model predict an increase in hearing
threshold levels, i.e. a positive charge on a capacitor indicated unbound DNQX. This crude method of
accommodating protein binding delayed the onset of a response but did not slow the subsequent rise that
was seen in the experimental data. Therefore, other methods of accommodating protein binding were
employed.
After removing the initial condition on the capacitors, the diffusion coefficient was empirically
altered to reflect a much larger molecule, DNQX bound to protein. The diffusivity was decreased 5-fold to
slow the diffusive transport in the model and more accurately represent the experimental findings. While
empirically chosen, the diffusion coefficient was estimated from an analysis of the diffusion-only case for
mass transport, thus assuring a physical significance for the value.
In the future, additional work should be done to accurately represent this and other clearance and
loss mechanisms limiting drug response. More loss elements (resistors) could be added to represent
metabolism, clearance to vasculature, diffusion through surrounding tissue, etc. Storage elements
(capacitors) could represent reversible binding to protein in tissue and refreshing of perilymph protein.
However, elucidating the individual contributions of these mechanisms may prove very difficult and
consuming. Figure 3.40 illustrates how additional elements could be incorporated into the model to
represent other biological aspects.
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Figure 3.40: Circuit diagram showing the inclusion of additional elements to model biological phenomena
3.8 COMPARISON OF THE MODEL TO EXPERIMENTAL DATA
The experimental data from 32 and 24 kHz could not be compared to the model since the threshold
almost immediately increased to and surpassed the maximum level the equipment could evaluate The
comparison of the modeled data to the experimental data at 16 and 12 kHz did not provide an adequate fit.
It was hypothesized that mixing and other complicated flow characteristics were present in the region near
the cannula insertion point that the model was not capturing. However, at some distance apical to the
insertion point, these phenomena were no longer dominating, and diffusion was dominating. This position
became the effective insertion point. In addition, a new initial concentration was established at this point
due to dilution in the mixed area. Figure 3.41 shows a schematic of the cochlea with relevant distances
marked. The location of the effective insertion point, 2.7 mm from the base, was determined from a curve
fit to the experimental data. The effective initial concentration is dependent on this location due to the
volume of perilymph diluting the drug. The volume was found to be four-fold greater than the volume of
the actual drug injection. Therefore, the initial concentration at the new effective insertion point was four-
fold smaller.
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Figure 3.41: Schematic of effective insertion location in cochlea
These values were then used to guide optimization of the model. The model was manually fit by varying the
insertion point and initial concentration. Figures 3.42 and 3.43 show the modeled data with an effective
insertion location of 2.7 mm and an initial concentration of 50 pM compared to the individual data for the
four experiments summarized above.
Figure 3.42: Comparison of experimental data to model at 16 kHz for guinea pig experiments. The light red
line shows the modeled result using the actual experimental insertion point and concentration rather than
the effective insertion point and concentration.
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Figure 3.43: Comparison of experimental data to model at 12 kHz for guinea pig experiments. The light red
line shows the modeled result using the actual experimental insertion point and concentration rather than
the effective insertion point and concentration.
3.9 LIMITATIONS OF THE MODEL
Many limitations in modeling the in vivo experiments exist. No direct method for measurement
of drug concentration in the cochlea exists, and direct fluid sampling from the cochlea is limited.
Creating access for sampling causes damage to hearing, and CSF contamination of the sample occurs
due to the guinea pigs' patent cochlea aqueduct. For these reasons, the concentration of drug must be
inferred from the biological response. In the case of DNQX, no dose-response curve exists, and
comparisons of this model were limited by the lack of knowledge of the relationship between
concentration and hearing threshold elevation over multiple orders of magnitude. The DNQX dose-
response curve had to be estimated. The potency of DNQX caused the thresholds to rise above hearing
measurement limits when the concentration may still have been increasing.
Very little is known of the interactions between drugs and structures in the cochlea. The time
courses of clearance and other loss and storage mechanisms are drug specific, and little research has been
conducted. Because of its inaccessibility and sensitivity, pharmacokinetic studies are very difficult. Drug
delivery up to this point has all been done by trial and error without methods to quantify concentrations and
transport and clearance rates.
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The impact of protein interactions with DNQX was believed to be significant, but only crude
estimates were available for modeling purposes. The decreased diffusivity due to protein binding was
empirically derived from the diffusion-only case. No long term experiments were conducted to learn the
true time course and impact of these mechanisms.
The model did not capture the complex fluidic interactions near the point of cannula insertion.
However, the model was useful for comparison to experimental results distant from this region. The effort
to understand the physical implications and to estimate the region where diffusion again dominated proved
very useful in gaining a broader understanding of drug delivery in the cochlea. This avenue of research and
corresponding model refinement will be pursued next.
3.10 ADAPTATION OF THE MODEL FOR HUMANS
Adaptation of the model for use in modeling of delivery in humans is straightforward. The
anatomical dimensions of the various cochlear structures must be adjusted, but these measurements are
available from the literature or from cadaver temporal bones. One important difference between humans
and guinea pigs is that most human cochlear aqueducts are not patent. The elements representing this
structure should be removed from the model.
3.11 CONCLUSION
A lumped parameter model was created to characterize drug transport in the cochlea delivered by
the pulsatile delivery system. This model was successfully validated using a bench-top flow visualization
technique. More knowledge of biological interaction with the drug would enhance the usefulness of
modeling in vivo studies. With additional refinement, a model such as this one would be extremely useful in
development of drugs and drug delivery systems specifically for the cochlea. Human cochleae cannot be
sampled in pharmacokinetic studies or clinical trials due to ethical concerns. Future device development can
be driven by the knowledge gained from the model and the interactions of specific elements of the model.
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4.0 PROTEIN COMPOSITION AND DEVICE INTERACTION
Protein interactions play a major role in the performance of implanted drug delivery systems.
The presence of some proteins, albumin among others, has been associated with biofouling, the build-
up of protein and cellular matter on the device materials. In the case of this device, any changes in the
flow path such as narrowing of channels could alter the delivery profile. In addition, drug selection must
be based on the knowledge of proteins present in the perilymph. Some drugs may be altered by
enzymes or bound to lipoproteins making them unavailable to the target tissue.
Due to a limited knowledge of perilymph protein composition, a mass-spectrometry analysis
was undertaken. Over 50 proteins were identified, many of which may impact drug delivery into the
cochlea. In addition, a bench-top study of protein effects on materials typically used in the device was
performed. Due to the small diameter channels in the recirculating system, there is a high potential for
clogging and flow restrictions. Design parameters must accommodate these potentialities.
4.1 PROTEIN COMPOSITION ANALYSIS
4.1.1 Introduction
A major design consideration for implantable drug delivery systems is their ability to function
properly while interacting with intrinsic biological factors. Proteins in perilymph can adsorb onto the
surfaces of the implant which may lead to biofouling and changes in delivery profiles [1, 2]. Knowledge
of protein composition of perilymph will help anticipate protein interactions with delivered agents and
will allow implants and drug delivery regimens to be tailored for optimal performance through the
device lifetime.
Previous analyses of proteins in perilymph were performed using electrophoretic techniques
and candidate approaches to identification [3-6]. With the advent of mass-spectrometry-based
proteomics, tools now exist to separate and identify in small sample quantities unprecedented numbers
of proteins and to automate the identification of explicit protein isoforms. Salt et al.'s [7] perilymph
collection procedures were adapted to the mouse to identify the most abundant proteins present in
mouse perilymph and cerebrospinal fluid (CSF). The mouse was chosen because its proteome is
relatively complete and because of its increasing importance as a genetic model for human disease.
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4.1.2 Methods
4.1.2.1 Sample collection
CBA/CAJ male mice (Jackson Laboratories, Bar Harbor, ME) 3 months of age were anesthetized
with a combination of 100 mg/kg of ketamine and 10 mg/kg of xylazine administered intraperitoneally.
Anesthetic boosters (1/3rd the original dose) were administered every 20 min throughout the surgery.
Procedures were performed in a heated (31 0 C) chamber. The surface of the tympanic bulla was
exposed after making an incision extending from the mandibular symphysis to the clavicle. The digastric
muscle was cut using a bipolar cautery. A wide opening in the bulla allowed access to the cochlear apex.
An indelible pen was used to make a small mark on the apex of the cochlea where sampling would
occur. Altering a method introduced by Salt et al. [7], the inner surface of the auditory bulla and the
cochlea were coated with liquid cyanoacrylate glue and allowed to dry for 10-15 minutes. A thin layer of
fingernail polish was applied on all surfaces within the bulla area to minimize contamination from
surrounding tissues. An opening in the apical turn was created with a new 175 nm diameter carbide drill
(Drill Bit City, Prospect Heights, IL). Samples were collected with a drawn glass capillary tube. After
discarding the first tube with approximately 100 nL of perilymph, an additional 0.5 pLL was collected and
stored at -80" C for the proteomics analysis.
CSF was collected from one additional animal as described by Vogelweid et al. [8]. Skin and
muscles layering the occipital bone and the atlas were removed, and the atlanto-occipital membrane
was exposed, cleaned and dried. To minimize contamination during CSF collection, a layer of fingernail
polish was placed over the membrane and allowed to dry for about 10-15 minutes. A 25 gauge needle
was used to perforate the membrane, and 1 pL CSF was collected with a drawn glass capillary tube. The
sample was stored at -800 C for analysis.
All procedures were approved by the Animal Care and Use Committee of the Massachusetts Eye
and Ear Infirmary.
4.1.2.2 Sample preparation
Four samples were utilized for analysis: 3 perilymph samples of 0.5 IpL, each collected from a
different mouse, and CSF from an additional mouse. The 4 samples were reduced, alkylated, trypsin-
digested and derivatized with the 114, 115, 116 and 117 iTRAQ reagents [9] using reagent solutions and
following the standard protocol supplied with the iTRAQTM kit (Applied Biosystems, Foster City, CA,
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Chemistry Reference Guide). Once the samples were separately labeled with iTRAQ reagents, they were
combined and cleaned by strong cation exchange (SCX) using a 4x15 mm POROSTM 50-HS SCX cartridge
(Applied Biosystems). Samples were applied to the SCX cartridge in 2 mL of load buffer (Applied
Biosystems, 10 mM potassium phosphate, 25% acetonitrile (ACN), pH 3.0). The column was washed with
1 mL of load buffer, and the pass through was collected. The sample was then eluted using 500 ipL
elution buffer (Applied Biosystems, 10 mM potassium phosphate, 375 mM potassium chloride, 25%
ACN, pH 3.0). The SCX elution solvent was removed by vacuum centrifugation. The peptides were re-
suspended in 0.1% trifluoracetic acid and cleaned on a C18 MicroSpin TM column (The Nest Group,
Southborough, MA, Vydac C18 Silica). The eluant was dried in a speedvac.
4.1.2.3 Capillary liquid chromatography-mass spectrometry/mass spectrometry
(LC-MS/MS) analysis
Data-dependent UPLC-MS/MS analyses were performed using a Waters nanoACQUITY UPLC®
chromatography system and a Waters Q-TOF Premier TM MS system (Waters, Milford, MA). The
combined sample (containing the 3 iTRAQ labeled perilymph samples and the CSF sample) was dissolved
in 20 pL of 2% ACN, 0.1% formic acid (FA) (solvent A), and quadruple analyses of the sample were
performed (2 with 5 pL of each and 2 with 2.5 pL of each) using the nanoACQUITY auto sampler. The
peptides were first trapped on a 180 pm ID X 20 mm trapping column packed with 5 pm Symmetry® C18
(Waters) with 3% ACN, 0.1% FA as the mobile phase, at a flow rate of 5 pL/min for 3 minutes. The flow
was then reduced to 350 nL/min and directed through the analytical 75 pm (ID) X 10 cm C18 capillary
UPLC® column (130 A, 1.7 pm BEH130 nanoACQUITY®, Waters, Inc.) A solvent gradient was run from 3
to 40% ACN in 0.1% FA in 110 min at a rate of 350 nL/min. Nanoelectrospray ionization was performed
at 3000 V with the heated capillary at 1800 C. During the gradient elution, data dependant scans were
performed with 4 scan events per cycle consisting of one full MS from mass/charge ratio (m/z) 300 -
1,800 followed by product ion scans on the 3 most intense ions in the full scan using charge state
optimized collision energy programs. Precursor ions used to obtain product ion scans were dynamically
excluded (m/z -0.1,+0.1) from reanalysis for 20 seconds. Lock-mass spectra (glucofibrogenen peptide,
Sigma, St. Louis, MO) were acquired at 30 second intervals throughout the analyses.
4.1.2.4 Database searching and iTRAQ quanitification
A Uniprot FASTA database containing all mouse protein sequences was downloaded from
http://www.informatics.jax.org/, the mouse genome informatics website, on July 31, 2008, and
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searched with Protein Lynx Global Server (PLGS) software (v2.2.5, Waters, Inc.). Variable modifications
that were searched for included: iTRAQ derivatives on N-term and lysine, oxidation of methionine and
alkylation of cysteine. The raw data was lock-mass corrected, de-isotoped, and charge state reduced by
PLGS. Results were combined from four repeat LCMS analyses of the sample for data analysis.
Determination of the iTRAQ reporter ion ratios was performed using the Expression Analysis routine in
PLGS.
All proteins identified by the PLGS search engine were then individually evaluated by manual
inspection. A concatenated target-decoy database analysis was also conducted to quantify the false
positive rate [10]. Only one reversed sequence was found in the group of proteins identified by 2 or
more peptides, resulting in an overall false positive rate of 1.75% for the reported protein
identifications.
4.1.2.5 Protein quantification
For each protein, relative content in the samples was based on determination of the
exponentially modified protein abundance index (emPAl) [11], which estimated relative protein
concentration based on the ratio of observed to observable unique peptides. The number of observable
peptides per protein was determined by (1) in-silico trypsin digestion of the identified proteins, (2)
counting of the resulting peptides that conformed to the range of HPLC retention values (calculated by
the procedure of Brown et al. [12]), and (3) molecular weight range observed from the list of all 443
peptides identified in all 4 analyses performed on the present set of samples. The iTRAQ reporter ion
ratios provided relative ratios of each protein in the 4 samples analyzed. Assuming the protein content
analyzed was the sum of the protein in each of the 4 contributing samples, an algebraic solution was
used to determine the protein content in each of the 4 iTRAQ labeled samples. To quantify the relative
amounts of each protein, a protein content index (P) was created for each of the 4 samples, where
Ptota = PCSF + Pperil Pperi2 + P eri3 Equation 4.1
iTRAQ reporter ion ratios provided the ratios of protein content in CSF to that in each of the
perilymph samples, so
P = Ptotal
CSF "pel P P
peril Pperi2 + Pperi3 +1 Equation 4.2PCSF PCSF PCSF
PCSF PCSF PCSF
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Relative content of each protein in a sample was expressed on a molar basis as the mol%.
The samples were not centrifuged after collection, and consequently some hemoglobin was
detected in the proteomics analysis. Still none of the samples appeared to have a reddish hue. The
hemoglobin content was excluded from the analysis.
4.1.3 Results
Approximately 130 proteins were identified in the iTRAQ analysis of the sample that combined 3
perilymph and 1 CSF samples. From this data set, 50 proteins (Table 4.1, with additional detail in the
supplementary table at the end of the chapter) were identified by at least 2 peptides and were judged
to have a greater than 98% probability of correct identification by counting the number of segregate
(reversed) proteins identified from the complete set of reversed sequences included in the database
searched. The ratio of iTRAQ reporter ions allowed determination of relative amounts of each protein in
each perilymph and CSF sample. The mass-spectrometry-based proteomics methods provided a
quantitative estimate of the amounts of each protein in the sample based on the ratio of observed to
observable tryptic peptides identified for each protein [11]. Using both the estimated total amounts of
each protein and the iTRAQ ratios, the relative amounts of each protein between each perilymph and
CSF sample were determined. The major proteins in perilymph and CSF were similar, though protein in
perilymph was on average 2.8 times more concentrated than in CSF.
Albumin, the single protein found in highest concentrations in perilymph, accounted for around
14% of the protein in perilymph. Other proteins in relatively high concentrations (5% to 6%) included
prostaglandin D synthase (a lipophilic ligand binding protein [13] thought to play a role in blood-organ
barriers), two serine protease inhibitors (serpin ald and serpin ala), and two apolipoproteins (apoA2
and apoD). Figure 4.1 summarizes the major categories of proteins found in perilymph. The major
family of proteins in perilymph was the group of protease inhibitors, which represented over 1/3rd of
the total protein content in perilymph. The predominant type of protease inhibitors were the serine
protease inhibitors or serpins (27.8%), followed by several cysteine protease inhibitors (HMW kininogen,
cystatin, and GUGU beta, 5.6%). The broad spectrum protease inhibitors (alpha-2-macroglobulin and
murinoglobulin) comprised the remaining (3.1%) protease inhibitors. Protease inhibitors bind to and
inactivate proteases. While their specific role in the perilymph is unknown, a general role for these
proteins is in mediating inflammation.
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Table 4.1: Major proteins identified in mouse perilymph listed in descending order of the molar
percentage in perilymph. For each peptide, a family or function is listed, though this categorization is
arbitrary since most peptides can have multiple functions and families.
Molecular Perilvmph CSF
Accession Protein Family or function
weiaht (mol%) (mol%)
PTGDSMOUSE prostaglandin D synthase enzyme 21052 6.3% 6.7%
APOA2_MOUSE apoA2 apolipoprotein 11311 5.3% 3.5%
Q3KQQ4_MOUSE serpin ala serpin 45867 4.3% 3.8%
A1AT1 _MOUSE serpin ala serpin 45973 4.1% 3.7%
cysteine protease
A2APX3_MOUSE cystatin inhibitor 11133 3.1% 6.9%
TRFEMOUSE serotransferrin iron binding 76673 3.2% 2.8%
PRDX2_MOUSE peroxiredoxin enzyme 21765 2.6% 4.0%
CTF2_MOUSE cardiotrophin 2 cell signaling 21986 2.5% 2.8%
ACTB MOUSE beta actin actin 41709 2.0% 3.0%
VTDBMOUSE vitamin D binding protein ligand binding 53565 1.5% 1.3%
1-39 protease
A2MMOUSE alpha 2 macroglobulin inhibitor 165775 1.6% 0.8%
1-39 protease
MUGI_MOUSE murinoglobulin inhibitor 165192 1.5% 0.7%
transcription
Q9CS04_MOUSE 13 days embryo liver cDNA coactivator 15919 1.3% 1.2%
PLMN_MOUSE plasminogen enzyme peptidase S1 90722 1.1% 1.0%
A2NHM3_MOUSE If kappa 24149 1.1% 0.7%
A1AG1 _MOUSE alpha 1 acid glycoprotein ligand binding 23880 0.8% 0.8%
B2RSIOMOUSE GTPase activator enzyme activator 155179 0.7% 0.8%
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KCD13_MOUSE BTB (POZ) domain protein transcription factor 36419 0.5% 0.2%
Q99K20_MOUSE lactate dehydrogenase enzyme 34481 0.4% 0.5%
B2ZP54_MOUSE phosphodiesterase enzyme 98834 0.3% 0.7%
A2RTAO MOUSE creatine kinase enzyme 43017 0.3% 0.6%
K2C73_MOUSE keratin 73 keratin 58874 0.3% 0.9%
ENOBMOUSE beta enolase enzyme 46995 0.% 0.4%
Q3UV17_MOUSE keratin 2p keratin 62805 0.2% 0.5%
LI tein
protease albumin
inhibitors apolipoproteins enzymes family keratin
Figure 4.1: The most abundant protein families as percentage of total protein.
Enzymatic proteins represented another large family of proteins in perilymph, comprising over
14% of the total. These included prostaglandin D synthase, carboxylesterase, carbonic anhydrase,
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lactate dehydrogenase, and several redox enzymes. Another major category of proteins in perilymph
were the apolipoproteins, which act as lipid binders and transporters [14]. Apolipoprotein D, Al, and A2
were relatively concentrated in perilymph compared to CSF. Apolipoprotein D may have a role in
maintenance and repair in the central and peripheral nervous systems.
A number of other proteins of potential interest to auditory biologists were identified. They did
not meet the criteria for inclusion based on an automated probability analysis but were considered to
be good identifications based on examination of individual spectra. These included cochlin, a secreted
protein known to be involved in autosomal dominant nonsyndromal sensorineural hearing loss (DFNA9)
[15], NF kappa B inhibitor, matrillin4, a protein involved in bone resorption, and malate dehydrogenase.
4.1.4 Discussion
4.1.4.1 Protein composition of perilymph
The results confirmed and extended the analysis of Thalmann and colleagues [4], which was
based on a candidate approach with two-dimensional electrophoresis, and which until now has been the
most extensive analysis of perilymph proteins. The current analysis found that while protein
concentration in mouse perilymph was higher than that in CSF, the composition was similar. The data
suggested protein concentration was 2.8 times higher in perilymph than in CSF, but this value should be
taken only as an estimate, given that it is based on derived measures. The number of unique peptide
fragments associated with each protein can be related to the quantity of protein injected, but is not a
direct measure. The estimated perilymph/CSF ratio of 2.8 was low compared to analyses performed in
other species. The ratio of total protein content in human perilymph to CSF has been reported to range
between 4.3 and 5 [4, 5]. Moreover, Thalmann found a perilymph/CSF protein ratio of 5 in human and
12.5 in guinea pig [3, 4]. The total protein in perilymph and CSF in guinea pig [3] was 2.757±0.238 and
0.219±0.089 mg/mL±SD, respectively. Thalmann's electrophoretic analysis of human and guinea pig
perilymph identified several of the major proteins found in this analysis including albumin, alpha-1
antitrypsins (serpinal), antichymotrypsin (serpina3k), and serotransferrin [3, 4]. These were also
identified in Arrer et al.'s [6] study of human perilymph.
It was unlikely that there was significant contamination of the perilymph samples with CSF.
Salt's [7] technique of collecting from the apical turn of the cochlea was modified and used, and only 0.5
VIL of fluid was collected. Flow out of the apical cochleostomy was not as robust in the mouse as in the
guinea pig, suggesting that the cochlear aqueduct may be less patent in the mouse than in the guinea
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pig. Minor contamination with red blood cells was suspected in both the CSF and perilymph samples
since hemoglobin was detected in both, but a number of other major proteins known to be present in
mouse plasma, including apolipoprotein B, fibronectin, complement C5, and complement C4 [16] were
not detected. The sample was not spun before analysis, though no red color was observed in the fluid
or in the dried protein. The extraordinarily high content of hemoglobin in red blood cells implies that
even small amounts of contamination will be detected.
For any given protein, the estimates of differences between CSF and perilymph were based on
the incorporation of iTRAQ reporter ions and were likely to be relatively accurate. Murinoglobulin,
alpha-2 macroglobulin, and some apolipoproteins (apoD, apoAl, and apoA2) were found to be major
proteins that were 5- to 6-fold higher in perilymph than in CSF. The results confirmed Thalmann et al.'s
earlier work in the guinea pig [3], which found high relative levels of apolipoprotein D compared to
plasma, and in human perilymph [17] compared to plasma and CSF. Alpha-2 macrogloblulin and
murinoglobulin are both members of the 1-39 family of protease inhibitors and inhibit all four families of
proteases. Apolipoproteins are transporter proteins that can carry a variety of ligands. A couple of
transcription-related proteins, BTB (POZ) domain protein and TAF7-like RNA polymerase, and liver
carboxylesterase were also found to be elevated around 5-fold in perilymph compared to CSF.
4.1.4.2 Implications for inner ear drug delivery
A concern with any implanted drug delivery device is the possibility of biofouling that can
change the parameters of delivery over time. Protein adsorption to materials mediates the response of
cells to the device, as well. Biofouling limits the usefulness of implanted biosensors and can influence
the inflammatory process [1, 18]. Extensive research on protein response to various materials is
ongoing [19-21]. Many studies use albumin, along with fibrinogen, as model proteins for understanding
biofouling parameters [19-21]. Because perilymph has a large amount of albumin, designs for
implantable devices should incorporate biofouling considerations.
One known source for biofouling is high-molecular-weight kininogen, which is present in
perilymph and is a factor in coagulation and inflammation [22]. High-molecular-weight kininogen,
produced in the liver, adsorbs to the surface of biomaterials that come in contact with blood in vivo [23].
Proteins found in perilymph may affect the metabolism and distribution of drugs delivered to
the cochlea. Many proteins may bind to the drug molecules, making them unavailable to the target
tissues. Albumin, alpha-1 acid glycoprotein, prostaglandin D synthase, and lipoproteins may act in this
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way. Albumin tends to bind acidic ligands. Alpha-1 acid glycoprotein, found in relatively small
quantities in perilymph, is the primary carrier for basic drugs. Apolipoproteins and prostaglandin D
synthase bind ligands with hydrophobic characteristics [14].
Enzymes account for almost 15% of the protein in perilymph. Prostaglandin D synthase, found
in relatively high concentrations in perilymph, is an enzyme which has, in addition to a variety of CNS
functions, a role in maintaining the integrity of the blood-brain, blood-eye, and blood-testis barriers. A
potential role in the blood-cochlear barrier is thus likely.
4.2 PROTEIN BIOFOULING
As discussed above, perilymph contains a large amount of protein, such as albumin, that has
been shown to cause biofouling. The microfluidic system operates in direct communication with
perilymph and is sensitive to changes in fluidic resistance which result from changes in channel
dimensions. With channel diameters in the 50-75 pm range, biofouling is a significant concern. Fouling
may affect flow characteristics and device performance.
4.2.1 Analysis
Sample calculations illustrate the effect of protein build-up on fluid flow. For example, a 7 mm
long tube with a diameter of 50 pm has a fluidic resistance (R) of 0.110 psi/liL/min calculated from
Equation 4.3.
128pLR = Equation 4.3
KcD 4
where p is dynamic viscosity (1.00e-3 Pa*s for water), L is tube length, and D is tube diameter. This
equation applies to steady, incompressible, laminar flow in a straight, smooth pipe. With pressure of 1
psi, volume flow rate (Q) is 9 pL/min using Equation 4.4.
PQ = Equation 4.4
R
where P is pressure. For a 3 pm reduction in diameter, the resulting resistance increased to 0.140
psi/pL/min and volume flow decreased to 7 pL/min under constant pressure of 1 psi. Thus 6% decrease
in tubing diameter resulted in 22% decrease in flow. With tubing diameter of 40 pm, the volume flow
was 3.7 pL/min, or 40% of the original flow.
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A calculation of the number of albumin molecules passing through the tube was done to check
that layers on the order of a couple of pm were possible. An arbitrary layer thickness of 2.5 pm was
used, and the number of albumin molecules required to create that layer was estimated. The results are
shown in Table 4.2.
Table 4.2: Calculation of albumin molecules in deposited protein layer
Arbitrary layer thickness (pm) 2.5
Tubing length (m) 0.007
Albumin solution concentration (g/L) 2.76
Volume flow rate (pL/min) 7
Amount of albumin passing through tube (mg/day) 27.8
Albumin molecular weight (Da) 6.6e4
Number of albumin molecules passing (#/day) 2.5e17
Albumin diameter (nm) [24] 7.4
Number of albumin molecules in column (#) 169
Surface area of albumin (m2) 1.7e-16
Surface area of inside of tube (m2) 1.1e-6
Total albumin molecules in layer (#) 1.1e12
From this estimation, orders of magnitude more molecules pass through the tube each day than
are necessary to form a micron-thick layer inside of the tubing. This would indicate that build-up of
protein over several days to weeks would be enough to influence the tubing resistance and flow
characteristics.
4.2.2 Method
A bench-top experiment was undertaken to compare protein build-up of various materials used
in the drug delivery system. The test set-up was designed to expose the materials to the flow
characteristics to which they would be exposed in the fully-operational device. These materials included
stainless steel, polyetheretherketone (PEEK), polyimide (Kapton®), and fused silica. The dimensions of
the material test sections were 50 pm in diameter and 7 mm in length, resulting in a fluidic resistance of
0.110 psi/pL/min. A protein solution of albumin in deionized water with a concentration matching the
total perilymph protein concentration in guinea pig (2.76 g/L) was used as the flow medium and filled
the test apparatus shown in Figure 4.2. The protein solution was used as a substitute for actual guinea
pig perilymph which is limited in quantity to a few pL per cochlea. Albumin, along with immunoglobulin
G (IgG) and fibrinogen, has been used as a model protein in numerous studies of biofouling [19, 21, 25,
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26]. In this study, IgG and fibrinogen were not added to the solution as these two proteins were not
identified in the mass-spectrometry analysis of perilymph. The liquid was maintained at a constant
pressure head of 1 psi. Using Equation 4.4, the initial flow rate was 9 jL/min which corresponded
approximately to the maximum flow condition in the outlet cannula of a functioning device.
The test apparatus is diagramed below in Figure 4.2. The protein solution was maintained at
37"C to more closely mimic the internal temperature in the implanted situation. At intervals of 1 to 3
days, a flow sensor (Sensirion 1430, Staefa, Switzerland) was placed at the outlet of the various
materials. The flow rate was recorded, and the fluidic resistance was determined from the recorded
value and constant pressure. Flow continued uninterrupted over periods of weeks with repeated
measurements. Fluidic resistance of measurement tubing was subtracted. Materials were also visually
inspected using microscopy.
Pressure
head
I I IL
Silica PEEK Steel Polyimide
Figure 4.2: Diagram of protein biofouling test apparatus
4.2.3 Results
Results of testing indicated that all materials were prone to clogging. More than half of the tests
of each type resulted in clogging within 10 days, as shown in Table 4.3. Clogging was defined as
complete occlusion with no measurable flow rate.
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Table 4.3: Material assessment of clogging
# tests clogging within 10 days
Silica 4/6
PEEK 5/7
Steel 3/4
Polyimide 3/4
Graphs showing change in resistance of each material for a number of tests are shown below in
Figure 4.3.
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Figure 4.3: Change in fluidic resistance over time for four materials
Micrographs of material cross-sections for tests starred in Figure 4.3 are shown below in Figure
4.4. These images were taken of the tubing after albumin solution flow for the number of days listed on
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each image. Each tube was compared to a control tube of the same material which did not experience
flow. In the top left image of Figure 4.4, the silica tube showed almost complete occlusion by protein,
corresponding to the high resistance (>0.2 psi/pL/min) shown in Figure 4.3. The diameter of the
polyimide tubing (top right) decreased to result in a calculated difference in resistance of 0.06
psi/pL/min. This corresponds to the graph above in Figure 4.3 showing approximate resistance
difference of 0.04 psi/pL/min. From the graph above (4.3), the steel tube was nearly occluded;
however, the microscope in the image below (4.4) did not capture the interior of the tubing. Little
difference is seen between the polyimide tube used in the experiment and the control tube. This
corresponds to the minimal change in resistance reflected above (4.3).
Figure 4.4: Micrograph images of materials (clockwise from top left, silica, PEEK, polyimide, steel) after
albumin solution flow for the number of days labeled.
4.2.4 Discussion
This experiment was initially designed to assist in material selection for the next generation
delivery device. However, a high likelihood of clogging in all 50 [lm diameter tubes tested was
discovered. Performance of the device components with small dimensions in any of these materials
may be impacted by protein biofouling and clogging. It is important to remember that the flow rate
achieved in this test was equivalent to that generated in the device during infusion into the inner ear.
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The majority of each duty cycle has substantially lower flow rates. It is hypothesized that lower flow
rates may allow greater protein build-up.
Various methods, both physical and chemical, may be explored to reduce biofouling and/or
associated flow restrictions. Most simply, the largest dimensions that satisfy design constraints should
be used. This may reduce the impact of increased fluidic resistance on flow characteristics. Sensors may
be added in the device to monitor flow over time and adjust pumping to maintain desired delivery.
Other design considerations may be employed such as multiple channels that may be used sequentially.
When the sensor determines that biofouling has reached a critical level, flow can be diverted to an
unused channel. The pump or other pressure source can be programmable to allow increased driving
force to maintain desired flow characteristics even as biofouling continues to cause increases in
resistance. Prior to loading the device, the drug and carrier should be carefully filtered to eliminate any
particles that could clog the tubing.
Chemical methods of minimizing biofouling have been reported, as well. Poly (ethylene glycol)
(PEG) films coated onto materials resist protein adsorption through steric repulsion. Popat et al.
reported on a vapor deposition technique that yielded film thicknesses of approximately 20 A. The
surface coating was studied under stationary and flow conditions and decreased protein adsorption by
70-80% [27, 28]. Other chemical modifications including hyaluronic acid and N-(triethoxylsilylpropyl)-O-
polyethylene oxide urethane (TESP) coatings reduced biofouling [19, 29]. Oligomaltose coating was
used to minimize nonspecific protein adsorption by steric hindrance. The variable saccharide lengths
were designed to mimic the glycocalyx. Measured under flow conditions, this surface modification led
to up to 90% reduction in biofouling.
As polyimide is a favored material for the device, studies on biofouling of fluorinated polyimide
were useful. The material was cured at three different temperatures, 50, 150 and 250°C, and difference
in protein adsorption with curing times of the polymer was investigated. The 250 0C cured polyimide
showed the least deposit of protein [30, 31].
Because this was an in vitro test, actual physiological activity in the guinea pig may not be
accurately represented by this test. In vivo protein biofouling may be significantly different in time
course and amount. This experiment was designed to begin to understand the role protein deposition
may play in the device performance and guide material selection for future device revisions.
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4.3 TISSUE BIOFOULING
In addition to protein biofouling, two other areas of concern for the implanted device exist.
Biofouling due to cell migration and ingrowth of the device outlet in the cochlea and the effect of the
device on surrounding tissue must be studied. Tissue ingrowth into and around the device outlet may
increase fluidic resistance or occlude the implanted cannula. As the fluidic outlet was on the order of 50
Ipm in diameter, the studies described above showed reason for concern. Inflammation from a foreign
body response to the implantation may result in damage to the fragile inner ear structures.
4.3.1 Introduction
Prior investigations have been reported in the context of electrodes for cochlear prostheses.
Studies have shown that cells migrate along cochlear implants from the site of implantation and create
new tissue growth [32]. Researchers report the presence of both fibrous tissue and new bone growth in
both animal and human temporal bones [32-37]. In addition, the amount of ossification has been
shown to be dependent on the site and method of implantation [37, 38]. In a study at the Temporal
Bone Lab at the Massachusetts Eye and Ear Infirmary, a three-dimensional model was constructed by
stacking sections of human temporal bones, and volume and distribution measurements of new bone
were made. The total volume filled by new bone was 2-30%, with mean of 14% (SD 10%, n=7). Trauma
of the insertion was seen as the primary influencing factor, accounting for 80% of the variance (Personal
conversation with Peter Li of Temporal Bone Lab at MEEI 6/12/06). A universal observation was that the
site of the cochleostomy showed the most bone growth. Bone cell migration may also be a concern
with this novel device due to the similar surgical implantation method.
These electrodes have been placed in deaf ears so damage to fine structures in the cochlea has
not been a concern. Minimizing surgical trauma and foreign body response will be of utmost
importance as the devices will likely be implanted into hearing ears.
4.3.2 Histologic preparation
In this study, the device was implanted in the guinea pig for thirty days and was set to infuse
every 3 min. The device was tested at 17 days by introducing DNQX into the system and testing guinea
pig hearing. Threshold levels rose as expected due to the drug action. However, when tested again at
30 days, no hearing response to DNQX was shown. At that time, the cause of the failure could not be
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determined but possible causes included occlusion inside of the cannula, failure of the pumping system,
or tissue growth around the cochleostomy.
At the conclusion of the experiment, the delivery cannula was left in place, and the tubing
connecting it to the device was cut. The animal was sacrificed with an overdose of sodium
pentobarbital, and the inner ear was fixed, decalcified, sectioned, and mounted for histology.
The anesthetized guinea pig was perfused intracardially with 2.5% glutaraldehyde and 1.5%
paraformaldehyde in a 0.1 M phosphate buffer. The whole head was kept in the same fixative at 4°C for
4 weeks. The bulla was dissected and decalcified in 0.4 M EDTA and 1% glutaraldehyde for an additional
4 weeks. After decalcification, the entire inner ear with bulla attached was washed in distilled water for
1 hr and soaked in 50% alcohol overnight. Dehydration in ethanol continued as follows: 70% for 1 day,
80% for 2 days, 95% for 2 days, and 100% for 3 days with alcohol changed daily. The sample was placed
in 100% propylene oxide for 2 days. The inner ear was embedded in Araldite resin (Huntsman,
Woodlands, TX) and sectioned in a plane perpendicular to the implanted cannula at 20 pm with a
carbide steel knife. Sections were stained with epoxy tissue stain (Electron Microscopy Science #14950,
Hatfield, PA), mounted with Permount (Science Co., Denver, CO) on microscope slides and coverslipped.
4.3.3 Results
The tissue was studied for evidence of inflammation and new bony tissue. The cannula was inspected to
determine the degree of occlusion. By studying the series of sections with portions of the cannula, it
became readily apparent that the end of the cannula was no longer located in the scala tympani, where
it had been implanted. The cannula end was outside of the inner ear, and a tissue barrier between it
and the scala had formed as shown in Figure 4.5. It is hypothesized that this occurred due to the body's
natural defense of expelling the cannula at the cochleostomy site. Another explanation could be that
the anchor site of the manifold holding the cannula (dental cement at the bulla) may have loosened and
caused the cannula to move. Evidence of this has been seen in other chronic attempts. The anchor spot
is in close proximity to the jaw, and constant motion from eating and drinking may cause slippage of the
manifold.
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Figure 4.5: Histological slice of a guinea pig cochlea at 2x. The cannula (shown with the arrow) is not
located in the basal turn of the scala tympani (shown with at star) where it was implanted.
The interior of the cannula was examined for tissue growth. If the inner diameter was
diminished, the flow profile would have been altered. Every slice containing portions of the cannula was
inspected, and no tissue growth was apparent inside the cannula. An example microscopic image is
shown in Figure 4.6
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Figure 4.6: The inner diameter of the cannula shown at 20x. The cannula is composed of polyimide
coated silica. The silica was cracked during the sectioning. Tissue was stained, as can be seen to the
right of the cannula, and no tissue was visible inside the cannula.
Analysis of tissue response near the cannula showed no inflammation. New bone and fibrous
tissue developed in the middle ear space, but there was no reaction in the inner ear as shown in Figures
4.7 and 4.8. The amount of growth in the middle ear did not pose a concern for hearing. This bone
growth may have been a response to the initial drilling when the cannula was placed.
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Figure 4.7: Same slice of guinea pig cochlea as shown in Figure 4.5 magnified to 10x. The white arrow
shows a region of new bone growth in the middle ear near the cannula, and the black area shows an
area of fibrous tissue. Over time, the fibrous tissue may be remodeled into bone.
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Figure 5.8: Same slice of guinea pig cochlea as shown in Figure 4.7 at 10x. The arrow shows the edge of
the scala tympani. No new bone has developed inside the inner ear.
As discussed above, studies of patients with cochlear prostheses have shown new bone
formation inside the scala tympani along the electrode. As such, bone growth in the inner ear was
expected in this case. This observation leads to the uncertainty of whether the flow from the device
reduces the likelihood of bone growth. If so, this knowledge could have significant impact on cochlear
implants where much research is being conducted on using the devices in ears with residual hearing. If
new bone formation could be minimized or eliminated, the cochlear implants would function more
effectively, and hearing would be better preserved.
4.4 CONCLUSION
The protein composition of mouse perilymph was very similar to CSF, though proteins were on
average 2.8 times more concentrated in perilymph than in CSF. Protease inhibitors comprised over 1/3 rd
of the total protein content in perilymph, and more than half of these were serine protease inhibitors.
Albumin was the single protein present in highest amounts.
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Histological study of a chronically implanted cochlea showed no reaction to the cannula inside
the cochlea. Additionally, no tissue build-up was observed within the cannula itself. While promising,
these results must be further verified with additional animals and with longer implant periods.
Rights were reserved to reprint portions of this chapter from: Swan, E., et al., Proteomics analysis of
perilymph and cerebrospinal fluid in mouse. Laryngoscope, 2009. 119(5): p. 953-958.
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Supplemental table for perilymph protein analysis: Proteins that were identified with imposed criteria
! Im
Accession Protein
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5/161 11311 1
serpin ala 45867 12/44
1.29 6.3% 0.97 1.67 5.26 6.3% 6.7%
1.05 5.2% 2.56 7.14 3.03 5.3% 3.5%
0.87 4.3% 2.08 5.00 2.63 4.3% 3.8%
serpin ala 45973 11/42 1 0.83 4.1% 2.04 4.76 2.56 1 4.1% 13.7%
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PRDX2_MOUSE peroxiredoxin 21765PRDX2 SE peroxiredoxin
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25/116
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0.56 2.7% 1.22 2.27 2.00 2.6% 4.0%
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3/52
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protein I
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keratin 73 588/4
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keratin 2p 62805
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*iTRAQ ratios 1-3 represent the ratios of the reporter ions of perilymph samples 1 through 3 to the reporter ion of the CSF.
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5.0 MICROFLUIDIC COMPONENTS: FABRICATION AND TESTING
5.1 INTRODUCTION
Implantable drug delivery systems require integration of a delivery module with miniaturized
electronics and power supply. Principal advantages of the MEMS-based (MicroElectroMechanical
Systems) delivery system are the potential for miniaturization, full integration of pumps, sensors and
control electronics, and the low cost of batch fabrication techniques for high-volume manufacturing.
Device development has focused on systems constructed using micromachined polymer components for
improved biocompatibility, advantageous mechanical properties and reduced cost. Two components of
the microfluidic system, a manual 5-valve manifold and a fluidic capacitor, were fabricated using a
versatile milling and lamination procedure. The process utilized laminate sheets of polyimide that were
milled using a standard X-Y milling tool. The components were entirely compatible with and would
permit integration into a complete delivery system including sensors, pumps, surface mounted
electronics, and printed circuitry.
Many fabrication techniques have been used for producing microfluidic components and
systems from polymers [1] including cast molding [2], embossing [3, 4], and other soft lithography
techniques [5]. Generally, the devices created with these techniques have been for short-term use, and
many cannot be seamlessly integrated with current electronics packaging.
Microfabrication using polyimide films provides a stable, versatile platform that can incorporate
both fluidic and electronic elements. Because of its combination of chemical inertness, high
temperature tolerance and robust mechanical properties, this material is routinely used in electronic
circuitry and packaging. Polyimide films have also been used for polymer MEMS applications and
biosensors [6-9].
Draper Laboratory has previously utilized polyimide in microfluidic applications. Laser-
machining techniques were used to construct a closed loop flow controller with an anemometer-based
flow sensor and electronically controlled microvalve [10]. Other laboratory capabilities include reactive
ion etching to thin film adhesive and partial depth cutting of films using laser machining [11].
Although useful, fabrication with polyimide films using laser machining was too expensive for
this project and required long lead times. Therefore, techniques for machining with an X-Y milling table
were developed. The tools were inexpensive and immediately available for rapid prototyping and low-
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volume production. Design changes were quickly incorporated. These tools achieved routing speeds of
60 in/min or higher and spindle speeds from 20 krpm to greater than 100 krpm (Quickcircuit, T-Tech,
Norcross, GA). Positional accuracies of approximately 5 pm (lateral) and 10 pm (vertical) were typical.
The availability of end mill diameters down to 100 pm provided the flexibility to machine a wide variety
of microfluidic structures.
Two diaphragm-based polyimide microfluidic components, fluidic capacitors and manual screw
valves, were developed using micromilling and lamination. The components were designed for
integration into the MEMS-based device for chronic drug delivery to the inner ear [12]. The fluidic
capacitors provided fluidic capacitance to filter the output of the pump. Tuning of these capacitive
elements along with series resistance optimized volume flow and displacement into the cochlea. The
pulsatile output was achieved, but the amplitude of flow rate fluctuations was reduced to prevent
damage to delicate cochlear structures. The manual microvalves provided the required drug loading and
purge functions with acceptably low leak rates [13].
The microfluidic components were seamlessly incorporated into the fluidic network used in
animal studies. Both components significantly contributed to a reduction in size of the system and
provided greater control over critical system variables. The valve and capacitor can be integrated into a
versatile laminated polyimide fabrication platform along with other microfluidic and electronic
components including flow sensing and control elements.
5.2 FABRICATION METHODS
5.2.1 Machining
The Quickcircuit 7000 (T-Tech, Norcross, GA) X-Y router table was used for machining. It had a 0
- 60 krpm variable spindle speed and a 0 - 60 in/min variable routing speed capability. Vertical position
resolution (cut depth resolution) of the end mill was 10 pm. Double-edged clockwise-spinning stub end
mills ranging from 100 to 375 lm in diameter were used. Conventional cutting (finished edge was to the
left, relative to the direction of tool travel), as compared to climb cutting (edge to the right), yielded
substantially better edge quality with less roughness. As a result, cutouts were routed in the clockwise
direction, and channels were cut out one edge at a time, with some offset, rather than cut in a single
pass as shown in Figure 5.1a. The films were placed on a sacrificial high-density fiberboard backer
mounted on the router table for all cutting as shown in Figure 5.1b. The milling was done using a
conservative spindle speed ranging from 10 to 20 krpm and material feed rates of 3 to 6 in/min.
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Choosing the optimal parameters for machining of the polymer was complex [14]. The machining
conditions were not necessarily optimized; however parametric studies varying spindle speed and feed
rate were conducted and samples were evaluated. The general behavior was consistent with theory
[14]: at high feed rates and low spindle speeds, cuts resulted in tears and poor edge quality, while at low
feed rate to spindle speed ratios, excessive heating resulted, also leading to poor cuts.
machined polyimide
layer
(a) (b)
Figure 5.1: (a) Milling of a channel using only conventional cutting to avoid climb cutting. The solid
arrow shows the top-view rotation of the tool; the dashed arrow shows the tool path. The finished part
is shaded, while the through cut is shown in white. (b) Typical material stack used for machining single
layer of polyimide (cover sheet required for thin layers only).
The components were developed using Kapton@ polyimide films and R/flex@1000 Kapton--
adhesive laminate materials from Rogers Corporation. Specifically, Kapton@ sheets with thickness of 1,
3, or 5 mil, Kapton@ sheets with 0.5 or 1 mil thickness thermosetting adhesive, and stand-alone
adhesive sheets of 1 mil thickness were used.
The typical machining procedure included the following. Alignment holes, typically 1/8 in
diameter with 2.25 in spacing, were routed in a blank sheet. One of the holes was oblong in the
direction of the axis of the two holes, permitting thermal expansion of the sheet during the lamination
process but still providing repeatable placement on the routing table. The sheet was then repositioned
onto mating alignment pins on the router table, and the pattern was milled through the full depth of the
sheet and into the backer board as shown in Figure 5.1b. The sides of the sheet were taped down to
improve part stability. To machine thin layers (1 mil thickness or less), the mounting procedure was
modified. In addition to the description above, a second sacrificial layer of either 5 mil polyimide or
medium tack tape was added on top of the layer to be machined. This provided sufficient mechanical
rigidity to prevent bowing and/or tearing of the part during machining.
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5.2.2 Cleaning
Parts were cleaned in a water-filled ultrasonic bath for 5 minutes. For sheets with adhesive, the
adhesive backing layer was removed prior to placement in the bath. A nitrogen gun removed excess
water, and a 30 min, 60 oC oven bake completed the drying process. Incomplete drying resulted in
bubble formation in the adhesive layers and degradation of adhesion strength.
5.2.3 Lamination
The purpose-built laminator consisted of two chambers: a heated vacuum chamber in which the
piece was placed and an upper high pressure chamber (420 kPaG maximum) which applied force to a
movable 6 in diameter o-ring-sealed piston between the two chambers. In order to fabricate devices
with free-standing diaphragms using a lamination process, it was necessary to minimize pressure
differentials that can develop across the diaphragm during lamination due to trapped air. Otherwise,
plastic deformation of the diaphragm may result. Using the same machining methods described above,
additional sheets of polyimide were patterned with features that provided venting or pressure
equilibration. In addition, a bleed valve may be used to control the pump-down speed in combination
with vent channels.
The stack loaded for lamination contained multiple layers in addition to the active device layers.
A 0.25 in thick aluminum base plate (typically 2.5 in square) with alignment pins of the same diameter
and spacing as those used in the machining process provided the means for layer alignment. A 0.25 in
thick aluminum top plate provided uniform pressure over the parts to be laminated. Multiple sheets of
5-mil polyimide were added to the stack as necessary to provide compliance to accommodate surface
roughness and non-planarity in the base and top plates, improving pressure uniformity, and thus bond
integrity. These extra layers were placed against the inner faces of the aluminum plates in the stack. As
described above, additional layers of 5-mil polyimide with machined vent channels were used for
pressure equilibration. These layers were placed immediately adjacent to the top and bottom active
layers of the device. Figure 5.2 shows an example case of the overall stack. Note that inlet and outlet
tubing may be positioned in milled grooves and included in the stack.
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Figure 5.2: Cross section of example membrane capacitor shown in lamination chamber (not to
scale).
Recommended lamination pressure for the adhesive was achieved by setting the upper chamber
pressure appropriately. Specifically, the desired adhesive lamination pressure was scaled by the ratio of
the laminated device area and the piston area to arrive at the required net laminator pressure (the
gauge pressure of the upper chamber minus the vacuum level of the lamination chamber).
A.
P - P + P die
set vac adhpiso n  Equation 5.1
where Pset is the upper chamber pressure setpoint, Pva is the vacuum level of the lower chamber, Padh is
the desired lamination pressure for the adhesive, and Adie and Apiston are the areas of the laminate stack
and piston. The vacuum level Pvoc was not used to achieve the desired Podh because residual air in the
lamination chamber resulted in bubble formation in the adhesive interfaces between polyimide layers.
A vacuum level of less than 0.5 kPa was maintained. The lamination conditions, including lamination
time and temperature, used for the process are shown in Table 5.1. Parameters were consistent with
the manufacturer's recommendations for R/flex®1000 of 1725-2760 kPa effective adhesive pressure.
Table 5.1: Lamination conditions
Vacuum level (kPa) < 0.5
Over pressure (kPaG) 275
Laminate/piston area ratio (AdielAplunger) 0.2
Temperature ramp rate (oC/min) 5
Dwell time (min) 60
Dwell temperature (°C) 175
Effective adhesive pressure (Padh) (kPa) 2000
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5.2.4 Hybrid material components
The need to produce diaphragms with versatility in compliance and size motivated the
development of hybrid material structures. Such implementations provided the freedom to use
membranes with properties different from the polyimide used as the primary structural material of the
microfluidic component. Besides a capacitor with a polyimide diaphragm, another capacitor with an
inserted silicone (Specialty Silicone Products SSP-M823) diaphragm was fabricated. The router tool did
not effectively cut the elastomer so biopsy punches were used to cut circular silicone diaphragms.
In addition to choice of diaphragm material, flexibility in the choice of material and
configuration of inlet and outlet ports was useful. In-plane tubing ports were fabricated using stainless
steel, polyimide, and polyetheretherketone (PEEK) tubing. Grooves with a width typically equal to the
tubing diameter were milled in the stacked layers to prevent crushing of the tubing as shown in Figure
5.2.
5.2.5 Permeability reduction
Capacitor diaphragms were gold sputter-coated after lamination in order to reduce vapor loss
through the thin membrane. Gold provided a good combination of ductility, corrosion resistance, and
low water permeability. A thin adhesion-promoting layer of titanium or chromium (300 A) was
deposited prior to the gold deposition. Stress control of these materials was an important design
consideration. Low stress gold films were achieved in a 6 in magnetron sputter system using an applied
power of 600 W and an argon pressure of 0.4 Pa. Finally, film thickness was critical. Because both
permeability and compliance were inverse functions of thickness, the design space for diaphragms with
low permeability was limited. For example, a 1500 A gold layer increased the tensile stiffness of a 1 mil
polyimide membrane by 20%. An example of a fabricated fluidic capacitor with gold coating is shown in
Figure 5.3.
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Figure 5.3: Gold-coated fluidic capacitor showing a partially fabricated device (background) and
completed device (foreground)
5.3 MEMBRANE CAPACITOR
The microfluidic device relies on system capacitance and series resistors to adjust output flow
from the pump for appropriate delivery to the ear. Early device iterations utilized long segments of
compliant tubing to provide necessary system capacitance. In order to miniaturize the system and move
to a more fully integrated circuit, the planar polyimide capacitor component was developed, as shown in
Figures 5.4 and 5.5. Similar compliant structures have proven versatile in microfluidics for valving,
pumping, and other uses [15, 16]. Compliant membrane structures have been previously described [15-
17].
clampedfluid portion of
channel~ membrane
free portion chamfered
of membrane channel
entry/exit
Figure 5.4: Depiction of fluidic capacitor with elastomer membrane. Top and side schematics of fluidic
capacitor are shown.
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Figure 5.5: Microfabricated fluidic capacitor shown in size relation to penny and the compliant tubing it
replaced.
Figure 5.6: Microfabricated fluidic capacitor elements. (a) 5mm diameter, 1 mil thickness polyimide,
(b) 3.6mm diameter, 4 mil thickness silicone. Membrane reservoir was potted prior to sectioning to
improve section cut quality.
Two example implementations of fluidic single-membrane capacitors, as shown in Figure 5.6,
were described, and the predicted differential capacitance to measured values for different membrane
diameters, thicknesses and materials were compared. In both cases, it was reasonable to assume a fully
built in (fixed and held) boundary condition for model purposes. The relationship between maximum
displacement and applied pressure for a circular diaphragm was then given approximately by
Pa4  (7-)(z 3
Et4 3(1-t Equation 5.2
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where P was pressure, a was membrane radius, E was tensile modulus, t was membrane thickness, v
was the Poisson ratio, z was axial displacement, and zo was the displacement at zero applied pressure.
The equation provided by Giovanni was modified [18] by neglecting the linear bending term of
16z/[3t(1-iv)] and by introducing an offset displacement zo. This allowed approximate characterization
of a membrane that was buckled and had a large displacement with no applied pressure. The offset
displacement zo was either positive or negative and equal in magnitude for the two cases if the
membrane had a symmetric buckling tendency. Total volume displacement (relative to the flat,
unbuckled state) was estimated from
2ta Z
V Equation 5.32
where it was assumed that displacements were significantly greater than membrane thickness, and the
membrane shape was approximately parabolic. For small displacements, where the membrane shape
was approximately sinusoidal (both buckle amplitude and pressure-induced displacement were less than
the diaphragm thickness), the denominator in Equation 5.3 was replaced by 1.68 and the linear term
missing from Equation 5.2 was included.
An example membrane volume displacement plot is shown in Figure 5.7. The rapid change in
volume at low pressures was indicative of buckling and a nearly symmetric function of pressure. The
data was measured from a polyimide membrane that had been sputter-coated with 1500 A of gold as a
permeation barrier. The membrane had a zero-pressure buckle displacement of positive or negative
0.17 mm, as measured by a Keyence CCD Laser Displacement Sensor LK-031. Values of E = 3.0 GPa
(thickness-weighted average of 2.5 GPa for Kapton ® and 78 GPa for gold), v = 0.3, t = 1 mil, and zo = +/-
0.17 mm were used in Equation 5.2 to tabulate the displacement z as a function of applied pressure, and
then Equation 5.3 was used to calculate the corresponding displacement volume shown as the model in
the graph. The nonlinear displacement behavior resulted in a large differential capacitance at low
pressure that decreased rapidly with increasing pressure amplitude as shown in Figure 5.8. The plots in
the figure represented the pressure derivative taken numerically for the measured data of the
displacement volume in Figure 5.7 and used no fit parameters. Also included in the figure was a best fit
of the raw measured data. The fit had the form of the pressure derivative of the displacement
described by Equation 5.2. The discrepancy between the model and fit of the measured data was
believed to result from at least two factors including the lack of precision of measurement of membrane
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displacement and the tendency of the buckled membrane to take on an asymmetric, non-parabolic
shape at low pressures.
-60 -40 0 2(
Pressure (kPa)
Figure 5.7: Polyimide capacitor membrane displacement volume as a function of applied fluid pressure.
The membrane had a thickness of 1 mil and a diameter of 8 mm. The measured buckle displacement
amplitude was 0.170 mm. The displacement volume was generated by a Harvard PHD2000 syringe
pump, and the pressure was measured with an Entran Model EPX-VO1 pressure transducer. The model
used zo = 0.17 mm for P < 0 kPa and zo = -0.17 mm for P > 0 kPa.
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Figure 5.8: Polyimide membrane capacitance as a function of applied fluid pressure. The membrane had
thickness of 1 mil and diameter of 8 mm. Buckle displacement amplitude was 0.17 mm.
As described above, the fabrication procedure provided a straightforward method for
incorporating different membrane materials into the laminate device structure. Figure 5.9 illustrates
the significant difference in volume displacement behavior versus pressure between the thin, high-
modulus membrane (polyimide) and the thicker, lower-modulus material (silicone). As reference, for the
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silicone membrane, a volume displacement of 0.63 pL occurred when the axial displacement equaled
the diaphragm thickness of 4 mil. This is approximately where the membrane transitioned from bending
mode to tensile mode expansion (the linear and cubic terms in the displacement versus pressure
equation were equal when z/t = 1.35 for v=0.3). Approximately linear behavior was observed up to this
displacement volume, which occurred at 3.5 kPa. This, not incidentally, was a reasonable upper bound
of operating pressure range for some of the membrane capacitors in the system. The polyimide
membrane, on the other hand, did not have a roughly linear displacement volume in this pressure
range.
2.5
1.5
E
-0.5 -
---- 3
- -1.5' -
4- - -- 1 mil polyimide, 5 mm diameter
- -- 4 mil silicone, 3.6 mm diameter
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-40 -20 0 20 40
Pressure (kPa)
Figure 5.9: Comparison between 1 mil thick, 5 mm diameter polyimide and 4 mil thick, 3.6 mm diameter
silicone membrane displacement volumes as a function of applied fluid pressure.
The above discussion illustrated the dependence of fluid capacitance on membrane material and
thickness. Capacitance also showed predictable dependence on membrane diameter. Figure 5.10 shows
measured small capacitance values (nominal pressure is 6.9 kPa) as a function of membrane diameter
using the silicone membrane. The theoretical plot was generated by taking the pressure derivative of
displacement as described by Equation 5.2 and then applying Equation 5.3 to obtain differential volume
change as a function of pressure with membrane radius as a parameter. Relatively good agreement
between measured values and the design model was demonstrated.
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Figure 5.10: Measured versus theoretical capacitance as a function of membrane diameter. Membrane
material was 4 mil-thick silicone.
5.4 MANUAL SCREW VALVE
In addition to fluid capacitors, manually-actuated screw valves were designed, built, and tested.
Manual microfluidic screw valves were demonstrated by the Whitesides group [19], but the screw acted
by direct compression on a silicone channel. Contrarily, this design used a laminate structure with a
ring-shaped valve seat and a membrane, as shown in Figure 5.11. Axial displacement of the screw
forced the membrane into contact with the valve seat and restricted flow between the inlet channel and
the outlet channel. The inlet channel terminated at the inner diameter of the valve seat, and the outlet
channel was in the form of a torus surrounding the valve seat. During fabrication, there were two valve
seat cuts which defined the valve seat perimeter and the torus portion of the outlet channel. The first
valve seat cut defined approximately 330 degrees of the seat perimeter. After lamination to the channel
spacer layer, the second valve seat cut defined the remaining 30 degrees of the seat perimeter.
Erin E. Leary Swan
::il-~~----'~~~ ;~~~~i~~~~~:~n~;Bi~-~~~
158 I P a g e
1st valve seat cut 2nd valve seat cut
Outlet channel
Inlet channel
Valve seat
Figure 5.11: Depiction of normally-open screw valve. Top view (upper) and cross-section (lower). Layers
3 and 4 were laminated together between the 1st and 2 nd valve seat cuts.
As with the microfluidic capacitors, these valves were built with different membrane materials and
in configurations within a larger manifold of components. A 5-valve manifold was designed for
functionality similar to that of a high performance liquid chromatography (HPLC) injection valve as
shown in Figure 5.12 and was manufactured in a 1.5 cm x 1.5 cm die format with top and bottom
aluminum plates as shown in Figure 5.13. Holes in the top plate aligned with valve seats. The holes were
tapped to provide placement for the actuation screws. The bottom plate was used in high-pressure
applications where large axial screw forces were applied, and coupling the plates with clamping bolts
prevented delamination of the top plate from the laminate stack.
Figure 5.12: 5-valve manifold shown in size comparison to the HPLC valve it replaced.
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Figure 5.13: (left) Drawing of 5-valve manifold showing aluminum plates and screw actuators. (right)
SEM cross-section of valve structure.
Two screw types were examined. The first was a steel 0-80 hex socket set screw with a cup point.
The diameter of the cup point was matched to the nominal diameter of the valve seat. While this
provided a very high effective pressure on the membrane during valve closure, it provided a relatively
small contact area requiring precise alignment of the aluminum top plate to the polyimide stack. In
addition, it generated wear on the outer surface of the membrane, severely limiting the cycle count of
the valve. The second screw type was a nylon 0-80 slotted head screw with a flat tip. This generated
approximately uniform pressure over the valve seat and significantly less wear on the membrane.
The manifold was useful for loading drugs into the fluidic network for animal testing and for
filling and purging of the system, as shown in Figure 5.14. Without change to the wetted parts, the
actuation mechanism could be altered for electronic control [10]. Given that the drug delivery system
internal fluid volume was approximately 100 ILL, and experiment duration could approach several
months, low leak rates were required. Open-state resistance and closed-state leak rates for multiple
polyimide-diaphragm valves using nylon screws to control water flow were measured and listed in Table
5.2. Open-state resistances were calculated from the slope of a linear fit of measured flow rate versus
pressure set-point, with at least five different set-points ranging from 0 to 50 kPa. Closed-state leak
rates were measured at a pressure set-point of 100 kPa. Flow rates in both cases were determined by
measurement of linear displacement over time of a water segment traveling through fine-bore tubing
attached to the output port of the valve under test.
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Figure 5.14: A functional comparison of the 5-valve manifold and a standard HPLC sample injector. The
valve was manipulated in various configurations to allow for drug infusion, reservoir filling, or bypass. It
also functioned as purge and refill ports.
Table 5.2: Measured valve characteristics using nylon screws
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Leak rate at 100 kPa (1 in'ounce 0.015 -
applied torque) (lL/min)* 0.040
Resistance in open position 0.028 -
(kPa min/VlL)t  0.065
Minimum resistance ratio, > 38 000
Closed:Open
-3 valves tested, -5 valves tested
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5.5 CONCLUSION
Diaphragm-based components were developed for a microfluidic drug delivery system using a
set of versatile fabrication techniques suitable for rapid prototyping of laminate-based polymer
microfluidic systems. The microfluidic components discussed were seamlessly incorporated into the
fluidic network used in animal studies to deliver active compounds directly into the inner ear for up to a
month. Both components significantly contributed to a reduction in size of the system and provided
greater control over critical system variables. The valve and capacitor may be integrated into a versatile
laminated polyimide fabrication platform along with other microfluidic and electronic components
including flow sensing and control elements and should prove useful for a broad range of microfluidic
applications.
Rights were reserved to reprint portions of this chapter from: Mescher, M., et al., Fabrication methods
and performance of low-permeability microfluidic components for a miniaturized wearable drug delivery
system. Journal of Microelectromechanical Systems, 2009. 18(3): p. 501-510.
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6.0 CONCLUSION
6.1 CONCLUDING REMARKS
Various biological aspects associated with long term drug delivery to the inner ear were
investigated in this thesis. The concentration profile resulting from delivery within the cochlea was
modeled using a lumped-parameter approach and implemented with electrical circuit simulator
software. The model was validated by comparison to the analytical solution of the diffusion-only case.
Additionally, a bench-top experiment using the device to deliver fluorescein into a glass tube was
undertaken. The delivery profile showed agreement with the modeled results. Many weaknesses in
modeling biological aspects such as protein binding and drug clearance limited the model's usefulness in
predicting the drug concentration distribution in the cochlea. Future refinement of the model is needed
to improve its capabilities. The effects of protein and tissue build-up on the flow parameters of the
device were studied through bench-top flow testing and histology preparations after in vivo
implantation. Characterization of the protein content of perilymph elucidated many individual proteins
that likely will impact delivery of drugs into the cochlea. Device design and drug choices must be based
on this knowledge. Finally, new microfluidic components were added to the delivery system to enhance
performance and advance miniaturization methods. Through this research, both the impact of this
device on the animal and the result of implantation on the device were more fully characterized.
6.2 FUTURE DIRECTIONS
6.2.1 Modeling
A number of improvements could be made in the model as it is further refined, but a better
understanding of biological phenomena in the cochlea is needed. A dose-response curve for DNQX
should be created with a broader range of concentrations measured. Also, a concentration that does
not cause the hearing level to rise above measurable limits must be used. Together, this data will lead
to a more accurate dose-response relationship from which to compare modeled and experimental
results. In addition, studies of protein binding rates and clearance rates for the cochlea are needed.
These values are drug-specific so numerous compounds will need to be studied. The measurements of
aqueduct resistance and round window compliance were only reported for a small pressure range.
Additional studies should be undertaken to expand this range to better understand the nonlinearity of
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the anatomical structures. The nonlinearity can be incorporated into the circuit simulation using
available elements in the software package.
6.2.2 Protein interactions
The protein flow study, though preliminary, showed the need to follow-up with more long-term
studies of biofouling in vivo. This will be a major design consideration for future iterations of the device.
After implantation for various lengths of time, the devices components should be inspected and tested
for the degree of biofouling and resulting flow restrictions. Flow sensors will be incorporated into the
system to allow for continuous monitoring of delivery profiles while the device is operating in animals.
At the end of these experiments, additional histological examination of the cochlea is needed.
6.2.3 Microfluidic device components
As the device evolves, the components will be integrated into a full microscale delivery system
on a single polyimide platform. The valves can be combined with an electrically-controlled actuator for
automated control, and electrical circuitry can be integrated with the entire microfluidic device using
similar microfabrication techniques.
While much progress was made on the specific aims, a great deal of work remains. Continued
efforts on this delivery system will lead to a better understanding of device and biological interactions.
More importantly, the inner ear delivery device may one day impact patient care if not in a form similar
to the way it has been envisioned, at least by the insight that has been gained throughout its
development.
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